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ABSTRACT

Most of the load-bearing demand placed on the human body is transduced by skeletal
tissue, and the capacity of the skeleton to articulate in various opposing directions is
essential for body movement and locomotion. Consequently, cartilage and bone defects
due to trauma, disease, and developmental abnormalities result in disabling pain and
immobility for millions of people worldwide. A novel way of promoting cartilage and
bone regeneration is through the incorporation of either primary cells or multipotent
progenitor cells in a three-dimensional (3D) biomaterial scaffold, and/or the addition of
exogenous growth and differentiation factors. The first part of this study reports a
protocol for using freshly isolated mature chondrocytes seeded in a 3D hydrogel
biomaterial scaffold, developed to explore mechanotransduction of engineered cartilage
constructs cultured in a designed bioreactor. The bioreactor was designed to allow the
application of physiological mechanical forces (compression and fluid flow), as well as a
non-invasive/non-destructive method for analyzing regenerating tissue in real time
through ultrasound transducers and a computerized monitoring system. In the second part
of this study, an engineered immortalized osteoprecursor cell line, designated OPC1
(osteoblastic precursor cell line 1), was used as a culture model system for exploring the
effects of exogenous growth and differentiation factors, mainly vitamin D, on early bone
development. OPC1 was previously designed to provide a consistent reproducible culture
system for direct comparisons of engineered bone constructs, evaluating bone
development and cell/biomaterial interactions, and for investigating putative bone
i

differentiating factors. One of the objectives of this research effort was to explore tissue
development and regeneration by culturing OPC1 in the presence of vitamin D
metabolites vitaD3 and 1,25OH2D3, while assaying the concomitant biological response.
Results indicate that OPC1 is capable of metabolizing the parental metabolite vitaD3, and
thus 25OHD3, to the active vitamin D form 1,25OH2D3. The metabolism of vita3 resulted
in an anti-proliferative and pro-differentiative influence on OPC-1 . These results support
the hypothesis that extra-endocrine synthesis of 1,25OH2D3 functions in a tissue specific
manner to regulate growth and differentiation, in addition to the classic calcimic actions
of the vitamin D endocrine pathway. Understanding the influence of vitamin D on bone
development will have significant implications on healthy aging, including the
susceptibility to skeletal disorders involved in development and aging, such as
osteoarthritis (OA) and osteoporosis.
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Figure A-5. Dissection of cartilage from the bovine metacarpophalangeal joint. (A) The
skin is removed, exposing the outer joint capsule. (B) An incision through the anterior
surface of the join capsule is made which spares the cartilage within. (C) After the joint
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Chapter I.

INTRODUCTION

Section 1.01

Tissue Engineering

Cartilage and bone defects are one of the most common causes of long-term
disability world-wide, an economic burden with an annual cost that exceeds 28 billion
dollars in orthopedic repair each year in the United States alone, and the number
continues to increase with an aging population suffering from bone and cartilage defects
caused by deterioration, disease, and trauma [Chao et al., 2007; Mason et al., 2011].
Tissue engineering (TE) and regenerative medicine are multidisciplinary fields that
integrate the principles of engineering (material sciences and biomedical engineering)
and life sciences (biochemistry, genetics, cellular and molecular biology) to develop
biological cellular/tissue/organ replacements that can repair, restore, maintain or improve
tissue function [Brockbank, 2000], and provides a promising solution for cellular and
tissue replacement therapies as well as an alternative for animal models used in clinical
research.
TE has two applications: therapeutic and diagnostic. Therapeutic applications
involve growing tissue either in vivo or ex vivo for subsequent transplantation, while
diagnostic applications involve growing tissue in vitro and using the tissue to study
biological mechanisms such as drug metabolism, uptake, and toxicity. The foundation
for most TE strategies, whether therapeutic or diagnostic, encompasses living cells
combined with a biomaterial scaffolds capable of mimicking the tissue-specific ECM,
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signaling factors that promote growth and differentiation, and/or specialized culture
devices or bioreactor that can facilitate growth and differentiation by creating physical
conditions that closely resembles the native environment [Tortelli & Cancedda, 2009;
Mason et al., 2011; Chao et al., 2007]. In addition, for diagnostic application of studying
metabolism of tissue growth and development, mathematical and computational
modeling can be used to characterize biological phenomena.
In the case of skeletal tissue, the key to long-term success of cell-based tissue
engineered constructs, depends largely on its ability to function mechanically and to
appropriately respond to biological and biomechanical signals [Freed et al., 2006; Haj et
al., 2005]. In native tissue, the forces created by the environment provides important
mechanical cues in directing cellular process, including adhesion, spreading, migration,
cytoskeletal organization, growth, differentiation, apoptosis, and tissue morphogenesis
[Cheung et al., 2009]. Mechanotransduction, the process of cells transducing mechanical
signals into chemical signals, is known to play an essential role in bone tissue remodeling
and repair; for example, dynamic mechanical loading at physiological magnitudes has
been shown to initiate bone deposition and remodeling in animal models and in organ
cultures, while the lack of mechanical load results in tissue atrophy and bone loss [Haj et
al., 2005].
There are several factors that need to be taken into consideration for TE
experimental design, such as cell source and acquisition, and appropriate signaling
molecules. For example, TE for bone regeneration generally utilizes a combination of
biomaterial scaffolding with either an osteoblast or precursor cell source and growth
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factors such as bone morphogenetic proteins (BMPs) [Winn et al., 1999], while many
studies have indicated that a primary cell culture from mature functional articular
cartilage, is a logical cell choice for cartilage TE [Hardingham, Tew, & Murdoch, 2002].
Each cell source has its benefit and challenge. One of the major challenges of using
mesenchymal stem cells (MSCs)/progenitor cells for in vitro and in vivo studies is the
isolation sufficiency and expansion for possible clinical applications [Huang et al., 2012].
MSCs and progenitor cells from bone marrow can differentiate into bone, cartilage, fat,
and fibrous connective tissue when guided by appropriate growth factors, however
isolates are typically heterogenous and limited by variability in their phenotypes,
including proliferation capacity, differentiation, expression of cell surface markers and
ability to secrete cytokines [Pevsner-Fischer, Levin, & Zipori, 2011]. Tissue-specific
differentiated cells isolated from mature tissue are also limited by the ability to isolate a
sufficient number of cells and maintain phenotypic stability. Primary cell cultures can
become senescent or dedifferentiate during the culture period [Fodor, 2003], which
causes them to loose phenotypic structure and function. In addition, repeated isolations of
primary human osteoblasts and chondrocytes have been reported to result in cellular
preparations that have variable differentiation potential and proliferative capacity during
expansion [Otero et al., 2012; Winn et al., 1999]. The incorporation of growth and
differentiation factors can facilitate proliferation and differentiation, however cannot
entirely control for phenotypic variability. Therefore, an established cell line with a
reproducible stable phenotype is most desirable for the diagnostic application of tissue
engineering. In the following studies, a primary cell culture protocol was established and
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used for cartilage tissue constructs, while an engineered osteoblast precursor cell line
(OPC1) was used for early bone tissue development.

Section 1.02

Three-Dimensional Culture System

While there have been rapid advancements in TE, to date, the properties and
structure of native cartilage and bone tissue have not been entirely mimicked by
engineered tissues. Limitations of current tissue replacement therapies, such as
autologous transplantation (the patient receives their own cells/tissue), include difficulty
in obtaining a required amount of cells for a TE construct, dedifferentiation during
cellular expansion, degeneration at the donor site, and long-term success rate.
Reconstruction of skeletal tissue can be accomplished by using an appropriate cell
source, biomaterial scaffold, and growth factors; however recreating the unique structure
of ECM and mechanical properties of load-bearing tissue is a major challenge in TE.
In healthy connective tissue, structural protein fibers such as collagen and elastin
fibers, which make up the ECM, entangle to form a nonwoven mesh that provides tensile
strength and elasticity [Zuwei, et al., 2005]. Cells embedded within the tissue are
responsible for the synthesis and maintenance of the tissue-specific ECM, thus they are
the true “tissue engineers.” It is the unique make-up of the ECM that allows mechanical
movement of the body. In order to successfully engineer load bearing connective tissue,
the distinctive structure and function that gives the tissue the capability of bearing
mechanical loads during daily activities has to be mimicked. It has been demonstrated
that cells often exhibit unnatural behavior when they are excised from their native 3D
4

environment and confined to a two-dimensional (2D) monolayer. A 2D monolayer
environment allows cells to attach to the bottom of culture vessels and gradually spread,
which causes them to lose their spherical morphology and acquire an elongated
fibroblast-like phenotype. Morphological alterations acquired in 2D culture are
accompanied by critical biochemical changes, which change the functionality of the cell.

(i) Biomaterial Scaffolds
In order to enhance cell and tissue growth, and maintain phenotype in vitro,
many studies have indicated the usefulness in employing a biomaterial scaffold as
a vehicle for growing tissue constructs [Tellisi & Nureddin, 2007]. Biomaterial
scaffolds can be used to recreate the native 3D environment and mimic the
physical structure, biological function, and biochemical nature of ECM
[Villanueva, Weigal, & Bryant, 2009]. In order for a biomaterial to function as an
ECM-like scaffold, a number of considerations and criteria have to be met,
depending on the TE application, such as biocompatibility, biodegradability, and
mechanical property.
Native ECM is a physical substrate that doesn’t just provide physical
support for cells and tissue, but also contains specific ligands for cell adhesion
and migration, as well as signaling factors that regulates and facilitates cellular
proliferation, differentiation, and function [Zuwei, et al., 2005]. Cartilage and
bone regenerative therapeutics under clinical development, have utilized

5

biomaterials as scaffolds to provide an anchor for attachment and differentiation
of endogenous migratory precursor cells [Winn, et al., 1999]. Cells must adhere,
migrate, proliferate, function, and secrete ECM macromolecules within the
provided space of the scaffold. Therefore, the scaffold has to be porous and
biocompatible, and for therapeutic TE constructs, it has to be non-immunogenic
and biocompatible with the body.
The overall purpose of the scaffold is to serve as a temporary support for
growing cells and new tissue formation, therefore it must be biodegradable in a
such a way that the scaffold degrades at a complimentary rate to the cellular
proliferation and ECM development, ultimately resulting in a TE construct that
consists entirely of newly formed tissue. During healthy balanced tissue
development and regulation, growth factors stimulate the anabolic synthesis of
ECM macromolecules, a process that is complimented by the catabolic
degradation of ECM during tissue remodeling and repair [Saha & Kohles, 2010;
Saha & Kohles, 2011]. In order for this process to take place in vitro, the
biomaterial scaffold needs to degrade at a rate that compliments the synthesis of
neotissue, be responsive to the local biological environment, and provide the
appropriate physical cues [Bahney, et al., 2011].
In

addition

to

facilitating

permeation,

attachment,

proliferation,

differenitation, and ECM turnover, the architecture of the scaffold has to mimic
the mechanical strength of native tissue. One of the greatest challenges of
engineering load-bearing tissue like cartilage and bone is producing a scaffold
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with adequate mechanical properties [O'Brien, 2011]. A scaffold needs to have
sufficient mechanical integrity to function from the time cells are seeded within it
to the completion of tissue remodeling. Therefore, the scaffold needs to maintain
its mechanical property as it degrades and is replaced with tissue-specific ECM.

(ii) Mechanical stimulation using a bioreactor
Conventional tissue culture methods are limited in their ability to replicate the
physiological anabolic and catabolic environment of the body. Normal cells and
tissue are continuously exposed to various forms of physiological stresses and
stimuli. Cells extracted from a 3D environment and expanded in a 2D monolayer
tend to dedifferentiate as they adhere and spread along the surface of the culture
vessel. Dedifferentiated cells that have been expanded in a 2D monolayer have
the capacity to redifferentiate if they are transferred into a 3D environment that
supports their native morphology; however, their original phenotype may not be
fully re-acquired if the in vitro environment does not mimic the physical native
environment [Barbero & Martina, 2007]. When 3D cellular constructs are grown
in static culture, cells on the outer surface of the constructs are typically viable
and proliferate, while cells within the construct may be less active or necrotic
[Cartnmell, et al., 2003].
3D culture techniques that encompass biomaterials allow spherical cells to
remain round, yielding cells that continue to express tissue specific genes, but are
limited relative to proliferation capacity and lack the ECM molecules found in
7

native tissue [Choi, et al., 2007]. Mechanical stimulation (fluid, solid, thermal,
etc.) of 3D constructs consisting of cells, biomaterials, and growth factors have
shown promising results in the production of viable load-bearing tissues such as
cartilage and bone [Kohles, Wilson, & Bonassar, 2007]. The transduction of
mechanical signals to chemical signals from cell-cell and cell-ECM interactions
determines the formation of healthy tissue morphology. Thus, preserving these
interactions is essential in recreating the native tissue.
A bioreactor is a tissue-culture device that provides a controllable,
physically active environment that can be used to study and potentially improve
engineered tissue structure and properties [Freed, et al., 2006]. For the cultivation
of engineered tissues, bioreactors can improve construct shape and size, cell and
ECM density and molecular composition, and can permit the studies of (i) mass
transport of oxygen and signaling factors, (ii) hydrodynamic conditions, and (iii)
mechanotransduction [Freed, et al., 2006], as well (iv) the study of drug
metabolism, intake and toxicity. Utilizing a bioreactor can help recreate the native
physiological mechanical environment and facilitate tissue development.
A novel bioreactor has been fabricated by Portland State University’s
Regenerative Bioengineering Laboratory, capable of providing mechanical
stimulation (compressive loading and fluid perfusion), real-time mechanical
characterization, optical inspection, and non-destructive ultrasonic assessment of
ECM-biomaterial content (Figure 1-1). The device combines a linear actuator
(Electro Force, Bose, Eden Prairie, MN) connected to five load transducers
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(1,000g, +/- 0.15 to 0.25%, Model 31 Mid, Sensotec/Honeywell, Golden Valley,
MN) connected to solid platens that contact specimens from above and apply
compressive solid mechanical loads. The actuator can be controlled via
displacement (+/- 2.5 mm) or force (20 N) to apply a variety of waveforms (Win
Test, Bose) for dynamic stimulation of five concurrent cube-shaped test samples.
Access for a digital video microscope and ultrasound transducers facilitates the
minimally invasive assessment of cultured tissue constructs. The entire bioreactor
can fit inside an incubator (Galaxy R Series Incubator, New Brunswick, Edison,
NJ) with sensor control of the internal environment chemistry, carbon dioxide
(CO2), oxygen (O2), and nitrogen (N2). The bioreactor is capable of controlled
monitoring of biological, chemical, and mechanical components associated with
engineered tissue constructs, which includes cells, biomaterials, growth
stimulants/inhibitors, and the developing neotissue in order to address the
complexities of developing native tissue.
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Figure 1-1: The fabricated, novel multiphysics bioreactor with five culture wells. The highresolution, copper-colored load-cells measure the dynamic loads transferred via the load-rods
through the square load-platens into the culture-well designs (upper right) and onto the cellbiomaterial constructs (pink cube, lower right) [Mason et al., 2011; Kohles et al., 2011].

(iii) Nondestructive techniques to assess 3D tissue constructs
Most mechanical and biochemical assessment of engineered tissue constructs
require destructive endpoint-testing and/or compromise the sterility of the
bioreactor environment used during construct formation [Walker, et al., 2011].
Ultrasonic imaging is a standard clinical diagnostic tool that is based on
propagating high-frequency (HF) sound waves and offers a technology for tissue
characterization and stimulation in a noninvasive and nondestructive manner. The
response to mechanical stimulation induced in passive tissues by external sources
10

such as low to high frequency vibration or compression can be used to analyze
tissue elasticity as a metric for tissue health [Hein & O'Brien, 1993]. Recently, it
has been shown that ultrasonic assessment can predict the process of native
cartilage regeneration and engineered cartilage histology [Hattori, et al., 2005].
The bioreactor described in the previous section has the capability of
providing ultrasonic assessment of 3D engineered tissue constructs. As a
ultrasonic wave passes through a specimen, the speed of attenuation provides a
metric associated with the density of accumulated matrix molecules, while the
speed of sound is associated with Young’s Modulus or elasticity (stress-strain)
[Kohles, Bowers, Vailas, & Vanderbery, 1997]. When a sound wave travels
through a medium, its amplitude decreases with distance. In homogenous
materials, the amplitude of sound waves are only reduced by the spreading of the
wave, however, in natural heterogenous materials, objects within the medium
(such as cells in tissue) weakens the amplitude which results from scattering (the
reflection of the sound waves in other directions) and absorption (the conversion
of sound energy to other energy forms) of the sound wave. Ultrasonic attenuation,
the decay rate of the wave as it propagates through the material, can be used to
explain physical or chemical phenomenon that decreases ultrasonic intensity,
while the speed of sound, which is related to elastic property and material density,
can be used to describe the mechanical property. Therefore, ultrasound provides a
nondestructive means to assess the mechanical properties of growing engineered
tissue in real time
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Section 1.03

Cartilage Tissue Engineering

Cartilage disease and injury affects more than 15% (approximately 40 million people)
of the US population and with more than 250,000 knee and hip replacements performed
each year, exceeds an annual cost of $60 billion per year [Chung & Burdick, 2008;
Steward, Liu, & Wagner, 2011]. With an aging population suffering from defects or
deterioration of articular cartilage by OA and trauma, the number continues to increase.
Articular cartilage provides a unique challenge for tissue engineering in that its structure
appears simple and it only contains one cell type, the chondrocyte, however the ECM is
highly organized and complex [Hardingham, et al., 2002]. Articular cartilage is not
innervated and avasculature so normal mechanisms involving the recruitment of cells
from blood or bone marrow to a wound site, can not occur, limiting the capacity of selfrepair [Vinatier, et al., 2009; Hardingham, et al., 2002]. In cases of cartilage damage
caused by trauma, severe injuries are frequently followed by degeneration [Appleman, et
al., 2009]. Because chondrocytes do not sustain a healing response on their own, tissue
engineering has the potential to provide functional cartilage tissue to help the millions of
people who suffer from degenerated, diseased, or damaged articular cartilage.
There have been rapid advancements in cell-based therapies, which include the in
vitro engineering of functional tissue substitutes for subsequent in vitro transplantation
[Chung & Burdick, 2008]. To date, however, the properties and structure of native
cartilage tissue have not been entirely mimicked by engineered tissue. Limitations of the
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current solutions such as autologous chondrocyte transplantation (ACT) include difficulty
in obtaining a required amount of cells for a construct and cellular dedifferentiation
during expansion, as well as degeneration at the donor site. Although recorded success
rates of ACT are between 60-90% depending on the localization of the injury [Yilmaz, et
al., 2010], long-term success rates are considerably lower.
Articular cartilage is a highly specialized tissue that reduces joint friction at the
extremities of long bones, and helps absorb mechanical load. Articular cartilage consists
of chondrocytes and ECM that is composed of a network of collagens, particular type II
collagen (ColII), which gives the tissue its shape and strength, and proteoglycans, which
give resistance to mechanical stress and compression [Vinatier, et al, 2009; Hardingham,
et al., 2002]. Although only about 10% by volume, the immobilized chondrocytes
embedded within the ECM are responsible for the synthesis, organization, and
maintenance of ECM macromolecules [Pazanno, et al., 2000; Lanza, Langer, & Vacanti,
2007; Hardingham, Tew, & Murdoch, 2002]. The continuous remodeling of cartilage
ECM in response to exogenous mechanical stimuli occurs through biokinetic anabolic
and catabolic reactions of ECM macromolecules [Saha & Kohles, 2011; Saha & Kohles,
2010a; Saha & Kohles, 2010b], which allow the tissue to respond to the physiological
environment and protect the underlying bone.
The structural integrity of cartilage is derived from the fibrous network formed by
the cartilage-specific collagen type II (ColII), which is immersed in a gelatin formed by
proteoglycans rich in sulfated glycosaminoglycans (GAG). Because it is abundant in
sulfate and carboxyl groups, GAG is negatively charged which draws water into the

13

tissue with such high affinity that it makes up ~70% of the total weight creating a large
osmotic swelling pressure [Wilson, et al., 2002; Hardingham, et al., 2002]. This hydration
permits the diffusion of water-soluble molecules throughout the tissue. GAG is too large
and immoble to redistribute itself, therefore swells and expands the ECM, placing the
collagen network under tension. Equilibrium in the tissue is reached when the tension
from the collagen network balances the swelling pressure. It is this unique molecular
combination that allows low friction movement of joint surfaces. In return, joint loading
from body movement induces fluid flow within the tissue, which maintains ion
movement, and nutrient/waste exchange, therefore reducing the need for vascularization.
Recreating this dynamic is a major challenge in TE.
Because chondrocytes from mature articular cartilage are capable of producing
ColII and GAG ECM macromolecules, it has been suggested that isolates from adult
articular cartilage is a logical cell choice for cartilage TE [Hardingham, et al., 2002].
Although chondrocytes have been widely used in cartilage repair, they have been shown
to be unstable when cultured in a standard 2D monolayer. In the body, cells exist,
proliferate, and differentiate, within a 3D environment, but when chondrocytes are
cultured in a 2D environment, they tend to lose their overall hyaline structure and
functional elasticity, thus their overall differentiated phenotype. In vitro expansion of
static monolayer cultures are associated with cellular dedifferentiation and reduced or
total loss of the ability to produce ECM and redifferentiate [Barbero & Martina, 2007;
Barlic & Kregar-Velikonja, 2008; Ando, et al., 2009]. Many authors have described a
fibrocartilaginous quality observed in chondrocytes prepared in monolayer [Ando, et al.,
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2009]. A 2D environment allows chondrocytes to attach and gradually spread, which
causes them to lose their spherical morphology and acquire an elongated fibroblast-like
phenotype. Morphological alterations acquired in monolayer are accompanied by critical
biochemical changes. Loss of the hyaline morphology is associated with the expression
or total loss of aggrecan and ColII synthesis, and an increase in the expression of
fibrocartillage associated ECM molecules collagen type I (ColI) and versican [Barbero &
Martina, 2007; Barlic & Kregar-Velikonja, 2008].
Chondrocytes that have dedifferentiated have the capacity to redifferentiate if they
are transferred to a 3D environment that supports their native spherical morphology;
however, their original phenotype may not fully be re-acquired [Barbero & Martina,
2007]. Because cartilage-specific ECM macromolecules bind to water with such high
affinity, hydrated biomaterials (hydrogels) can be used to recreate the native 3D
environment and mimic the physical structure, biological function, and biochemical
nature of cartilage ECM. Natural or synthetic polymers such as proteoglycan aggrecans
and collagen have been found to provide 3D support, induce chondrocyte proliferation
and improve their synthetic function [Tellisi & Nureddin, 2007]. Recent studies have
indicated that bioabsorbable polymers such as polyglycolic acid (PGA), enhances
proteoglycan synthesis, while collagen scaffolds stimulate collagen synthesis [Atala &
Lanza, 2002]. It has been shown that 3D cultures, such as those grown in with alginate or
agarose allows chondrocytes to remain round and supports cartilage-specific gene
expression [Hardingham, Tew, & Murdoch, 2002], but may be limited relative to
proliferation capacity and lack the zonal distribution of cells and ECM molecules found
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in native tissue [Choi, et al., 2007]. Part of the challenge of engineering cartilage is
providing the essential cells and signals that will establish cartilage ECM and recapitulate
the molecular organization that forms the basis for the essential mechanical properties of
the tissue [Hardingham, et al., 2002].
Although cartilage is made up of only one cell type, it is characterized by zonal
differences in architecture and distribution of ECM components. There are four
histologically distinct zones (superficial tangential or resting zone, proliferative of middle
zone, hypertrophic or deep zone, and the calcified zone) characterized by orientation and
density of ECM molecules, morphology, and biochemistry [Kohles et al. 2012; Atala &
Lanza, 2002]. Because of the depth-dependent structural arrangement of chondrocytes
and ECM macromolecules, articular cartilage is a heterogenous and mechanically
anisotropic material. Assessing the mechanical properties of cartilage constructs in realtime via ultrasound while tissue is developing may elucidate the physical interactions and
localized biomechanics (stresse, strain, and elastic property) between cell-cell and cell
ECM that occurs within and between zones.
Healthy chondrocytes undergo hydrostatic, compressive, tensile, and shear forces
within a physiological environment, which act to maintain the phenotype and promote
production of new cartilage tissue [Ramage, et al., 2009]. Abnormal mechanical forces,
such as those sustained in traumatic skeletal injuries, can alter chondrocyte behavior,
regulating in degradation of cartilage from increased catabolic activity and apoptosis. In
order to engineer a cartilage construct ex vivo an environment that supports chondrocyte
development into functional cartilage needs to be recreated, including the appropriate
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scaffold bioactivity and mechanical stimulation [Appleman, et al., 2009]. Since normal
cartilage is continuously exposed to various forms of physiological stresses, diffusionbased nutrient supply is believed to be a vital mechanism for the maintenance of cartilage
homeostasis, along with the concurrent physiological stimulations [Park, et al., 2007].
Utilizing a multi-scale bioreactor as previously described, can recreate native
biomechanical and biochemical stimuli, facilitate cartilage development investigations,
and validate ongoing biokinetic modeling.
Section 1.04

Engineering Bone Development

Imbalances between osteoblastic bone formation and osteoclastic bone resorption
can result in a net bone loss and osteoporosis [Hens, et al., 2005]. While many therapies
aim to inhibit bone resorption, in order to cure skeletal diseases associated with bone loss,
new bone formation is essential. Bone formation in the embryo or during adult bone
repair or remodeling involves the progeny of MSCs (osteoprecursors) [Bruder, et al.,
1994]. MSCs are multipotent cells that continuously replicate while a portion become
committed to the mesenchymal cell lineage such as bone, cartilage, tendon, ligament and
muscle (see Figure 1-2). Bone regeneration is based on the hypothesis that healthy
progenitor cells, either recruited or delivered to a bone defect, can regenerate damaged or
degenerated tissue [Shea, et al., 2000]. Culturing osteogenic cells in an enviornment that
supports bone formation is a possible solution for the treatment of extensive bone defects
and osteoprosis. A source of human cells that can be produced in large numbers and can
predictably differentiate into bone is critical for the therapeutic application of engineering
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human bone replacements [Marolt, et al., 2010], and for the diagnostic application of
studying bone formation in vitro.
The differentiation of MSCs and progenitor cells within each specialized celular
lineage is a complex multistep pathway involving discrete cellular transitions that depend
on the presence of specific signaling factors, nutrients, and environmental cues. An
important aspect of bone biology is to experimentally address the regulatory events
related to the commitment of progenitor cells into the developmental pathway and
elucidating the regulatory factors that influence bone formation, remodeling, and
regeneration [Lian & Stein, 1995]. While human-derived immortalized and conditionally
immortalized osteogenic cell lines that have been used as model systems to develop bone
constructs, a human derived cell-line that exhibits a consistent differentiation pattern and
is stable over generations is essential for modeling bone development, and for studying
biomaterial-cellular interactions necessary for optimizing bone regenerative therapies.
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Figure 1-2. MSC bone developmental pathway. An important aspect of bone biology is to address the
regulatory events related to commitment of pluri
pluripotent
potent progenitor cells into the developmental pathway that
restricts options for specialization to either the osteoblast and chondrocyte pathways [ Lian & Stein, 1992].

(i) Engineered Osteoprecursor Cell Culture System
Advancements in the design of biomedical engineering technologies, especially
those supporting regenerative medicine through cell and tissue engineering,
include the use of precursor cell lines
lines, which can consistently be manipulated to
develop neotissue. A
An osteoblastic
blastic precursor cell line (OPC1), derived from
human fetal bone
one tissue from the periosteum and femur, was originally
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established to provide a consistent and reproducible culture system for evaluating
bone development and cell/biomaterial interactions, and for screening putative
differentiating factors in a culture system that would be applicable to a clinical
situation [Winn, et al., 1999]. In addition, OPC1 can be used to study the growth
and differentiation of osteoprogenitors and offers the possibility of examining
events associated with stem cell differentiation to osteoblasts. Because OPC1 is a
stable osteoblast precursor that has displayed consistent reproducible cultures, and
may be useful for elucidating bone differentiation patterns during bone
development and evaluating putative differentiating factors, it is an ideal culture
system to study the effects of vitamin D on bone development.

(ii) In vitro bone development
Several osteoblast culture systems have demonstrated that cells undergo a
temporal developmental sequence that starts with a proliferation phase and results
in fully mature osteocyte-like cells embedded in mineralized ECM [Pockwinse et
al., 1995; Owen et al., 1991]. There are three stages of in vitro bone development
that have been characterized by morphology and gene expression: (1) a
proliferation and ECM biosynthesis stage, (2) an ECM development and
maturation stage noted by an increase in ALP activity, and (3) a final stage of
ECM mineralization in which hydroxyapetite is organized and deposited (see
Figure 1-3) [Pockwinse et al., 1995; Owen et al., 1991; Lian & Stein, 1995].
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In the first stage, following initial cell-seeding, the cells actively proliferate
for the first 10 to 12 days of culture and several genes associated with ECM
formation, including procollagen type I (proColI) and osteopontin (OP), are
actively expressed then gradually decline as proliferation rate decreases and ECM
maturation begins (see Figure 1-3). Immediately following the decrease in
proliferation, ALP activity is greatly increased. This post-proliferative period
occurs between days 12 and 18, and it is during this time that the ECM matures
and becomes competent for mineralization [Pockwinse et al., 1995; Lian & Stein,
1995]. ALP expression is used as a marker for osteoblast phenotype, however its
function still remains unclear. It has been postulated to increase concentration of
inorganic phosphate, a concept known as the “booster hypothesis” [Golub &
Boesze-Battaglia, 2007]. During the third stage of bone development, ALP
expression decreases and other genes associated with bone mineralization are
expressed at maximal level [Owen et al., 1991; Lian & Stein, 1995; Golub &
Boesze-Battaglia, 2007], which include OP and osteocalcin (OC) and are known
to interact with the mineralized ECM in vivo [Lian & Stein, 1995]. OP is
expressed in both the proliferation and mineralization periods, and downregulated post-proliferatively during matrix maturation; however, during
proliferation, OP expression reaches only about 25% of its maximal level which
peaks between days 16 and 20 during mineralization. In contrast, OC, the calcium
binding protein that binds to hydroxyapatite, is expressed only post-proliferatively

21

with the onset of nodule formation, and is expresse
expressed
d maximally with ECM
mineralization in vivo and in vitro [Lian & Stein, 1995].

Figure 1-3. Temporal expression of cell growth and osteoblast phenotype during in vitro
formation of bone tissue. This figure is based on studies conducted by Lian & Stein, 1995.
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Section 1.05

Vitamin D

Vitamin D, also known as calciferol, refers to a collective group of fat-soluble
pluripotent, seco-steroid metabolites that together carry out the known vitamin D-related
functions. The classic understanding of vitamin D stems from the essential role it plays in
the regulation and maintenance of calcium and phosphorous homeostasis and bone
metabolism. Elucidating the steps required for the metabolism of vitamin D precursors,
vitaD3 (cholecalciferol) and 25OHD3 (calcidiol), to the active hormone 1,25OH2D3
(calcitriol) led to the discovery of regulatory cytochrome P-450 (CYP) hydroxylases
involved in the activation and inactivation of vitamin D, and the nuclear vitamin D
receptor (VDR) and its interactions with transcriptional machinery inside vitamin D
target cells [Jones, et al., 1998]. 1,25OH2D3 directly influences osteoblasts, by binding to
VDR, which consequently elicits nuclear and extra-nuclear cellular responses related to
the production and maintenance of the skeleton [Biswas & Zanello, 2009].
Once it was demonstrated that VDR and vitamin D regulatory CYPs were present
in multiple tissues and cells not involved in the classic endocrine actions of vitamin D, it
was acknowledged that its functions extended far beyond mineral homeostasis and bone
metabolism. It is now recognized that vitamin D is associated with the regulation of many
cellular process including proliferation, differentiation, and apoptosis in multiple tissues
in an autocrine/paracrine manner [Brannon, 2012; Hobaus et al., 2013; Jones et al.,
1998]. However, because there are few detailed reports of the extrarenal synthesis of
1,25OH2D3, and limited reporting on the extrahepatic metabolism of vitaD3, extraendocrine vitamin D metabolism is not widely recognized.
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(i) Photosynthesis of Vitamin D
Vitamin D is one of the oldest prohormes that has been produced by almost all
life forms for over 750 million years [Hollick, 2003]. The production of vitaD3
begins with the photosynthesis of the subcutaneous pro-vitamin D 7dehydrocholesterol (7-DHC) in the basal and suprabasal layers of the skin when it
is exposed to ultraviolet (UVB) light (See Figure 1-4) [Hollick et al., 2008; Jones
et al., 1998; Lehman, 2008]. Once 7-DHC is photochemically transformed to
previtamin D3 (previtaD3), then it undergoes thermal-isomerization to vitaD3
[Kumar, 1990; Lehman, 2008; MacLaughlin et al., 1982]. During prolonged
exposure to the sun, both previtaD3 and vitaD3, undergo reversible
photoisomerization reactions to biologically inert sterols, including lumisterol and
tachysterol [Lehman, 2008]. Consequently, this prohibits vitamin D toxicity from
prolonged sun exposure because it limits vitaD3 formation. PrevitaD3 is also
subject to reversal leading to the regeneration of 7-DHC [Lehman, 2008]. There
are several intrinsic and extrinsic factors that influence the conversion of 7-DHC
to previtaD3, including pigmentation, age, percent of body-fat, latitude, season,
time of day, and the usage of sunscreen [Lehman, 2008].
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Figure 1-4. Schematic of photosynthesis, metabolism, and regulation of vitamin D metabolites. Vitamin D
precursors and metabolites are in black, and metabolic enzymes are in blue.
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(ii) Vitamin D Metabolism and Regulation
After vitaD3 is endogenously made from cholesterol via themerisomerization of
previtaD3, it passively diffuses into the blood and slowly transfers to the vitamin
D binding protein (DBP), a highly polymorphic glycoprotein that is a member of
a gene family including albumin and α-fetoprotein [Berg, 1999; Kumar, 1990;
Ahmed and Shoker, 2010]. Alternatively vitamin D can be acquired by diet in
either the vitaD3 (derived from animals) or vitaD2 (derived from plants) form.
VitaD3, the metabolic precursor to 25OHD3, itself is biologically inert, or
inactive, in that it does not directly increase the active transport of calcium or
mediate any of the other vitamin D-related activities in physiological
concentrations unless it its metabolized to a more polar compound (Kumar, 1990).
There are many metabolites or isomers of vitamin D. The active metabolite,
1,25OH2D3, and the immediate metabolic precursor to the active metabolite,
25OHD3, are among the most studied. In the classic endocrine metabolic pathway
of vitamin D, both endogenous and dietary vitaD3, are transloacted by DBP to the
liver and kidney, sequentially for bioactivation. Generally, the first stop for
circulation vitaD3 is the liver, where it is hydroxylated to the major circulating
form, 25OHD3, by CYP-related 25-hydroxylases CYP2R1 (microsomal) or by
CYP27A1 (mitochondrial) [Ahmed & Shoker 2010; Norman, 1998; Jones et al.
1998]. Circulating 25OHD3 from the liver is transported via DBP to the kidney,
where it is metabolized by the biologically active form 1,25OH2D3 by 25hydroxyvitaminD3-1α-hydroxylase (CYP27B1) in the kidneys [Ahmed & Shoker
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2010; Norman, 1998; Jones et al. 1998]. CYP27B1 is a mixed function oxidase
comprised of a ferredoxin and an iron sulfur protein, and is regulated by several
factors that work in concert to maintain normal concentrations of plasma calcium
and phosphorous [Kumar 1990]. During states of calcium or phosphorus demand,
1,25OH2D3 is readily converted from the circulating 25OHD3 metabolite;
conversely, during states of calcium and phosphate homeostatic balance, 25OHD3
is metabolized to the inactive 24R,25OH2D3 metabolite [Kumar, 1990], which is
excreted from the endocrine system.
While early data suggested that the liver is the only significant site of 25hydroxylation in vivo, there have been occasional reports of extrahepatic 25hydroxylation of vitamin D3 [Jones et al., 1998; Hollick, 2010]. Recently
extrarenal metabolism of 25OHD3 to 1,25OH2D3 has been demonstrated [Zhou et
al., 2012; Hobaus et al., 2013]. In vitro, many non-renal cells, including MSCs,
bone, cartilage, keratinocytes, placenta, prostrate, macrophages, lymphocytes,
dendritic cells, and several cancer cell lines can convert 25OHD3 to 1,25OH2D3
[Zhou et al., 2012]. Several of these cell types have been shown to express both
CYP27A1 and CYP27B1, which may explain the occasional reports of
extrahepatic 25-hydroxylation of vitaD3 [Lehman, 2008; Hollick, 2010; Jones et
al.,1998]. Besides the local renal activity of 1,25OH2D3, the hormonally active
vitamin D metabolite is translocated by DBP to other target tissues that express
VDR to operate in a genomic or nongenomic manner [Lehman, 2008].
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The action of vitamin D is limited by the catabolic enzyme 24-hydroxylase
(CYP24A1), which results in a compound that is more soluble and has a
substantially lower affinity for VDR [Trump, et al., 2010; Ahmed & Shoker,
2010; Ambrecht, et al.,1998]. CYP24A1 has been shown to hydroxylate both
25OHD3 and 1,25OH2D3 to form 24,25OH2D3 and 1,24,25OH3D3, respectively
[Flanagan, et al., 2006]. The main function of CYP24A1 is to regulate the
circulating concentration of vitamin D metabolites. 1,25OH2D3 induces and
mediates CYP24A1 via an autocatalytic loop through vitamin D response
elements (VDRE) located in the promoter region of the CYP24 gene [Chen et al.,
2011]. Generally, basal expression of CYP24 is extremely low but the gene is
highly induced by 1,25OH2D3 [Geng, et al., 2011; Atkins, et al., 2007]. Thus, the
synthesis and degradation of 1,25OH2D3 is highly regulated, and the concentration
is controlled at the cellular level.

(iii) Signal Transduction and Gene Expression.
The molecular effects of vitamin D are mediated through the intra-nuclear
receptor VDR, which acts as a ligand-activated transcription factor for target
genes when bound to 1,25OH2D3 [Seiffert et al., 2004]. VDR is a member of the
superfamily of nuclear hormone receptors, and like other members of the nuclear
receptor family, is composed of distinct structural domains within the protein that
include a ligand binding domain (LBD) and DNA binding domain (DBD)
[Ahmed & Shoker, 2010]. LBD is responsible for hormone binding, strong
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receptor dimerization and interaction with co-repressors and co-activators, which
are all essential for the regulation of VDR transcriptional activities.
VDR has a high affinity for 1,25OH2D3, and following 1,25OH2D3 binding
forms a heterodimer with the retinoid X receptor, which allows it to bind to the
response/receptor element (VDRE) in the promoter regions of target genes
[Flanagan et al., 2006; Brannon, 2012; Geng et al., 2011]. VDR heterodimers and
associated factors binding to the VDRE of vitamin D responsive genes increases
the rate of transcription of vitamin D associated genes by RNA polymerase II
(RNAPII) [Adorini et al., 2007]. Responsive genes include those associated with
calcium homeostasis, immune response and maintenance of immune cells,
cellular growth, differentiation, cell cycle arrest, apoptosis, and the enzymes
required for vitamin D metabolism (Figure 1-5) [Chen et al., 2011; Flanagan et
al., 2006; Boyan et al., 2009; Geng et al., 2011]. VDR is nearly ubiquitously
expressed, and almost all cells are genetically regulated by 1,25OH2D3 [Bouillon,
et al., 2008]. In summary, VDR has been reported to regulate a large range of
genes (200-3065) and has been estimated to modulate 5-10% of the human
genome [Morris & Anderson, 2010; Flanagan et al., 2006; Hollick, 2010;
Norman, 1998; Naeem, 2010].
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Figure 1-5. The active metabolite of vitaD3, 1,25OH2D3, regulates calcium-phosphorous
calciu
homeostasis and bone health through its classic hormonal actions in concert with its nuclear
transcriptional factor, VDR, on ta
target genes containing the VDRE [Brannon,, 2012].
2012]

(iv) Nongenomic
Nongenomic[not sure what you mean by nongenomic – but this is not how
the word is typically used
used] Effects of Vitamin D.
It has previously been shown that the nongenotropic actions of 1,25OH2D3 at the
level of the plasma membrane leads to the activation of ion channels and the
induction of regulated exocytosis in osteoblasts
osteoblasts.. These activities are predicted to
be related to the bone anabolic functions of the vitamin D [Biswas & Zanello,
2009].. In osteoblasts, 1,25OH2D3 increases intracellular
lular calcium concentration by
opening calcium--permeating
permeating channels present in the plasma membrane and
depleting internal Ca2+ stores [Biswas & Zanello, 2009].. 1,25OH2D3 initiates
rapid membrane--associated
associated signaling pathways via the 1,25OH2D3 membrane
binding
ng protein PDIA3 (protein disulfide isomerase, family A, member 3) [Boyan
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et al., 2012]. The mechanisms involved in membrane-associated 1,25OH2D3
signal transduction include activation of voltage gated Ca2+ ion channels and Ca2+
influx, as well as activation of several kinase cascades including protein kinase C
(PKC) [Boyan et al., 2012]. 1,25OH2D3 activates PKC signaling in both
osteoblasts and chondrocytes via VDR and PDIA3 [Boyan et al., 2012; OlivaresNavarrete et al., 2012].

(v) Free Hormones and Local Vitamin D Storage Pools
The serum concentration of hormones depends on the concentration of their
respective transport proteins, and only the concentration of free hormone is
considered to be physiologically important [Boulion, et al.,1981], this concept is
known as the “free hormone hypothesis”. Vitamin D metabolites are transported
and circulated throughout the body by DBP, which is generally found in high
concentrations in plasma. 25OHD3 is the main ligand for DBP, and therefore the
major “circulating” form. While it was originally thought that there is no
correlation between the serum concentration of 25OHD3 and DBP, an indication
that the level of free 25OHD3 is not feedback regulated [Boulion et al., 1981], it
was recently demonstrated that the amount of DBP inversely influenced the
available free 25OHD3 in cultured human monocytes [Brannon 2012]. There has
also been a significant positive correlation between the increase of 1,25OH2D3
and DBP, which indicates that it is feedback regulated.
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The binding affinity of vitamin D metabolites to DBP plays a large role in
regulating vitamin D concentration. 25OHD3 has a very high binding affinity
(Km) to DBP, and with the high concentrations of DBP seen in plasma (0.30.5mg/ml; 5-6µmol/L) virtually all 25OHD3 molecules in the circulatory system
are bound to DBP, and only ~0.03% are found in the free form [Ahmed & Shoker,
2010; Lehman, 2008]. Although 1,25OH2D3 has lower affinity for DBP, 0.4%,
approximately 6 x 10-13 M, of 1,25OH2D3 circulating in free form, a concentration
that is approximately ten times lower than 25OHD3 [Lehman, 2008; Berg, 1999].
In a study conducted on the serum levels of DBP in pregnant and normal woman,
it was found that there was a 10-fold difference in free concentrations of
1,25OH2D3 over 25OHD3, while there was a 320-fold molar excess of total
25OHD3 over 1,25OH2D3 [Boulion et al. 1981].
Many studies have shown that antiproliferative effects of 1,25OH2D3
requires unbound concentrations higher than 10-8 M, which is equivalent to a
highly unphysiological concentration of approximately 2.5 x 10-6 M circulating in
blood [Lehman, 2008], although it is believed that local vitamin D storage pools
throughout the body that may account for this [Brannon , 2012]. According to the
‘free hormone’ hypothesis, the sterols bound to DPB are a reservoir that can be
made available to vitamin D receptors or enzymes that modify the sterols by
dissociation from the DBP [Berg, 1999]. The ‘free hormone’ and ‘local vitamin D
storage’ hypotheses change the traditional endocrine views of vitamin D
metabolism, and explain paracrine and autocrine mechanisms of vitamin D
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metabolism, involved in the regulation of proliferation and differentiation that
have been observed in vitro in response to supraphysiological doses of
1,25OH2D3 and 25OHD3 (Figure 1-6 and 1-7).
DBP may also slow the release of 25OHD3 and regulate the level of free
sterol available, as free 25OHD3 can diffuse across cell membranes, which
appears to be nearly a ubiquitous mechanism of vitamin D uptake [Brannon ,
2012], preventing the rapid metabolism and excretion of vitamin D.
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Figure 11-6. The ‘free hormone’ and ‘local vitamin D storage’ hypotheses
change the traditional endocrine views of vitamin D metabolism, and
a
explain paracrine and autocrine mechanisms of vitamin D metabolism,
involved in the regulation of proliferation and differentiation that have
been observed in vitro in response to supraphysiological doses of
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Figure 1-7.. Traditional vitamin D endocrine mode of action (A) and revised vitamin D mode of
action (B) based on the ‘free hormone hypothesis’ and the theory of ‘local vitamin D storage
pool’ [Brannon, 2012; and Berg, 1999].
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(vi) The Autocrine/Paracrine Vitamin D Paradigm
In the early 1900’s vitamin D was the fourth identified essential vitamin, thus
named vitamin “D” by convention. It wasn’t until 50 years later that it was
realized that vitamin D is metabolized and acts as a steroid hormone in an
endocrine manner, a paradigm that has dominated the classic thought of vitamin
D function until the end of the 20th century [Morris & Anderson, 2010]. Recently,
it has been demonstrated that number of organ systems are influenced by vitamin
D in an autocrine manner, that is 1,25OH2D3 is being synthesized within those
cells, and/or within adjacent cells (paracrine action) (see Figure 1-6 and 1-7). It
has been hypothesized that local production of 1,25OH2D3 in extrarenal tissues
regulates cell growth, differentiation, and apoptosis, however there are few
detailed reports and is still not widely recognized [Atkins, et al., 2007].
There has been reports of extra-endocrine CYP27 hydroxylase expression
in the parathyroid gland, lymph nodes, macrophages, prostate cells, skin, colon,
adrenal medulla, dendritic cells, endothelial cells, brain, hypothalamus, and
placenta [van Driel, et al., 2006]. Interestingly enough, the expression of the
enzymes required to metabolize and activate vitamin D were reported in human
bone cultures 25 years ago, but bone is still not identified as a vitamin D
synthesizing tissue.
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(vii) Vitamin D and In Vitro Bone Development
1,25OH2D3 influences many aspects of bone cell biology, and has been
implicated in the regulation of both osteoblastic and osteoclastic activity
affecting both resorptive and synthetic phases of bone remodeling [Atkins, et al.,
2007]. Bone remodeling is a dynamic process coordinated by osteoblasts (boneforming) and osteoclasts (bone-resorbing), in which resorption is followed by
bone formation. An imbalance in this process can lead to bone density loss and
osteoporosis. A typical feature of vitamin D deficiency is impairment of bone
formation and mineralization. Paradoxically, 1,25OH2D3 has been demonstrated
to indirectly simulate bone formation and mineralization by stimulating
intestinal calcium absorption, and induce bone resorption by inducing calcium
mobilization from bone [Suda, et al., 2012].
Interestingly enough, the benefits of using vitamin D for bone
development in vitro, is separate from the in vivo calcimic actions. 1,25OH2D3
has been demonstrated to regulate osteoblast and chondrocyte gene
transcription, proliferation, differentiation, and mineralization of ECM [Boyan
et al., 2009; Atkins et al., 2007]. In addition, 1,25OH2D3 has been shown to
stimulate the osteoblastogenesis of MSCs, which suggests that vitamin D
metabolism may play an autocrine/paracrine role in osteoblast differentiation of
MSCs [Zhou et al., 2012].
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Chapter II.

OBJECTIVES

Section 2.01

3D Cell Culture for Cartilage Tissue Engineering

Previous studies focusing on engineering cartilage have indicated that a primary
chondrocyte cell culture isolated and harvested from mature functional articular cartilage
is a logical cell choice for cartilage constructs [Hardingham, et al., 2002]. Due to the
avascular and hypoxic nature of cartilage, chondrocytes can be isolated from both postoperative and post-mortem cartilage tissue, as well as from refrigerated stored tissue
[Tew, et al., 2008]. The first objective for the present research was to develop a protocol
for harvesting articular cartilage tissue and isolating chondrocytes from the
metacarpophalangeal joints of freshly slaughtered bovine. These procedures are described
in detail in Chapter 3.
Successful engineered cartilage constructs require a combination of several
components, including the appropriate cell type and a temporary artificial and/or
molecular scaffold to provide structure for regenerating tissue [Steward, et al., 2011]. In
vivo, chondrocytes exist, proliferate, and differentiate, within a 3D enviornment. When
they are excised from their native enviornment, and placed in a 2D monolayer for
expansion, the naturally round chondrocytes, attach and spread, causing them to lose their
spherical morphology and acquire an elongated fibroblast-like phenotype. These
morphological alterations are accompanied by critical biochemical changes associated
with the loss of mechanical function. Because cartilage-specific GAG binds to water with
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such high affinity, natural hydrated biomaterials can be used to recreate the 3D
enviornment.
Using agarose as a biomaterial scaffold has been shown to allow chondrocytes to
remain round, promote chondrogenic induction, induce cartilage phenotype and support
cartilage-specific gene expression [Hardingham, et al., 2002; Steward, et al., 2011].
While agarose has an advantage in its inherent biocompatiility, the mechanical properties
of agarose can be a set back, as they have a compressive modulus that is about 15% of
native cartilage tissue [Steward, Liu, & Wagner, 2011]. Photocrosslinkable hydrogels
such as poly(ethylene glycol) (PEG) can be modified for photopolymerization, which
enables spatial and temporal control of the gelation process, and has been shown to
support MSC survival, differentiation, and accumulation of chondrogenic ECM. In the
current study, 3D culture protocols using low-melting point agarose and PEG are
described in Chapter 3 and Chapter 4 for maintaining cellular and biomolecular
constituents within defined parameters.
Mechanical and chemical signals are instrumental in the development,
remodeling,

and

pathogenesis

of

load-bearing

tissues

through

cellular

mechanotransduction. In vivo, chondrocytes experience hydrostatic, compresive, tensile,
and shear forces within a physiologic 3D environment which maintains the phenotype
and production of regenerating cartilage tissue. Abnormal mechanical forces have been
shown to alter chondrocyte behavior, resulting in pathological matrix synthesis, increased
catabolic activity (degradation), and ultimately cell death. Convential culture methods
are limited in their ability to replicate the natural balance of anabolic and catabolic
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reactions necessary for tissue remodeling and regeneration. A variety of designs have
been applied to regenerative medicine through tissue engineering applications including
rotating vessels [Pollack, et al., 2000], pressure combined with fluid perfusion
[Cartnmell, et al., 2003], and direct perfusion [Pazanno, et al., 2000]. As an extension of
these technologies, a bioreactor has been designed which provides compressive
mechanical stimulation (solid and fluid), real-time mechanical characterization, optical
inspection, and integrated ultrasonic assessment of ECM, that can fit on a shelf of a
standard incubator (Figure 1-1). Preliminary validation of the bioreactor’s form and
function, expected bioassays of the resulting matrix components, and application to
biokietic models are described in Chapter 3.
Non-destructive techniques characterising the mechanical properties of cells,
tissues, and biomaterials provide baseline metrics for tissue engineering design.
Ultrasonic wave propagation and attentuation has previously demonstrated the dynamics
of ECM synthesis in chondrocyte-seeded hydrogel constructs in a non-invasive and nondestructive manner [Kohles, et al., 2012]. In Chapter 4, an ultrasonic method to analyse
two of the construct elements used to engineer articular cartilage in real-time, native
cartilage explants and an agarose biomaterial is described.
The overall objective of this project was to characterize biomechanical influence on
the anabolic and catabolic behavior of chondrocytes cultured in a 3D enviornment, and to
characterize the developing ECM response to mechanical stimuli. In addition, protocols
which established the environment most effective in developing healthy adaptive cellular
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responses such as cellular proliferation, cytoskeleton remodeling, induction of
differentiation, and ECM regulation.
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Section 2.02

OPC1 Bone Development and Vitamin D Metabolism

A novel way of promoting cartilage and bone regeneration as a tissue development
model is through the use of MSCs or multipotent progenitor cell lines. MSCs can expand
rapidly in culture, but the rate of expansion and the yield of multipotential progenitors are
inversely related to the plating density and incubation time of each passage [Sekiya, et
al., 2002], which could lead to a heterogenous population of precursors of different
potential over time. OPC1 is a multipotent progenitor cell line derived from human fetal
bone tissue that provides a stable and reproducible culture system and represents a
homogenous osteogenic cell line with the capacity to generate programmed
differentiation [Winn, et al., 1999]. The specific objective of this project was to
characterize the influence of vitamin D and other commonly used osteogenic factors on
the programmed differentiation of OPC1 during early bone development.
Because OPC1 is a homogenous, stable, and reproducible culture system, it
provides a means to screen for putative growth and differentiation factors for bone
development. While recent studies have shown extra-renal metabolism of 25OHD3
[Zhou, et al., 2012], the immediate precursor to the active vitamin D hormone
1,25OH2D3, there has been occasional reports of extrahepatic 25-hydroxylation of the
parental precursor vitamin D3 [Jones, et al., 1998]. In the present study, the capacity for
osteoblast precursors to convert parental vitamin D3 to 1,25OH2D3 in a dose-dependent
manner was examined and described in Chapter 5. The objective of this study was to
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investigate the potential of parental vitaD3 to induce 1,25OH2D3 bone-associated
biological responses during early stages of bone development.
One major goal of bone-tissue engineering is the ability to predictably enforce the
osteoinductive program of stem and progenitor cells [De Kok, et al., 2006]. In addition to
extrahepatic vitamin D metabolism, the influence of vitamin D metabolites in
combination of commonly used osteogenic factors ascorbic acid, β-glycerophosphate,
bone morphogenetic protein-2 (BMP-2), and the synthetic steroid, dexamethasone, on
OPC1 ECM maturation and mineralization during bone development was explored. The
objective of the study described in Chapter 6 was to investigate the influence of vitamin
D metabolites vitaD3 and 1,25OH2D3 with or without osteogenic factors on the temporal
development stage sequences of early bone development in order to find the optimal
chemical environment for ECM maturation and mineralization.
The overall goal of the studies described in Chapter 5 and Chapter 6 were to
establish a reproducible culture system for the in vitro osteogenic differentitation of
human osteoblast precursor cells, and to characterize the capacity of osteoblast precursors
to convert vitaD3 to 1,25OH2D3 and the potential of vitaD3 to induce 1,25OH2D3
associated biological activities. In addition, to investigate the effects of vitamin D
metabolites as ostegenic factors on the temporal development sequence of bone
development which include proliferation, maturation, and mineralization. These studies
will provide a 2D culture foundation for future 3D engineered tissue studies using the
OPC1 cell line.
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Section 3.01

Preface

The chapter is comprised of material from a manuscript submitted to the Journal of
Nanotechnology in Engineering and Medicine as a Design Innovation Paper (NANO-111022) and published in March 2011. This paper encompasses protocols for 3D cartilage
TE culture systems and mathematical modeling that characterizes the organization,
mechanical properties, and physiologic response at multiple scales, from molecular to
cellular, and to tissue and organ levels.

Section 3.02

Authors Contributions

The work presented here was carried out in collaboration between all authors.
SSM, SSK, SRW, and RDZ defined the research theme. SSM designed the biological
methods and experiments, while SSK and AKS designed the mathematical modeling and
statistical analysis. SSM and SSK wrote the paper. All authors have contributed to, seen
and approved the manuscript.
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Section 3.03

Abstract

There has been considerable progress in cellular and molecular engineering due to
recent advances in multiscale TE technology. Such technologies allow controlled
manipulation of physiochemical interactions among cells in tissue culture. In particular, a
novel chemomechanical bioreactor has recently been designed for the study of bone and
cartilage tissue development, with particular focus on extracellular matrix formation. The
bioreactor is equally significant as a tool for validation of mathematical models that
explore biokinetic regulatory thresholds [Saha and Kohles, 2010, J Nanotechnol Eng
Med. 1(3):031005; Saha and Kohles, 2010, J Nanotechnol Eng Med. 1(4):041001]. In the
current study, three-dimensional culture protocols are described for maintaining the
cellular and biomolecular constituents within defined parameters. Preliminary validation
of the bioreactor’s form and function, expected bioassays of the resulting matrix
components, and application to biokinetic models are described. This approach provides
a framework for future detailed explorations combining multiscale experimental and
mathematical analyses, at nanoscale sensitivity, to describe cell and biomolecule
dynamics in different environmental regimes.
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Section 3.04

Introduction

Cartilage and bone defects are a leading cause of disability, an economic burden
that exceeds 28 billion dollars in orthopedic repair in the United States alone [Chao et al.,
2007]. More than 250,000 knee and hip replacements are performed each year [Chung,
2008], and the number continues to increase with an aging population suffering from
defects or deterioration of articular cartilage caused by osteoarthritis and trauma. Because
cartilage is avascular, and has a limited capability for self-repair, it has been the focus of
many bioengineering investigations in nanomedicine. TE is an evolving field that has the
potential to provide functional cartilage tissue to help the millions of people who suffer
from degenerated, diseased, or damaged articular cartilage. There have been rapid
advancements in cell-based therapies, which includes the in vitro engineering of
functional tissue substitutes for subsequent in vitro transplantation [Chung, 2008]. To
date, however, the properties and structure of native cartilage tissue have not been
entirely mimicked by engineered tissue (Figure 3-1). Limitations of the current solutions
such as autologous chondrocyte transplantation (ACT) include difficulty in obtaining a
required amount of cells for a construct and cellular dedifferentiation during expansion,
as well as degeneration at the donor site. Although recorded success rates of ACT are
between 60-90% depending on the localization of the injury [Yilmaz et al., 2010], longterm success rates are considerably lower.
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Figure 3-1: Three-dimensional reconstruction
via micro-computed tomography of a throughthickness section of human articular cartilage
[after Jadin and Sah, 2006]. The total transverse
slice dimension is 1,500 mm representing the
articular surface (top), three histologic zonal
layers, and the bony osteochondral transition
(bottom).

TE is the process of creating functional 3D tissues using cells combined with
scaffolds, signaling factors, and devices that facilitate growth, organization and
differentiation. The development of mathematical models based on the interaction
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between cells and biomaterials can help understand the basic mechanisms of cartilage
physiology [Tortelli & Cancedda, 2009]. In order to create an environment for tissue
development, the mathematical models need to characterize the organization, mechanical
properties, and physiologic response at multiple scales, from cellular to molecular to
tissue levels. Harnessing nanobiotechnology, this approach can help design new drug
development and delivery systems, regenerative medicine, and tissue remodeling
procedures [Saha and Kohles, 2010a; 2010b; 2011].
In healthy connective tissue, structural protein fibers such as collagen and elastin
fibers have diameters ranging from several tens to several hundreds of nanometers. The
nanoscale protein fibers entangle with each other to form a nonwoven mesh that provides
tensile strength and elasticity for the connective tissue [Zuewei et al., 2005]. Articular
cartilage is composed of immobilized chondrocytes which secret the cartilage specific
biomolecules that make up the tissue’s ECM [Pazano et al. 2000; Lanza et al. 2007].
Physiological regulation, synthesis and maintenance of ECM are maintained by the
chondrocytes (although only 10% of the volume) through biokinetic reactions [Saha and
Kohles, 2010a; 2010b; 2011]. The structural integrity of cartilage is derived from the
fibrous network formed by the cartilage-specific protein, collagen type II (ColII), which
is immersed in a gelatin formed by proteoglycans rich in sulfated glycosaminoglycans
(GAG), and water, which binds with such high affinity that it makes up ~70% of the total
weight [Wilson et al., 2002]. It is this unique ECM that allows low friction movement of
joint surfaces. In return, joint loading from body movement induces fluid velocities in the
tissue that maintain waste and nutrient flow, as well as ion movement. Recreating the
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unique mechanical properties that give cartilage tissue the capability of bearing
compressive loads during daily activities is a major challenge in TE.

(i)

Biomaterial Scaffolds and Three-Dimensional Culture

Recent work has shown that cells often exhibit unnatural behavior when they are
excised from their native 3D environment and confined to a 2D monolayer. The
acute disparities in cellular function between 2D and 3D cultures warrant further
biological examination [Tibbitt and Anseth, 2009]. When articular chondrocytes
are cultured in a static 2D monolayer, they lose their overall hyaline structure and
functional elasticity. In vitro expansion of such cultures is associated with cellular
dedifferentiation and reduced or total loss of their ability to redifferentiate
[Barbero and Martin, 2007; Barlic and Kregar-Velikonja, 2008]. A 2D
environment allows chondrocytes to attach and gradually spread, which causes
them to lose their spherical morphology and acquire an elongated fibroblast-like
phenotype. In our current work, we observed morphological changes that occur
within the first few days of cells cultured in a static monolayer, as the freshly
isolated cells begin to adhere and spread along the culture vessel.
Morphological alterations acquired in monolayer are accompanied by critical
biochemical changes. Loss of the hyaline morphology is associated with the
expression or total loss of aggrecan and ColII synthesis, and an increase in the
expression of fibrocartillage associated ECM molecules collagen type I (ColI) and
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versican [Barbero and Martin 2007; Barlic and Kregar-Velikonja 2008]. Hydrated
biomaterials may recreate the native 3D environment and mimic the physical
structure, biological function, and biochemical nature of ECM. Native ECM
provides physical support for cells, as well as a substrate with specific ligands for
cell adhesion and migration, and regulates cellular proliferation and function by
providing growth factors [Zuewei et al., 2005]. During healthy balanced tissue
regulation, growth factors stimulate the anabolic synthesis of essential ECM
macromolecules, a process that is complemented by the catabolic degradation of
ECM by proteinases during tissue remodeling and repair [Saha and Kohles,
2010a; 2010b; 2011]. In order for this process to take place in vitro the
biomaterial scaffold needs to degrade at a rate that compliments the synthesis of
neotissue and be responsive to the local biological environment [Bahney et al.,
2011].
For the experimental design described herein, hydrated polymers (hydrogel)
offer a biomaterial scaffold with customizable and biomimetic properties. This
material is manipulated by photopolymerization for quick formation of the liquid
mixture into gel when exposed to ultraviolet B (UVB) rays. Photopolymerization
has been examined as a method to create scaffolds with specific nanoscale
topography to promote control of cell migration and function [Elisseeff et al.,
2000].
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(ii) Mechanical Stimulation and Biological Response
Dedifferentiated chondrocytes have the capacity to redifferentiate if they are
transferred into a 3D environment that supports a spherical morphology; however,
their original phenotype may not be fully re-acquired [Barbero and Martin, 2007].
When 3D cellular constructs are grown in static culture, cells on the outer surface
of the constructs are typically viable and proliferate, while cells within the
construct may be less active or necrotic [Cartmell et al., 2003]. 3D culture
techniques that encompass biomaterials and so allow chondrocytes to remain
round yield cells that continue to express cartilage specific genes, but are limited
relative to proliferation capacity and lack the zonal distribution of cells and ECM
molecules found in native tissue [Choi et al., 2007]. Mechanical stimulation
(fluid, solid, thermal, etc.) of 3D constructs consisting of cells, biomaterials, and
growth stimulant inhibitors have shown promising results in the production of
viable load-bearing tissues such as cartilage and bone [Kohles et al., 2007]. The
transmission of biochemical and biomechanical signals from the cell-cell and cellECM interactions determines the formation of healthy tissue morphology. Thus,
preserving these interactions is essential in recreating the native tissue.
In one cartilage engineering approach, it has been suggested that isolating
cells from distinct histological zones and seeding the cells layer-wise within a
scaffold may help to preserve the native zonal distribution that contributes to the
function of absorbing compressive and tensile forces. Utilizing a multiscale
bioreactor as described in this design innovation paper, that can recreate native

52

biomechanical and biochemical stimuli, will facilitate tissue development
investigations and validate ongoing biokinetic modeling.
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Section 3.05

Eng
Engineering
ineering and Experimental Design Methods:

(i) Bioreactor Design and Application
A chemomechanical bioreactor was recently designed [Quinn et al. 2009; Chiu
et al., 2010] with the primary objectives of providing mechanical stimulus (solid
and fluid), mechanical characterization, optical inspection, and ultrasonic
assessment of engineered tissue development (Figure 33-2).
2). In humans, articular
cartilage is a thin layer of 0.5 to 5 mm thick hyd
hydrated
rated soft tissue [Mahmoudifar &
Doran, 2005]; as such the 3D culture env
environment
ironment was designed to support
constructs 5-mm
mm in height to mimic native cartilage geometry.

Figure 3-2: A solid model of the
assembled
chemomechanical
bioreactor for three-dimensional
three
culture [after Quinn et al., 2009].
The image includes the upper
electromechanical
lectromechanical actuator applying
high-resolution
resolution
load-deformation
load
control to the ‘hat’ which distributes
the mechanical stimulus to the five
load arms and, as such, to the five
culture-wells
wells below. The wells can
be rotated into the view of single
ultrasonic or digital imaging
sensors.
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A prototype bioreactor has now been fabricated for stimulating and monitoring
cell, ECM, and scaffold development of 3D engineered cartilage constructs
(Figure 3-3). The device combines a linear actuator (ElectroForce, Bose, Eden
Prairie, MN) connected to an array of five load transducers (1,000g, +/- 0.15 to
0.25%, Model 31 Mid, Sensotec/Honeywell, Golden Valley, MN). The actuator
can be controlled via displacement (+/- 2.5 mm) or force (20 N) to apply a variety
of waveforms (WinTest, Bose) for dynamic stimulation of five concurrent cubeshaped test samples (Figure 3-4). Access for a digital video microscope and
ultrasound transducers facilitate minimally invasive construct assessment. The
entire bioreactor is sized to fit inside an incubator (Galaxy R Series Incubator,
New Brunswick, Edison, NJ) with sensor control of the internal environment
chemistry, carbon dioxide (CO2), oxygen (O2), and nitrogen (N2).
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Figure 3-3: The now-fabricated, novel chemomechanical bioreactor with five culture
wells (on the left) and a load-train applying load-displacement for measuring exact loads
(on the right). The high-resolution, copper-colored load-cells measure the dynamic loads
transferred via the load-rods through the square load-platens into the culture-wells and
onto the eventual cell-biomaterial constructs.

Figure 3-4: Open-view (model) of a bioreactor test chamber for engineered tissue
chemomechanical stimulation indicating the a) cell-biomaterial construct (125 mm3
pink cube) and b) three current well designs for static and dynamic three-dimensional
culture. The middle culture-well, which provides perfused flow and dynamic culture
will be described in a future article [Kohles et al., 2011].
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Elastic moduli of 3D hydrogel-cell constructs are typically measured in
compression after 2, 4, and 6 weeks of in vitro culture time. Samples are initially
unloaded, then subjected to compressive strain at a rate of 0.5 mm/min [Rice et
al., 2009]. The compression modulus will be determined by analyzing the linear
regions of the stress versus strain curve on samples at low deformation (<15%).
Initial mechanical stimulation will relate dynamic constituent masses with elastic
properties applying a basic rule of mixtures. More complex spherical-composite
models will eventually be applied [Kohles et al., 2007]. The modeled (and
measured) scaffold and cell-ECM masses (mi) can be converted to constituent
volumes (Vi) using density values (ri):

VCE =
Cell-ECM:

Vs =
Scaffold:

mCE
ρ CE

(totaled for multiple ECM constituents)

ms
ρs

(1)

The total porosity (P) of the construct can be calculated from constituent volumes
estimated from the biomarkers and the current gross volume of the construct
composite (Vo) using the relationship:

P=

Vo − (Vs + VCE )
(V + VCE )
=1− s
Vo
Vo
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(2)

For constructs with distinct porosities, the elastic modulus of the cell-ECMscaffold

composite

structure

(Estructure)

may

be

characterized

by

the

phenomenological relationship [Martin et al., 1998]:

Estructure = Esolid (1-P) k

(3)

Where k is a curve-fit parameter and Esolid can be defined by the cell-ECM (ECE)
and polymeric scaffold (Es) moduli using the two-phase, Voigt model [Hashin and
Shtrikman, 1963]:

Esolid = vCEECE + vsEs

(4)

Here, the solid volume of the engineered construct is defined by the volume
fractions of the cell-ECM (vCE) and polymeric scaffold (vs), respectively:

v CE =
Cell-ECM:

vs =
Scaffold:

VCE
Vs + VCE

Vs
Vs + VCE where vCE + vs = 1

(5)

This preliminary micromechanical arrangement assumes that the scaffold and
neo-ECM experience equivalent deformation in response to an applied load
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[Jones, 1999]. These metrics will provide a quantitative means of comparing the
developing engineered tissues with native tissues as an approach for assessing the
designed 3D culture environment.

(ii) Cartilage Dissection and Disaggregation
In the initial preparations of cell-scaffold constructs which will be developed
into cell-ECM-scaffold constructs using the bioreactor, fresh tissue is excised
from the chondylar surface cartilage of 6 month to 2 year old bovine
metacarpophalangeal joints contributed by a local abattoir within 1 to 8 hours of
death (Mark's Meat, Canby, OR). To decrease the chances of contamination, the
joints are dissected in cold, sterile dissection solution containing a high
concentration (5%) of antibiotic/antimycotic (AB/AM) solution (100x) stabilized
(Sigma) in Dulbecco's phosphate buffered saline (DPBS; Sigma Aldrich Co., St.
Louis, MO) to give a final concentration of 250 µg/mL or 0.625 µg/mL
amphotericin B. The soft muscle and connective tissue is removed utilizing a
sterile scalpel (sizes 11 and 23), and cartilage is carved from the bone utilizing a
sterile scalpel (size 15) from the bone and separated from any remaining soft
tissue. The excised tissue is rinsed several times with cold DPBS and 2.5%
AB/AM solution through a 70-µm mesh filter (Cell Mirco Sieves TM, BioDesign
Inc. of New York), weighed, and measured for ultrasonic propagation as
described in Section vii. The resulting tissue fragments are mechanically
disaggregated and finely minced with surgical scissors and opposing scalpels into
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~1 mm3 pieces. The cells released from supporting matrix during disaggregation
are centrifuged and resuspended in 5 ml of media containing Dulbecco's modified
eagle medium mixture and Ham's F12 nutrient mixture (DMEM/F12 (1:1);
Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, HyClone), 5%
L-Glutamine (L-Glut Lonza-BioWhitaker), 1% AB/AM, and stored at 4°C until
digestion is complete. To allow timely detection of microbial contamination, it
has been suggested to incubate the fragments for 24 to 48 hrs before digestion
[Harris, Graham, & Rickwood, 2006].

(iii) Enzymatic Digestion.
The explanted tissue fragments are consecutively digested with 0.25% trypsin
(BioWhittaker, Lonza, Basel, Switzerland) and 0.5% collagenase (Liberase
Blendzyme III, Roche Diagnostics, Madison, WI) to release the chondrocytes
from the ECM with a high cell count of ~5 x 106/ml per calf hoof. Warm
trypsinization is carried out at 37°C on a hot-plate/magnetic stirrer for 1 hour in
Hank's buffered salt solution (HBSS; Lonza) supplemented with 1% AB/AM
solution. Culture media containing fetal bovine serum (FBS; Thermo Scientific
HyClone, Logan, UT) is added to inhibit trypsin activity and the cell suspension
obtained is filtered through a 70-µm sterile nylon filter to remove any tissue
debris. Cells are collected by centrifugation at 1,500 rpm for 10 min and rinsed
several times with culture media, which consisted of Dulbecco's modified Eagle's
medium and Ham's F-12 nutrient mixture (DMEM/F12: Sigma), and resuspended
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in 5 ml chondrocyte culture media containing DMEM/F12 supplemented with
10% FBS, 5% L-Glutamine (Lonza), and 1% AB-AM and stored at 4°C until
further digestion with collagenase is complete. The undigested tissue debris
collected after trypsination, which appeared more gelatinous then solid, is
digested overnight in 0.5% collagenase at 37°C for 16 to 24 h. Sterile disposable
15 ml transfer pipets (VWR Int., Radnor, PA) are used to aspirate the fragments
several times in order to release loosened cells from the gelatinous tissue debris.
Digestion is continued in the samples that appeared to have tissue fragments still
intact or a low cell count, at a higher concentration (0.75%) for an additional
hour. Isolated viable chondrocytes from each collection set (i.e., cells from
disaggregation, trypsin and collagenase digestion) were counted using a
hemocytometer and trypan-blue exclusion dye (0.4% in DPBS). The sample
collections having a cellular health viability of >75% as indicated by a lack of
trypan dye incorporation are resuspended in chondrocyte media at a concentration
of ~5 x 106/ml.

(iv) Cell-Seeding and Biomaterial Polymerization
The hydrogel scaffold mixture, consisting of poly(ethylene oxide) (PEO),
poly(ethylene glycol) dimethacrylate (PEGDM), and the photoinitiator, 1hydroxycyclohexyl phenyl ketone (Sigma Aldrich), is dissolved in sterile saline,
penicillin G, and streptomycin to form a 20% (w/v) solution [Gibson and Kohles,
2010]. The hydrogel constituents are combined in a 3:2 ratio (PEO:PEGDM). The
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UV photoinitiator creates a final concentration of 0.05% [Elisseeff et al., 2000].
Individual 125-µl aliquots of chondrocyte suspension (5 x 106 cells/ml in growth
media as applied previously [Wilson et al., 2002]) are added and polymerized
layer-wise in cubic molds of 125-mm3 under 365-nm UV light for 3 min, a
wavelength not harmful to the living cells [Fedorovich et al., 2009]. The resulting
hydrogels (five per batch) are removed from the 125mm3 cubic molds using a
sterile spatula, weighed, and measured for ultrasonic propagation (as input for
equations 1 to 5) before being placed into each of the five culture wells fabricated
for the bioreactor (Figures 3-3 and 3-4).

(v) Biomolecular Assays
Constituents representing the greatest total volume fraction and primary
influence on cartilage biology and biomechanics will be monitored during
cartilage development and biokinetic interactions. These are the chondrocytes,
proteoglycan, and collagen content. Cell density can be measured through
fluorometric assay as an indicator of proliferation or death overtime [Rice et al.,
2009]. The primary components of ECM are easily measured by colorimetric
assay after construct digestion, and constituent distribution is assessed through
histological staining of the neotissue sections. Specific proteoglycans and
collagen isoforms, namely aggrecan and collagen type II, can be quantified
through immunoassays or visualized by antibody staining [Rice et al., 2009].
Total GAG content is quantified utilizing dimethyl-methylene blue assay; total
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collagen content is quantified by a hydroxyproline assay. DNA content can be
measured by Hoeschst-33258 and related to cell number by dividing DNA content
by 7.7 ρg per chondrocyte [Rice et al., 2009]. While these techniques provide
useful information about the tissue grown in vitro, they require digestion and
destroy the samples at specific end points. Ongoing design efforts are directed
toward development of a bioreactor in which the quality of the neo-ECM and
scaffold may be measured in real-time, utilizing digital imaging and ultrasonic
sensors.

(vi) Histochemical Staining
At typical selected time points of 2, 4, and 6 weeks, constructs are removed
from the chemomechanical culture environment, fixed in 10% formalin for 8 to
24 h, dehydrated, paraffin-embedded, and partially sectioned (10-µm thick) using
a microtome. Sections are then stained with fast green and safranin-O (GAGs
stains red-orange), and Masson's trichrome method (collagen stains blue) (Figure
3-5). Colorimetric assays will determine planar and volumetric densities of the
assayed constituents as harvested time points. Remaining section geometries will
be weighed and measured for ultrasonic propagation (as input for equations 1 to
5). The biomolecular assays characterize the state of the ECM as assessment of
the tissue development as well as input for validation of the biokinetic models
(Table 3-1). The primary assays will characterize antibodies associated with
immunohistochemistry and histochemical staining to include:
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Type II Collagen as the predominant collagen in healthy articular
cartilage. Type II collagen forms a three-dimensional fibrillar network
essential for the tensile stiffness and strength of cartilage [Oesser and
Seifert 2003].

Aggrecan as the third major component of articular cartilage, constituting
the majority of the proteoglycan-hyaluronic acid polymers. These large
macromolecules are embedded within the fibrous network of collagen type
II, providing the compressibility and elasticity of cartilage. During tissue
turnover aggrecan and its fragments originating from the core protein part
of aggrecan are released into the supernatant of cartilage explant cultures.
The total aggrecan can be identified via an enzyme-immunoassay for the
quantitative determination of aggrecan and its fragments containing the
G1 and/or G2 domains that are released into the supernatant from articular
cartilage explants [Oesser and Seifert 2003].

Type I Collagen as an indicator of dedifferentiation of articular
chondrocytes during expansion of cells grown in a monolayer and as an
indicator for fibrocartilage. An assay kit is designed to quantify the
amount of ColI from bovine cell and/or tissue cultures (Chondrex, Inc.).
Type X Collagen (ColX) as an indicator of hypertrophic cartilage.
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Biomarkers

Assay Product

Cell Secretion Rate (in vitro values)

Type II Collagen

Rhuemera® Native Type II Collagen
Capture*

~1.5 to 3.0 µg per 106 chondrocytes
(basal media) [Oesser and Seifet, 2003]

Glycosaminoglycan
(GAG)

Rhuemera® Assay Kit for
Proteoglycan*

~55 to 105 mg per 106 chondrocytes
(basal media)

Type I Collagen

Rhuemera® Type I Collagen Kit*

~10 to 15 ng per 106 fibroblasts

Type X Collagen

Kit for Collagen Type X**

? µg per 106 chondrocytes

Table 3-1: Focal biomarkers and the assay products applied to evaluate the state of extracellular matrix
biokinetics. The biomarkers and the listed typical secretion standards will be measured as boundary
conditions characterizing the experimental progress of the engineered tissue development. These data will
also provide input for model initiation and validation during statistical comparison. *Enzyme-linked
immuno-sorbent assay (ELISA), Rhuemera and Immunodiagnostics System (Astarte Biologics, LLC,
Redmond, WA). ** ELISA (Antibodies-online, Atlanta, GA). ***Sircol (Biocolor Life Science Assays,
Carrickfergus, UK.

Figure 3-5: Expected cell-matrix preparations [after Rice et al., 2009]. During matrix
synthesis, cells will be distributed throughout the collagen (on the left, stained with Masson's
Trichome) and aggrecan (on the right, stained with safranin-O/fast) constituents as are typical
for this cell-scaffold arrangement. The solid dark circles each represent a single cell at ~20 mm
in diameter.
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(vii) Ultrasound Analysis
Ultrasound transmission velocities are measured in vitro with the objective of
defining acute and post facto elasticity metrics for characterizing developing
engineered cartilage constituents. Ultrasound analysis is non-destructive
techniques that can assess macroscopic construct properties and constituent
quality. Ultrasonic longitudinal (vii) and transverse (vij) wave propagation
velocities are measured in three orthogonal orientations (planar and thickness
directions) for 6 measurements per sample. The test set-up includes a pulserreceiver (Model 5058PR, Panametrics, Olympic Corp., Waltham, MA), a
multichannel oscilloscope (Model TDS460A, Tektronix, Beaverton, OR), and an
array of sending-receiving transducers: 5 MHz (Model V156), 10 MHz (Model
V112), 50 kHz (Model X1021), and 100 kHz (Models X1020 and V1548)
transducers (Panametrics) facilitating a total of at most 1,050 measurements.
Aggregate cell-ECM-scaffold densities (r) of the samples are determined and
system time delays are accounted for during each transducer arrangement. Bulk
(K = rfvii2) and aggregate (Ha = rsvii2) moduli can be measured from separated
fluid (f) and solid (s) ultrasound propagations, respectively [Shull, 2002], and
used as input for equations 3 and 4. The measurement of intrinsic ultrasonic
properties may indicate the structure and composition of the tissue under
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investigation, as well as its mechanical and physical properties [Rice et al. 2005].
Initial cartilage pieces are excised as described earlier under aseptic conditions,
sliced into 800-1000 µm sections with a microtome. Preliminary native cartilage
testing confirmed density (r = 1,330 kg/m3) and propagation velocities similar to
that reported in the literature (1,500 to 1,720 m/s) [Agemura et al., 1990].

(viii) Mathematical Model Input
Previous

mathematical

frameworks

characterized

nanoscale

biokinetic

mechanisms as stimulated within the micromechanical environment of a single
cell [Saha and Kohles, 2010a; 2010b; 2011]. The model results described the
influence of mechanical stress on the anabolic and catabolic pathways including
the interactions with cytokines (C) and growth factors (G), fundamental
regulatory processes that lead to matrix homeostasis. The engineering and
experimental designs presented here monitor the catabolic (negative influence)
and anabolic (positive influence) effects of chemomechanical stimuli (T), C, and
G on a multi-cellular level using the mathematical framework exploring these
differential interactions through time (dt):

d
(collagen + GAG) = f (C,G,collagen + GAG, λ,δ)
dt
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(6)

This computational framework defines the secretion rates of C and G as functions
(f) of the their current levels and associated rate constants derived from the tissue
engineering literature (ai, bi, and Wi) and the bioreactor controls (ξi), for i = C or
G, as previously described [Saha and Kohles, 2010a; 2010b; 2011]. The dynamic
state of the C and G is then applied as a positive or negative influence on the
accumulation rate of ECM, defined as the total amount of collagen plus GAG.
Boundary conditions for these levels will be determined from the protocols
described in Sections v and vi (Table 3-1). The dynamic state of the ECM is
defined as a function of the matrix molecules themselves and rate constants (l and
d) modified to optimize description of the model with the collected data. This is
an iterative modeling process which will allow us to initiate an assumed
biokinetic state and ‘back calculate’ the levels of C and G from the measured
ECM abundance through multiple iterations. Combinations of positive and
negative feedback/influences can be explored by varying the chemomechanical
bioreactor control system. Iterative analyses of the biokinetic models (equation 6)
are run through 5 x103 to 10 x105 normalized time steps using commercial
software (MathCAD 14.0, Parametric Technology Corp., Needham, MA) at each
sample harvest/collection period (Figure 3-6). Recreating the tissue in vitro by
utilizing the bioreactor’s capability provides an approach to validate biokinetic
models as a descriptor of dynamic inter- and intra-cellular interactions, necessary
to promote tissue synthesis, regulation and maintenance of the resulting ECM.
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tistical validation and assessment of influencing variables will be conducted
Statistical
with multiple analyses of co
co-variance
variance (MANCOVA) techniques (JMP v9, SAS
Concepts, Inc., Cary, NC).

Figure 3-6: Representative biokinetic modeling results (applying equation 6) from
expected biomolecular accumulation data as gathered from the chemomechanical
bioreactor (as boundary conditions and validation). Here the model is initially allowed to
run as the ECM concentration (%, GAG and co
collagen)
llagen) peaks in the response to local
resources and then drops to a steady state level. A chemomechanical stimulus is then
applied at 5 x105 relative time units, driving the accumulation upward in an anabolic
response.
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Section 3.06

Discussion

The successful large-scale production of engineered tissues requires an adequate
source of healthy expandable cells, the optimization of biomaterial scaffolds, and the
application of bioreactors, which mimic the in vivo environment of the body and are
amenable to scale-up [Griffith and Naughton 2002]. The in vitro environment provided
by the chemomechanical bioreactor described here provides an experimental platform to
explore cell-cell and cell-matrix molecular communication associated with ECM
synthesis and degradation as a nanomedicine application. The importance of static or
dynamic chemical and/or mechanical stimulation as characterized in biokinetic models
for cartilage has indicated mechanisms which increase proteoglycan and collagen
expression, thus suggesting an active role in maintaining healthy chondrocytic phenotype
[Tortelli and Cancedda, 2009].
The engineering and experimental design innovation described here recreates the
in vivo environment of load bearing articular cartilage on micro- to milli-scales (cells and
scaffold architecture) by measuring/modeling nano-scale biomolecular interactions. As
an approach to exploring highly resolved, intra-sample heterogeneity, distinct zonal
distributions of ECM macromolecules and chondrocyte morphology in articular cartilage
may be controlled through layer-wise construct fabrication. Articular cartilage is
stratified in a depth-dependent manner with distinct layers (superficial, middle, and
deep). Each distinct zone is well characterized by cellular shape, ECM ultra-structure,
and material properties (Figure 3-1). The superficial region has a dense network of
collagen fibers primarily aligned parallel to the joint surface, whereas collagen fiber
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orientation is more random in the middle and perpendicular in the deepest zone
[Vanderploeg et al., 2008]. Being avascular in nature, it is not a surprise that articular
cartilage has reduced oxygen tension, and each zone has varying oxygen levels that
decrease from superficial (~6% O2) to deep (~1% O2) zones [Fermor et al., 2007].
Oxygen tension can alter matrix synthesis, as well as the material properties of articular
cartilage in vitro, which can be a testable explanation for the zonal distribution along the
depth of the tissue. The bioreactor described here has the potential to test the influence of
many such parameters including oxygen tension and offers a novel arrangement in
comparison to current bioreactor designs [Cartmell et al., 2003; Lujan et al., 2011].
Ongoing efforts are exploring the chemomechanical environments in support of
dynamic cell and tissue culture. These efforts include optimizing the scaffold’s material
and structural properties (local stiffness, porosity, etc.) in a manner that supports cell,
nutrient, waste, and other biomolecular transport concomitant with controllable
mechanical properties. Future capabilities will monitor and evaluate the developing
neotissue in a nondestructive manner, accommodating real-time measurement. Utilizing a
bioreactor that encompasses the ability to culture tissue as well as monitor matrix growth
and maintenance may have a much broader scope then facilitating tissue development; it
has the potential of replacing animal models in drug response studies, cellular and
molecular engineering, and regenerative medicine. It may be possible to better
understand the roles of specific mammalian genes involved with essential metabolic
pathways without manipulating an animal model.
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Section 4.01

Preface

The following chapter encompasses material from a manuscript submitted to the
International Journal of Biomedical Engineering and Technology as a Research Paper
(IJBET) in February 2012, and published in April 2012. The application of ultrasound
analysis presented here will be used to distinguish between the fluid and solid properties
of engineered cartilage constructs, including the cell and matrix biokinetics as a nondestructive means to evaluate growing tissue, as well as a validation of previous
mathematical models described in Chapter 3.

Section 4.02

Authors Contribution

The work presented here was carried out in collaboration between all authors. SSM
and SSK defined the research theme. SSM designed the biological methods and
experiments, while SSK designed the engineering methods and mathematical modeling.
SSM, APA, RJB, JB, FG, JR, and ISW carried out the laboratory experiments. SSM and
SSK analyzed the data, interpreted the results and wrote the paper. AKS co-designed the
mathematical modeling. All authors have contributed to, seen and approved the
manuscript.

Section 4.03

Hypothesis

Using ultrasound as an application of acoustoelastic analysis, agarose, as a natural
biomaterial scaffold, will have similar elastic and shear properties as cartilage explants.
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Section 4.04

Abstract

Nondestructive techniques characterizing the mechanical properties of cells,
tissues, and biomaterials provide baseline metrics for tissue engineering design.
Ultrasonic wave propagation and attenuation has previously demonstrated the dynamics
of extracellular matrix synthesis in chondrocyte-seeded hydrogel constructs. In this paper,
we describe an ultrasonic method to analyze two of the construct elements used to
engineer articular cartilage in real-time, native cartilage explants and an agarose
biomaterial. Results indicated a similarity in wave propagation velocity ranges for both
longitudinal (1,500 to 1,745 m/s) and transverse (350 to 950 m/s) waveforms. Future
work will apply an acoustoelastic analysis to distinguish between the fluid and solid
properties including the cell and matrix biokinetics as a validation of previous
mathematical models.
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Section 4.05

Introduction

Cartilage tissue engineering (TE) is a promising solution for cellular and tissue
replacement therapies as well as an alternative for animal models used in clinical
research; however, many of the current TE approaches have not been fully validated.
Most mechanical and biochemical assessment of TE constructs require destructive
endpoint-testing and/or compromise the sterility of the bioreactor environment used
during construct formation [Walker et al., 2011]. Ultrasonic imaging is a standard clinical
diagnostic tool that is based on propagating sound waves and offers a technology for
tissue characterization and stimulation in a noninvasive and nondestructive manner. The
response to mechanical stimulation induced in passive tissues by external sources such as
low to high frequency vibration or compression can be used to analyze tissue elasticity as
a metric for tissue health [Hein et al., 1993]. Recently, it has been shown that ultrasonic
assessment can predict the process of native cartilage regeneration and engineered
cartilage histology [Hattori et al., 2005].
Native articular cartilage is divided into four distinct histological zones
(superficial tangential or resting zone; the proliferative or middle zone; the hypertrophic
or deep zone; and the calcified zone) based on the preferential orientation of matrix
molecules, cellular morphology, and biochemistry. Ultrastructural studies of adult
cartilage have shown that the preferential orientation of collagen fibrils varies from the
articular surface to the intermediate and deep zones [Agemura et al., 1990]. The depthdependent structural arrangement of chondrocytes and extracellular matrix (ECM)
macromolecules, such as proteoglycans (PG) and fibrillar collagens, mainly collagen type
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II (ColII), results in a structurally heterogeneous and mechanically anisotropic material.
For example, at any given depth from the articular surface, PG concentration may change
as a function of the distance from the chondrocytes [Jurvelin et al., 1997]. The zonal
distribution of ECM molecules gives rise to the tissue’s unique poroelastic properties and
ability to act as a load-bearing cushion in which mechanical forces transmitted through
the joint to the underlying subchondral bone can be properly distributed [Waldman et al.,
2004].
The localized biomechanics (stresses, strains, and elastic properties) of articular
cartilage ECM is thought to be actively modulated by chondrocyte-matrix interaction
driving biosynthesis regulation [Korhonen et al., 2008; Saha and Kohles, 2012].
Characterizing the mechanical properties of cartilage constituents including cells and
ECM as a means to define constitutive relationships between stress and strain may
elucidate their physical interactions and contribute to the understanding of cartilage
development, adaptation, and degeneration [Kohles et al., 2007]. In addition, the distinct
histologic zones within articular cartilage have exhibited distinct material properties at
both the cell and tissue level [Ginat et al., 2006; Shieh and Athanasiou, 2006]. Selection
of cells and replication of matrix organization based on zonal mimicry may provide
strong design specifications when constructing regenerative or tissue replacement
therapies. In this work, ultrasonic wave transmission was investigated as one of many
baseline bioengineering design metrics with the objective of characterizing and
comparing key engineered cartilage constituents.
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Section 4.06

Methods

(i) Articular Cartilage Harvest and Ultrasonic Testing
Full-thickness articular cartilage was harvested from a two-year-old steer
(Mark's Meat, Canby, OR) within 4 hours of slaughter. The cartilage was
extracted from the metacarpophalangeal joint using a scalpel (Figure 4-2). Fullthickness cartilage parallelepipeds (typically x = 4 mm, y = 4 mm, and z or t =
1.5 mm) were created from the tissue samples. Ultrasonic longitudinal (vii) and
transverse (vij) wave propagation velocities were measured in three orthogonal
orientations (planar and thickness directions indicated by i, j subscripts) for 6
measurements per sample (Figure 4-1). The experimental test set-up included a
pulser-receiver (Model 5058PR, Panametrics, Billerica, MA, USA), a
multichannel oscilloscope (Model TDS460A, Tektronix, Beaverton, OR, USA),
and an array of sending-receiving transducers: 5 MHz (Model V156), 10 MHz
(Model V112), 50 kHz (Model X1021), and 100 kHz (Models X1020 and V1548)
transducers (Panametrics) facilitating a total of 1,050 measurements. Aggregate
tissue density (ρt) of the samples was determined and system time delays were
accounted for during each transducer arrangement.
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Figure 4-1: Schematics of explant anatomic orientation and propagating ultrasonic waveforms.
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Figure 4-2: Images of harvested bovine cartilage tissue (a) and fabricated agarose hydrogel
scaffold cubes (b).
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(ii) Hydrogel Scaffold Fabrication and Ultrasonic Testing
An agarose hydrogel formulation has been widely accepted as a host-biomaterial
for cartilage TE culture [Nicodemus & Bryant, 2008], providing an appropriate
technology for the bioengineering of modern scaffolds [Mata, 2011; Morsi et al.,
2011]. Here, a 2% agarose solution was made by slowly adding low-melting
agarose (Type VII, Sigma-Aldrich, St. Louis, MO, USA) to a beaker containing
Dulbecco's phosphate buffered solution (DPBS, Sigma-Aldrich) while being
stirred on a hot plate. The concentration change due to excessive heating was
taken into consideration in order to maintain a 2% concentration by weighing the
beaker and solution prior to heating. The solution was brought to a boil for 10
minutes stirring continuously until the agarose was completely dissolved. Hot
sterile water was added to return the contents to the original weight and mixed
continuously. The mixture was allowed to cool to 45°C and casted in a 5mm x
5mm x 5 mm mold, immediately being placed in a refrigerator at 4°C for 10
minutes.
For an equal-weighted statistical comparison with the cartilage explants,
35 agarose samples were prepared (Figure 4-2). Due to the homogeneity of the
125-mm3 agarose cubes, ultrasonic longitudinal (vii) and transverse (vij) wave
propagation velocities

were only measured in the z-direction. Three

measurements per sample from each of the five sending-receiving transducers,
described above, were used facilitating a total of 525 measurements per sample.
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Aggregate biomaterial density (ρb) of all of the samples was determined and
system time delays were accounted for during each transducer arrangement.
(iii) Elastic and Statistical Analysis
The measured propagation velocities were examined as a distinguishing elastic
feature between the cartilage/hydrogel structure (when wavelength, λ > t,
typically at kHz) or the constituent matrix/polymer material (when λ < t, typically
at MHz). Transverse isotropy was tested and confirmed in the cartilage samples,
while full-isotropy was affirmed in the agarose samples. Generalized stiffness or
moduli (as a Young’s and Shear Moduli variants) were calculated (ρvii2 and ρvij2)
for both the cartilage explants and agarose samples. An analysis of variance was
applied for all comparisons (JMP v5.0.1, SAS Institute, Inc., Cary, NC, USA).
Means (+/- standard deviation, SD) are shown for graphical comparisons.
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Section 4.07

Results

In this work, ultrasonic measurements analyzed an agarose hydrogel formulation as
a scaffold substrate for cartilage TE in comparison with native cartilage samples. The
analyzed cartilage samples confirmed an aggregate density (here ρt = 1,330 kg/m3) and
both longitudinal and transverse propagation velocities similar to that reported in the
literature (vii = 1,500 to 1,720 m/s) [Agemura et al., 1990] (Figure 4-3). The statistical
influence of propagation orientation on longitudinal (p = 0.8763) and transverse (p =
0.0006) wave velocities in the native cartilage samples was statistically inconsistent.
However, the wavelength of propagating waves relative to the propagating distance as
indicated by MHz (λ < t) versus kHz (λ > t) frequencies was statistically significant for
both longitudinal (p = 0.0001) and transverse (p = 0.0001) waves within the cartilage
samples.
In comparison, the fabricated agarose cubes had a mean density of ρb = 1,110
kg/m3. A longitudinal propagation velocity range of 1,595 to 1,745 m/s was also
determined for the biomaterial indicating a statistical similarity (p > 0.05) with native
cartilage (Figure 4-4). Overall, the basic calculation addressing the ultrasonic elastic and
shear moduli for both the cartilage and hydrogel samples was dominated by similar
density, propagation velocity measurements, and water content (nearly 80%) [D’Arrigo
& Paparelli, 1988]. These influences produced statistically similar (p > 0.05) hydrated
stiffness values having large magnitudes dominated by the incompressible nature of
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water when assessed with both longitudinal and transverse wave propagation modes
(Figure 4-5).

Figure 4-3: Mean (+/- SD) longitudinal (a) and trans
transverse
verse (b) propagation wave velocities as
gathered from through-thickness
thickness (anterior
(anterior-posterior) and within-plane (superior-inferior
inferior plus
medial-lateral)
lateral) orientations of harvested cartilage explants.
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transducers.
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Section 4.08

Discussion

The application of ultrasonic wave propagation was explored as a means to
compare an agarose biomaterial as a scaffold for cartilage TE design. Here, the results
provided baseline measurements for analyzing future neotissue growth in a
nondestructive manner. It was found that 2% agarose constructs had an ultrasonic
propagation velocity similar to that of native cartilage, and that this approach may be
used to assess the integrity of agarose constructs seeded with chondrocytes while ECM
macromolecules are being synthesized without destroying the engineered tissue. Due to
the aqueous nature of both the articular cartilage explants and the agarose hydrogels, the
reported propagation values are highly dominated by the mechanical wave transfer
through the water constituent.
As a limitation in this approach, the ultrasonic propagation velocities themselves
may not provide critical information in assessing native or TE cartilage. However, the
signal resolution may be tuned in a manner sufficient to identify cellular or molecular
influences on wave propagation during chondrocyte and ECM biokinetics. The difference
in ultrasonic signals when comparing isolated agarose with cell-seeded agarose, may be
used to assess the elastic properties of chondrocytes and newly developing ECM.
Mechanical loading of hydrated materials such as cartilage tissue has also been shown to
influence ultrasonic propagation velocity measurements [Nieminen et al., 2007]. Tissueequivalent phantoms may eventually aid in standardizing the accuracy of developing cellbiomaterial construct measurements [Singh et al., 2008]. Articular cartilage is a highly
hydrated tissue due to the negatively charged PG that binds fluid within its matrix. The
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mechanical performance of cartilage is dominated by these solid/fluid interactions. When
the tissue degenerates through injury or disease, the PG and collagen network is
disturbed, altering the load transfer to the subchondral bone. This cascade of degeneration
ultimately compromises the tissue and joint mechanical properties, as recently assessed
with ultrasound [Brown et al., 2007].
Ultrasonic wave transmission offers a highly resolved technique for characterizing
these subtle changes in the tissue properties. However, distinguishing the ultrasonic
propagation through its water content (~1,482 m/s) from the composite solid components
(ECM and cells) will be very challenging. Ongoing efforts will apply forward and reverse
acoustoelastic analysis to decipher bulk (K = ρfvii2) and aggregate (Ha = ρsvii2) moduli,
which can be measured from separated fluid (f) and solid (s) ultrasound signals,
respectively [Shull, 2002; Kobayashi & Vanderby, 2007]. Recent efforts have correlated
matrix content and mechanics in developing engineered cartilage constructs with positive
success by applying reflective ultrasound [Rice et al., 2009]. In that work, the speed of
sound (SoS) and slope of attenuation (SoA) were compared between developing cellbiomaterial constructs and nondegrading hydrogel controls from 50 and 100 MHz
ultrasound data. SoA was shown to be a better indicator of the density of accumulated
matrix molecules than SoS, while SoS correlated better with mechanical modulus than
SoA.
These promising data have encouraged the incorporation of ultrasound sensors as
described within two recent reports characterizing a novel bioreactor design for cell and
tissue engineering [Mason et al., 2011; Popp et al., 2012]. This non-destructive approach
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reduces the bench-top assessment modality to a practical tool for online, real-time
evaluation of the developing analogous living system created within the bioreactor
environment. As neotissue forms within the cell-seeded agarose constructs, it will be
important to detect any critical changes to the mechanical properties in a nondestructive
manner in order to optimize TE development. Overall, ultrasonic wave propagation offers
a potential means to gather constituent content and mechanical metrics for characterizing
the biokinetics of native and engineered cartilage.

Section 4.09

Conclusion

In this work, we explored the application of ultrasonic propagation velocity as a
metric for comparing native cartilage explants and a hydrogel biomaterial as design
specifications for ongoing cartilage tissue engineering. This approach has identified both
the benefits of interfacing ultrasonic sensors with a novel bioreactor as well as the
limitations of assaying hydrated materials, where the resulting wave propagation is
dominated by the water content. A more refined acoustoelastic analysis will facilitate
distinguishing the cell and matrix biokinetics as modeled previously.
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Section 5.01

Preface

This chapter contains material from a manuscript that was submitted to:
International Scholarly Research Network (ISRN) Biomedical Engineering as a Research
Paper (MS # 956362) in March 2013. The final version was published In May 2013. The
work presented here was the 1st part of a two-series experiment on the influence of extraendocrine vitaD3 metabolism on the in vitro temporal bone development sequence.

Section 5.02

Authors Contribution

The work presented here was carried out in collaboration between all authors.
SSM, SSK, SRW, and RDZ defined the research theme. SSM designed the biological
methods and experiments, while SSK designed the mathematical modeling. SSM carried
out the laboratory experiments, analyzed the data, interpreted the results and wrote the
paper. SSK co-worked on associated data collection and their interpretation. SRW codesigned the biological experiments. All authors have contributed to, seen and approved
the manuscript.
Section 5.03

Hypothesis

The overall goal of these experiments was to demonstrate the extrahepatic
metabolism of parental vitaD3 precursor to the active vitamin D metabolite 1,25OH2D3
by osteoblast precursor cells in a dose-dependent manner. The global hypothesis was that
the conversion of vitaD3 to 1,25OH2D3 would lead to an increase in alkaline phosphatase
(ALP) activity associated with osteoblast ECM maturation and an increase ECM
mineralization indicated by calcium deposition detected by alizarin red stain (ARS).
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Section 5.04

Abstract

Osteoblastic precursors experience distinct stages during differentiation and bone
development, which include proliferation, extracellular matrix (ECM) maturation, and
ECM mineralization. It is well known that vitamin D plays a large role in the regulation
of bone mineralization and homeostasis via the endocrine system. The activation of
vitamin D requires two sequential hydroxylation steps, first in the kidney and then in the
liver, in order to carry out its role in calcium homeostasis. Recent research has
demonstrated that human-derived mesenchymal stem cells (MSCs) and osteoblasts can
metabolize the immediate vitamin D precursor 25-dihydroxyvitamin D3 (25OHD3) to the
active steroid 1α,25-dihydroxyvitamin D3 (1,25OH2D3), and elicit an osteogenic
response. However, reports of extrahepatic metabolism of vitamin D3 (vitaD3), the
parental vitamin D precursor, have been limited. In this study, we investigated whether
osteoblast precursors have the capacity to convert vitaD3 to 1,25OH2D3 and examined the
potential of vitaD3 to induce 1,25OH2D3 associated biological activities in osteoblast
precursors. It was demonstrated that the engineered osteoblast precursor derived from
human marrow (OPC1) is capable of metabolizing vitamin D3 to 1,25OH2D3 in a dosedependent manner. It was also demonstrated that administration of vitaD3 leads to the
increase in alkaline phosphatase (ALP) activity associated with osteoblast ECM
maturation and calcium deposits, and a decrease in cellular proliferation in both
osteoblast precursor cell lines OPC1 and MC3T3-E1. These findings provide a two-
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dimensional culture foundation for future three-dimensional engineered tissue studies
using the OPC1 cell line.
Section 5.05

Introduction

An osteoblastic precursor cell line (OPC1), derived from human fetal bone tissue,
was originally established to provide a consistent and reproducible culture system for
evaluating bone development, cell/biomaterial interactions, and screening putative bone
differentiating factors (Winn et al., 1999). In addition, OPC1 can be used to study the
growth and differentiation of osteoprogenitors and offers the possibility of examining
events associated with stem cell differentiation to osteoblasts. Proliferation and
differentiation of osteoblasts is regulated by their respective microenvironment, which
encompasses cells, growth factors and cytokines, and their extracellular matrix (ECM)
[Atanga et al., 2011]. Osteoblasts are a main target for calcitropic hormones including
vitamin D [Biswas & Zanello, 2009].
Several studies have demonstrated changes in bone devlopment in response to the
steroid hormone vitamin D, especially with regard to the inhibition of growth during the
proliferation stage and the stimulation of osteogenic differentiation during the maturation
and mineralization stages, albeit the outcomes appear to be variable and dependent upon
the stage of cellular maturation or differentiation at the time of hormone responsivness
[Pockwinse et al., 1995; Lian & Stein, 1995]. Because OPC1 is a stable osteoblast
precursor that has displayed consistent reproducible cultures, it is an ideal culture system
to study the effects of vitamin D on bone development, and elucidate the extraendocrine
metabolism of vitamin D in osteoblasts.
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Vitamin D, also known as calciferol, refers to a collective group of fat-soluble
pluripotent, seco-steroid metabolites that together carry out the known vitamin D-related
functions. The classic understanding of vitamin D is the essential role it plays in the
regulation and maintenance of calcium and phosphorous homeostasis and bone
metabolism. Elucidating the steps required for the metabolism of vitamin D precursors,
vitamin D3 (cholecalciferol) and 25-hydroxyvitamin D3 (25OHD3; calcidiol), to the active
hormone 1α,25-dihydroxyvitamin D3 (1,25OH2D3; calcitriol) led to the discovery of
regulatory cytochrome P-450 (CYP-related hydroxylases) involved in the activation and
inactivation of vitamin D, and the nuclear vitamin D receptor (VDR) and its interactions
with transcriptional machinery inside vitamin D target cells [Jones, Strugnel, & DeLuca,
1998]. 1,25OH2D3 directly influences osteoblast binding to the VDR, which consequently
elicits nuclear and extra-nuclear cellular responses related to the production and
maintenance of the skeleton [Biswas & Zanello, 2009]. Once it was demonstrated that
VDR and vitamin D regulatory CYPs were present in multiple tissues and cells not
involved in the classic endocrine actions of vitamin D, it was acknowledged that its
functions extended far beyond mineral homeostasis and bone metabolism. It is now
recognized that vitamin D is associated with the regulation of many cellular process
including proliferation, differentiation, and apoptosis in multiple tissues in a
paracrine/autocrine manner [Brannon, 2012; Hobaus et al., 2013; Jones et al., 1998].
Vitamin D, in the form of vitamin D3, is endogenously made from cholesterol in
the skin when it is exposed to ultra-violet light (UVB). Alternatively vitamin D can be
acquired by diet in either the vitaD3 (derived from animals) or vitamin D2 (derived from
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plants) form. There are many metabolites or isomers of vitamin D. The active metabolite
1,25OH2D3 and the immediate metabolic precursor to the active metabolite, 25OHD3, are
among the most studied. Vitamin D3, the metabolic precursor to 25OHD3, itself is
biologically inert, or inactive, in that it does not directly increase the active transport of
calcium or mediate any of the other vitamin D-related activities in physiological
concentrations unless it its metabolized to a more polar compound [Kumar, 1990].
In the classic endocrine metabolic pathway of vitamin D, both endogenous and
dietary vitamin D3 undergoes sequential steps of activation by being hydroxylated in the
liver to 25OHD3 by CYP-related 25-hydroxylase (CYP27A1) and then to 1,25OH2D3 by
25-hydroxyvitaminD3-1α-hydroxylase (CYP27B1) in the kidneys (Ahmed & Shoker
2010; Norman, 1998; Jones et al. 1998). While early data suggested that the liver is the
only significant site of 25-hydroxylation in vivo, there have been occasional reports of
extrahepatic 25-hydroxylation of vitamin D3 (Jones et al., 1998; Hollick, 2010). Recently
extrarenal metabolism of 25OHD3 to 1,25OH2D3 has been demonstrated definitively
(Zhou et al., 2012; Hobaus et al., 2013). In vitro, many non-renal cells, including
mesenchymal stem cells (MSCs), bone, cartilage, keratinocytes, placenta, prostrate,
macrophages, lymphocytes, dendritic cells, and several cancer cell lines can convert
25OHD3 to 1,25OH2D3 (Zhou et al., 2012). Several of these cell types have been shown
to express both CYP27 hydroxylase enzymes required for the activation of vitamin D3,
which may explain the occasional reports of extrahepatic 25-hydroxylation of vitamin D3
[Lehman, 2008; Hollick, 2010; Jones et al.,1998].
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The molecular effects of vitamin D are mediated through the intra-nuclear
receptor VDR, which acts as a ligand-activated transcription factor for target genes when
bound to 1,25OH2D3 [Seiffert et al., 2004]. 1,25OH2D3 has a high affinity for VDR and
upon binding forms a heterodimer with the retinoid X receptor, which allows it to bind to
the response/receptor element (VDRE) in the promoter regions of target genes [Flanagan
et al., 2006; Brannon, 2012; Geng et al., 2011]. The genes include those associated with
calcium homeostasis, immune response and maintenance of immune cells, cellular
growth, differentiation, cell cycle arrest, apoptosis, and the enzymes required for their
own metabolism [Chen et al., 2011; Flanagan et al., 2006; Boyan et al., 2009; Geng et al.,
2011]. 1,25OH2D3 influences many aspects of bone cell biology, and has been implicated
in the regulation of both osteoblastic and osteoclastic activity affecting both resorptive
and synthetic phases of bone remodeling [Atkins, et al., 2007]. In addition, 1,25OH2D3
has been demonstrated to regulate osteoblast and chondrocyte gene transcription,
proliferation, differentiation, and mineralization of ECM [Boyan et al., 2009; Atkins et
al., 2007]. More than 30 tissues are known to have nuclear receptors for 1,25OH2D3, and
it is known to regulate the function of more than 200 genes [Flanagan et al., 2006;
Hollick, 2010; Norman, 1998; Naeem, 2010]. Because of its role in proliferation and
differentiation, it has been hypothesized that the local production of 1,25OH2D3 in
extrarenal tissues serves to regulate growth and differentiation in an autocrine/paracrine
fashion [Atkins et al., 2007; Lehmann & Meurer, 2003].
Despite the increase in research over the last few decades, further investigation on
vitamin D metabolism and regulation needs to be carried out in order to elucidate extra-
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endocrine metabolism and local production of 1,25OH2D3. While there has been an
increase in the reports of extrarenal 1,25OH2D3 synthesis and occasional reports of
extrahepatic 25-hydroxylation of vitamin D3, to our knowledge, there is no detailed
analysis of extrahepatic vitamin D3 metabolism in osteoblast precursors. Furthermore,
paracrine/autocrine regulation and gene expression that results in local changes in
proliferation and differentiation need to be further investigated to understand the potential
application of vitamin D for regenerative medicine. In this study, we investigated whether
osteoblast precursors have the capacity to convert the parental vitamin D precursor,
vitamin D3, to 1,25OH2D3 and examined the potential of vitamin D3 to induce 1,25OH2D3
associated biological activities in osteoblast precursors.

Section 5.06

Materials and Methods

(i) OPC-1 and MC3T3-E1 Cell Cultures
Vitamin D3 (cholecalciferol) and 1,25OH2D3 (calcitriol) were purchased and
maintained in 10 mM and 10 µM stock solutions in ethanol, respectively (SigmaAldrich, St. Louis, MO). All other reagents and chemicals were purchased from
the same vendor unless otherwise indicated. Original OPC1 and MC3T3-E1 cell
lines were cultured on-site (Department of Molecular & Medical Genetics,
Oregon Health & Science University, Portland, OR). Cells were cultured at
populations of 2.5 x 105 in 75 cm2 tissue culture flasks in alpha modified essential
medium (α-MEM) with 5% fetal bovine serum (FBS). Once confluent, OPCs
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were plated in 12-well plates after trypsin-ethylenediaminetetraacetic acid
(EDTA) enzymatic removal and counted with 0.4% trypan blue (1:1) on a
hemacytometer. Cultures were then prepared in duplicate at a seeding density of
2.5 x 104 cells/well in the initial bone medium (designated as BM-) with 200mM
L-Glutamine and antibiotics for at least 4 hours before creating experimental
groups based on additive culture medium. Six types of medium-based groups
were prepared. BM- provided a negative control (Group 1) and the additional
groups included: BM- supplemented with 1 µM vitamin D3 (Group 2); BMsupplemented with 10 nM 1,25OH2D3 (Group 3); BM- supplemented with
osteogenic factors (BM+) comprised of 10 mM β-glycerophosphate, 10nM
dexamethasone, and 50 µg/ml of ascorbic acid phosphate (Wako Chemical,
Osaka, Japan) represented the positive control (Group 4); BM+ supplemented
with 1µM vitaD3 (Group 5); and BM+ supplemented with 10nM 1,25OH2D3
(Group 6). Fresh medium was added every 1 to 3 days.

(ii) Cell Proliferation
OPC1 and MC3T3-E1 cell lines were evaluated for growth kinetics while
maintained in the presence of vitamin D metabolites, vitaD3 and 1,25OH2D3, with
(BM+) or without (BM-) osteogenic factors, at the indicated experimental group
concentrations. Each sample set was cultured for at least two weeks in duplicate
or quadruplicate. Every 2 to 5 days, following the addition of experimental media
and at the end of each incubation period, cell proliferation was measured using
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crystal violet solution (CVS, Sigma-Aldrich). Cultures were rinsed with
Dulbecco’s phosphate buffered saline (DPBS) and fixed for 15 minutes in 95%
ethanol. The fixed cells were rinsed several times with distilled water, and stained
for 10 minutes with CVS. The CVS was then extracted from the cells after a 4 h
incubation in 1% Triton X-100 at room temperature. The samples were then
stored at -80°C until the end of each experimental period. Triton extracts were
measured at 570 nm on a microplate reader (Cary 50, Varian Australia Pty. Ltd).
Absorbance values were converted into cell numbers extrapolated from standard
growth curves.

(iii) Alkaline Phosphatase
As described above, OPC-1 and MC3T3-E1 were treated with both vitaD3 and
1,25OH2D3 in the BM- and BM+ experimental groups. Alkaline phosphatase
(ALP) activity was measured every 3 to 4 days. At the end of the incubation, the
cell layers were washed three times with DPBS, scraped off of the plates with 500
µl DPBS and stored at -80°C until the end of each experimental period (2 to 3
weeks). Each sample was subjected to three freeze-thaw cycles in order to lyse the
cells. ALP activity in the cell lysates was measured using ρ-nitrophenyl phosphate
liquid substrate system at 37°C for 30 minutes. Protein content was measured
using a micro-volume spectrophometer system (Epoch, Biotek, Winooski, VT).

107

(iv) Matrix Mineralization
A histochemical analysis of mineralization was evaluated utilizing an Alizarin
Red S (ARS) assay. ARS staining is used to evaluate calcium-rich deposits by
cells in culture, and is considered a functional in vitro endpoint reflecting
advanced cell differentiation (Hoemann et al. 2009). In brief, after 10 to 15 days
in culture, cells were fixed in 95% ethanol for 15 minutes, then rinsed thoroughly
with distilled water and stained with 40 mM of ARS (pH = 4.1) at room
temperature for 20 min with gentle shaking. The cell layers were efficiently rinsed
with distilled water and observed both grossly and microscopically. For semiquantification, ARS was extracted from the cells after incubating for one hour in
at room temperature in 10% volume to volume (v/v) acetic acid with gentle
shaking, and then the residual dye was further extracted by scraping the cells and
heating at 85°C on a heating block with a layer of mineral oil to prevent
evaporation. The samples were neutralized with 10% (v/v) ammonium hydroxide
and the extracts were read at a resolution of 405 nm on the microplate-reader. The
samples were compared to a serially diluted ARS standard. The resulting data
were normalized using cell numbers extrapolated from the CVS proliferation data.

(v) Vitamin D3 Metabolism
Vitamin D metabolism by OPC1 was performed in a dose-dependent manner
over a 24-hour period. The conversion of 1,25OH2D3 from vitamin D was
quantitatively measured using an enzyme-linked immuno sorbent assay (ELISA)
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kit (Human1,25-dihydroxyvitamin D3 DVD/DHVD3, NB-E10878, Novatein
Biosciences, Cambridge, MA). OPC-1 was plated in 6-well plates at a seeding
density of 105 cells/well. Upon confluency, experimental media was added in
duplicates when creating experimental groups slightly modified from those
described in Section 2.1: base medium (BM-) provided a negative control (Group
1): BM- supplemented with 10 nM 1m25OH2D3 as a positive control (Group 2);
BM- supplemented with 10 nM vitaD3 (Group 3); BM- supplemented with 1 µM
vitaD3 (Group 4); and BM- supplemented with 10 µM vitamin D3 (Group 5). The
assay was carried out via manufacturer’s protocol.

(vi) Statistical Analysis and Mathematical Modeling
Statistical analyses were carried out using commercial software (Prism, Irvine,
CA; JMP Pro v10, SAS Concepts, Inc., Cary, NC; Excel, Microsoft, Redmond,
WA). Data were expressed as means ± standard error of the mean (SEM) of
samples characterized in three two-week sample sets plated in duplicate or
quadruplicate, and assayed in duplicate (n = 12 or n = 24, respectively). One-way
and two-way analysis of variance (ANOVA) and linear regression statistically
assessed the culture treatments through time and between experimental groups,
with asterisks of *p<0.05, **p<0.01 and ***p<0.001 indicating varying levels of
statistical significance. Bonferonni Post-test (direct comparisons with controls)
and Dunnett’s Test (pairwise comparisons) were applied where appropriate.
Through the ELISA assay protocol for examining the dose-response of the
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metabolized form of vitamin D, the input dosage levels (x-values) were controlled
and distributed at logarithmic concentration levels (in units of ng/ml). A log-base10 model was applied to the resulting response data (y-values in pmol/mg protein)
in the form:

y = m Log10 x

(1)

Here, the coefficient (m) was identified as a fitting parameter optimizing the
model’s representation of the collected data. The model was applied to the
metabolized vitamin D concentration data. Least squares estimates were
constructed for the log-coefficient via a quasi-Newton convergence method with
commercially available software (Solver, Frontline Systems, Inc., Incline Village,
NV; Excel, Microsoft, Redmond, WA). The model fit was again determined by
minimizing the root mean square error (RMSE) between the actual and response
concentrations. The correlation coefficient (R2) further assayed the strength of the
modeled relationship.

(vii) Microscopic Imaging
Microscopic images were taken using an advanced transmitted light inverted
microscope

(EVOS-XL)

and

accompanying

software

(EVOS3),

both

commercially available (Advanced Microscopy Group, Bothell, WA). Images
were processed using an open source, image-processing package (FIJI, ImageJ
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v1.47d, National Institutes of Health, Bethesda, MD). To maintain consistency,
each image was processed in the same manner including maintaining consistent
light intensities during optical density measurements. The operations included the
background subtraction command, mean filter, and local contrast (CLAHE
commands: blocksize 100, bin 256, and maximum slope 2.50, respectively).
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Section 5.07

Results

(i) ALP Activity and Early Matrix Mineralization
As described, in order to determine the optimal dose of vitaD3, OPC1 and
MC3T3-E1 cells were cultured at a seeding density of 5.0 x 104 in quadruplicates
with 1 or 10 µM vitaD3 in standard bone medium (BM-), or in a BM- vehicle
control containing the equivalent amount of ethanol for 10 days in 12-well plates.
After 10 days, two wells from each group were prepared for ALP assay, and two
wells were stained with ARS to assess ECM calcium deposition. [the previous
sentences are Methods, and should be moved to that section] OPC1 treated with
vitamin D3 at concentrations of 1 or 10 µM had a statistically significant (p <
0.001) increase in ALP activity compared to that of the control (Figure 5-1).
There was no statistically significant difference (p > 0.05) between experimental
groups containing either 1 µM or 10 µM vitamin D3. There was also no
statistically significant difference (p = 0.2388) in ALP activity between MC3T3E1 treated with either 1 µM or 10 µM vitamin D3 compared to that of the control,
however in the wells treated with 10 µM vitamin D3 we observed a variable affect
on ALP activity and an adverse affect on cell viability (not shown), which was
observed microscopically throughout the experiment (Figures 2 and 3). There was
not a significant increase in calcium deposition in ECM in either cell lines
compared to the ethanol vehicle control (p > 0.05).
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Figure 5-1.
1. Alkaline phosphatase activity (ALP) off osteoblast precursor OPC1 and
MC3T3-E1
E1 after 10 days in culture after being treated with or without vitaD
vita 3 (BMControl). After 10 days there was not a significant effect ((p = 0.2166) on ALP
activity between treatment wi
with either 1 µM or 10 µM vitaD3, however there was an
overall statically significant increase ((p = 0.0026) in ALP activity between vitaD
vita 3
treated cultures and controls.
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Figure 5-2. Osteoblast precursor cell lines OPC1 (A
(A-C) and MC3T3-E1 (D-F)
F) stained with ARS
after 10 days in culture. OPC1 without treatment of vitamin D3 (ethanol control) (A) did not absorb
a statistically significant amount of ARS per cell population (see Figure 3), than with treatment of
either 1 µM vitamin D3 (B) or 10 µM vitamin D3 (C).. Similar results were seen with MC3T3-E1
MC3T3
without vitamin D3 (ethanol control) (D), 1 µM vitamin D3 (E), and 10-µM vitamin D3 (F).
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Figure 5-3. Semi-quantification
quantification of matrix mineralization was conducted by taking the
optical density (resolution, 450 nm) of the ARS extracted from each treatment group
(shown in Figure 2). Vitamin D3 at both 1 µM and 10 µM
M did not have a statistically
significant effect
ect on the ECM mineralization of OPC1 ((p = 0.2881) or MC3T3-E1
E1 (p
( =
0.1101) after 10 days, compared to the control group.
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(ii) Influence of Vitamin D3 and 1,25OH2D3 on Osteoprecursors
(a) Antiproliferative Effects
As described, OPC1 and MC3T3-E1 were cultured for two weeks with
either 10-µM vitaD3 or 10 nM 1,25OH2D3 with (BM+) or without osteogenic
factors (BM-), and then compared to BM- and BM+ ethanol vehicle controls.
Proliferation kinetics was quantitatively compared after conducting a CVS assay
as a function of time. The CVS proliferation assay indicated a statistically
significant inhibition of cell proliferation in OPC1 treated with 10 µM vitaD3 in
the same manner as cells treated with 10 nM 1,25OH2D3, compared to that of the
BM- and BM+ ethanol controls (shown as absolute cell populations and
percentages in Figures 5-4 and 5-5, respectively). Groups containing BM+
overall, had lower proliferation rates than with BM- groups, however groups
treated with BM+ containing either vitaD3 or 1,25OH2D3 were significantly lower
then the BM- groups. Growth kinetics of MC3T3-E1 cultured with BM+ and
10µM vitaD3 was indistinguishable from cells cultured in BM+ containing 10nM
1,25OH2D3 (shown as absolute cell populations and percentages in Figures 6 and
7, respectively).
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Figure 5-4. Absolute proliferation of OPC1 cells maintained in six types of tissue culture
medium over three two
two-week
week periods (n = 24). At day 5, the OPC1 cell counts in the wells
containing vitamin D m
metabolites
etabolites ± osteogenic factors (BM+) were statistically lower then than
the negative control (BM
(BM-). OPC1 treated with BM+ and 1,25OH2D3 experienced the largest
statistically (p < 0.001) anti
anti-proliferative effect. The effect of vitamin D3 was similar to
1,25OH2D3 in both groups of medium.
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Figure 5-5. Percent proliferation of OPC1 cells maintained in six types of tissue culture medium
over three two-week
week periods ((n = 24). By 7 to 10 days, the OPC1 cell counts in the wells
containingg vitamin D metabolites ± osteogenic factors (BM+) were statistically lower then than
the negative control (BM-).
). By day 10, OPC1 treated with BM+ and active 1,25OH2D3 remained
around 50% of the BM- cellular confluency. In both BM
BM- and BM+ groups, vitamin D3 treated
cells proliferated in a manner very similar to those treated with 1,25OH2D3.
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Figure 5-6. Absolute proliferation of MC3T3
MC3T3-E1
E1 cells maintained in six types of tissue
culture medium in duplicates over three two
two-week periods, and assayed in duplicates (n =
12). Two types of medium was used, one with osteogenic factors (BM+), and one without
(BM-).
). At day 5, the MC3T3
MC3T3-E1
E1 cell counts in the wells containing vitamin D metabolites
± osteogenic factor were statistically lower then than the negative control (BM-).
(BM MC3T3E1 cells treated with BM+ and vitamin D3 were indistinguishable from 1,25OH2D3, in that
both experienced the largest statistically ((p < 0.001) anti-proliferative
proliferative effect.
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Figure 5-7. Percent proliferation of MC3T3-E1
E1 cells maintained in six types of tissue
culture medium. At day 10, the OPC1 cell counts in the wells containing vitamin D
metabolites ± osteogenic factors (BM+) were very statistically lower (***) then than the
negative control (BM-)) and remained at around 50% of the BM- cellular confluency. By
day 10, MC3T3-E1
E1 cells treated with BM+ and vitamin D3 were indistinguishable from
1,25OH2D3, as in the absolute proliferation, both experienced the most significant (p
( <
0.001) anti-proliferative
proliferative effect.
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(b) ECM Maturation
Increased ALP activity was directly associated with osteoblast function and
matrix maturation during the active stages of bone development (Figure 8).
Treatment of OPC-1 cells with standard bone medium (BM-) and both vitaD3 and
1,25OH2D3 stimulated a 2 to 3 fold increase in ALP activity after two weeks
relative to the parallel control culture, while treatment with osteogenic medium
(BM+) containing 1,25OH2D3 stimulated a 5 fold increase in ALP activity in
comparison to BM- and a 20% increase in comparison with the BM+ control
(Figure 9). However, treatment of MC3T3-E1 cells with BM- containing either
vitaD3 or 1,25OH2D3 showed a slight increase in ALP Activity, while BM+
containing either vitamin D metabolite was increased by 20% when compared to
the parallel control, and a 70 to 80% increase when compared to the BM- control
(Figure 5-10).
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Figure 5-8. ALP activity of OPC1 and MC3T3
MC3T3-E1
E1 cells maintained in six types of tissue
culture medium aggregated over three two
two-week periods (n = 12). After two-weeks,
two
the
OPC1 ALP activity of 1,25OH2D3 and osteogenic factors (BM+) treated cells were
statistically greater when compared to the negative control (BM
(BM-).
). ALP activity of OPC1
treated with vitamin D3 and BM+ was significantly higher then BM-,, but not higher then the
BM+ control containing ethanol vehicle. All cellular groups containing BM+ had a
significantly higher ALP activity compared to the control within the MC3T3
MC3T3-E1
E1 cell line.
MC3T3-E1
E1 response to vitamin D3 was indistinguishable from
rom the response to 1,25OH2D3
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Figure 5-9. ALP activity of OPC1 cells maintained in six types of tissue culture
medium described over three two
two-week periods (n = 12). After two-weeks,
weeks, the OPC1
ALP activity of 1,25OH2D3 and osteogenic factors (BM+) treated cells were
statistically greater than the negative control (BM
(BM-).
). ALP activity of OPC1 treated
with vitamin D3 and BM+ was significantly higher than BM-, but not higher than the
BM+ control containing ethanol vehicle.
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Figure 5-10. ALP activity of MC3T3
MC3T3-E1
E1 cells maintained in six types of tissue culture
medium and characterized over three two
two-week periods (n = 12). After two-weeks,
two
the
MC3T3-E1
E1 ALP activity of 1,25OH2D3 and osteogenic factors (BM+) treated cells were
again statistically greater than the negative control (BM
(BM-).
). All groups containing BM+ had
a statistically greater ALP activity compared to the control in the MC3T3
MC3T3-E1
E1 cell line. The
MC3T3-E1
E1 response to vitamin D3 treatment was indistinguishable from the response to
1,25OH2D3 treatment.
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(c) ECM Mineralization
The ability to mineralize the ECM during bone development provides the
functional niche of osteoblasts in vitro and in vivo (Halvorsen et al., 2001). OPC1
groups cultured in BM+ containing vitaD3 (n = 8) or 1,25OH2D3 (n = 8) had a
statistically larger amount of ECM calcium compared to the BM- (p < 0.001) and
BM+ (p = 0.027) ethanol vehicle controls based on ARS measurements (Figure
11). The optical density of the OPC1 cell culture (measured in normalized ARS),
increased by 100% relative to the negative control (BM-) and by about 10%
compared to the BM+ parallel control (Figure 13). OPC1 cells treated with BM+
and vitaD3 (39.68 ng/mg/106 cells ± 0.75, n = 8) were indistinguishable from cells
cultured with BM+ and 1,25OH2D3 (39.69 mean ± 1.00, n = 8) (p<0.05). MC3T3E1 groups cultured in BM+ containing vitaD3 (n = 8) or 1,25OH2D3 (n = 8) had a
statistical greater amount of ECM calcium compared with treatment groups with
only BM- (p < 0.001). Meanwhile, cultures with BM+ and 1,25OH2D3 had a
statistically greater amount of ECM calcium compared with the BM+ parallel
control (p = 0.0055) (Figures 12 and 13).
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Figure 5-11. Osteoblast precursor cell lines OPC1 stained with ARS after two weeks in
experimental conditions. Images of OPC1 cells without either osteogenic factors (BM-)
(BM or vitamin
D (ethanol control) (A), BM
BM- with 1 µM vitamin D3 (B), and BM- with 10 µM
M vitamin D3 (C),
consistently did not absorb a statistically perceptible amount of ARS compared to groups
containing
ining osteogenic factors (BM+) (D
(D-F).
F). However, cells cultured with BM+ and 1 µM vitamin
D3 (E), and BM+ with 10 µM vitamin D3 (F) had a statistically significant (p < 0.05) amount of
calcium associated with ECM mineralization compared to the BM+ control (D
(D).
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Figure 5-12. Osteoblast precursor cell line MC3T3
MC3T3-E1
E1 stained with ARS after two weeks within
the experimental treatment groups. MC3T3
MC3T3-E1
E1 cells without either osteogenic factors (BM-)
(BM or
vitamin D (ethanol control) (A), BM
BM- with 1µM vitamin D3 (B), and BM- with 10 nM 1,25OH2D3
(C), consistently did not absorb a significant amount of ARS compared to groups containing
osteogenic factors (BM+) (D
(D-F). Cells cultured with vitamin D3 and BM+ (E) were statistically
significant compared to the negative control (A), but were not comparable with the parallel
control (D). However, cells cultured with BM+ and 10 nM 1,25OH2D3 (F) had a statistically
significant (p = 0.0055) amount of calcium associated with ECM mineralization compared to the
BM+ control (D).
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Figure 5-13. Semi
Semi-quantification
quantification of matrix mineralization of cultured experimental
groups qualitatively shown in Figuress 11 and 12). OPC1 treated with vitamin D3 or
1,25OH2D3 in BM+ had a statistically significant ((p < 0.05) amount of calcium
deposition in comparison to both BM
BM- and BM+ controls. MC3T3-E1
E1 cells cultured
with 1,25OH2D3 in BM+ had a statistically significant (p = 0.0055) amount of
calcium deposition in comparison with both BM
BM- and BM+ controls.
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(iii) Endogenous 1,25OH2D3 Synthesis by OPC1.
OPC1 cultures were tested for their ability to synthesize 1,25OH2D3 from the
parental precursor vitaD3. For this dose-response assay, cells were cultured at
high density in order to maximize the concentration of secreted 1,25OH2D3. Low
serum conditions were also used and compared with a serum control to account
for any potential influence of vitamin D metabolites present in the serum. OPC1
cultured in the presence of vitaD3 produced a detectable level of 1,25OH2D3 that
elevated with increasing concentration. The synthesis of 1,25OH2D3 in OPC1
correlated logarithmically to the dosage of vitaD3 when applying the log-model of
equation 1 (R2 = 0.9898, p = 0.0051, m = 7.23 ng/ml) (Figure 5-14).

129

Figure 5-14.
14. Endogenous production of 1,25OH2D3 by OPC1 in response to
incubation with vitamin D3. A 1,25OH2D3/VDR ELISA was performed to analyze the
metabolism of precursor vitamin D3 to the hormonally active form. The dose of
vitamin D3 was controlled and administered at logarithmic concentration levels. A log
base-10
10 model was applied to the resulting response data.

130

Section 5.08

Discussion

We investigated whether osteoblast precursors have the capacity to convert vitaD3
to 1,25OH2D3 and examined the potential of vitaD3 to induce 1,25OH2D3 associated
biological activities in osteoblast precursors. The active form of vitamin D, 1,25OH2D3,
is generated from the parental precursor of vitamin D3which requires two sequential
hydroxylation steps catalyzed by mitochondrial cytochrome P450 enzymes, CYP27A1
and CYP27B1, respectively (Hewison et al., 2004). We found that OPC1 is capable of
synthesizing 1,25OH2D3 by administering vitaD3 in a dose-dependent manner, and that
the influences of vitaD3 on antiproliferation and osteoblast differentiation was very
similar to 1,25OH2D3. It was also found that vitaD3 induced ALP activity and calcium
deposition associated with ECM maturation and mineralization during early bone
development in a manner that was indistinguishable from groups treated with
1,25OH2D3. These findings have important implications for bone and vitamin D research
because it provides further evidence that local production of active 1,25OH2D3 can occur
in osteoprecursors and the local metabolism of vitaD3 can influence bone development.
Several osteoblast culture systems have demonstrated that cells undergo a
temporal developmental sequence that starts with a proliferation phase and results in fully
mature osteocyte-like cells embedded in mineralized ECM (Pockwinse et al., 1995;
Owen et al., 1991). There are three stages of in vitro bone development that have been
characterized by morphology and gene expression. These are (1) a proliferation and ECM
biosynthesis stage, (2) an ECM development and maturation stage noted by an increase in
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ALP activity, and (3) a final stage of ECM mineralization in which hydroxyapetite is
organized and deposited (Pockwinse et al., 1995; Owen et al., 1991; Lian & Stein, 1995).
In the first stage, following initial cell-seeding, the cells actively proliferate for the first
10 to 12 days of culture and several genes associated with ECM formation, including
type I collagen and osteopontin, are actively expressed then gradually decline as
proliferation rate decreases and ECM maturation begins. We report that both vitaD3 and
1,25OH2D3 had similar effects on two osteoprecursor cell lines, which influenced the
proliferation stage of bone development by significantly hampering the growth rate.
Immediately following the decrease in proliferation, ALP activity is greatly
increased. This post-proliferative period occurs between days 12 and 18, and it is during
this time that the ECM matures and becomes competent for mineralization (Pockwinse et
al., 1995; Lian & Stein, 1995). Here, ALP activity of untreated osteoprecursors steadily
increased, while the groups containing osteogenic factors (BM+) and either vitaD3 or
1,25OH2D3 increased more then 10 fold over a two week period of time. While the
measurement of increased ALP expression is used as an osteogenic marker as an
indication of osteoblast phenotype, its function still remains unclear. It has been
postulated to increase concentration of inorganic phosphate, a concept known as the
“booster hypothesis” (Golub & Boesze-Battaglia, 2007). During the third stage of bone
development, ALP expression decreases and other genes associated with bone
mineralization are expressed at maximal level (Owen et al., 1991; Lian & Stein, 1995;
Golub & Boesze-Battaglia, 2007). These bone cell synthesized proteins include
osteopontin (OP) and osteocalcin (OC) and are known to interact with the mineralized
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ECM in vivo (Lian & Stein, 1995). OP is expressed in both the proliferation and
mineralization periods, and down-regulated post-proliferatively during matrix maturation;
however, during proliferation, OP expression reaches only about 25% of its maximal
level which peaks between days 16 and 20 during mineralization. In contrast, the calcium
binding protein OC, which binds to hydroxyapetite, is expressed only post-proliferatively
with the onset of nodule formation, and is expressed maximally with ECM mineralization
in vivo and in vitro (Lian & Stein, 1995). We saw minimal calcium mineralization after
two weeks in untreated cell cultures as well as calcium mineralization of the ECM in
cultures that were treated with osteogenic factors (BM+) and vitaD3 or 1,25OH2D3.
However, further studies need to be carried out for a longer duration to see maximal
levels of ECM mineralization that is associated with bone development.
The osteoprecursor cultures observed in the present work were non-confluent
cultures with actively dividing cells. Because vitamin D has an anti-proliferative effect, it
is important to look at its influence on osteoblast precursors after proliferation begins to
decrease in order to get a better understanding of how vitamin D effects a confluent cell
population. Both OPC1 and MC3T3-E1 cultures treated with vitaD3 or 1,25OH2D3 did
not reach confluency during the 15 day culture period, while the control groups reached
confluency at around 10 to 12 days after an initial seeding density of about 6,500
cells/cm2. Confluent osteogenic cultures, including MC3T3-E1 cells and human bone
marrow derived stromal cells (BMSCs), follow a two-stage developmental process
including a 1 to 2 week initiation phase during which cells slowly proliferate, express
ALP activity and other bone specific genes, and produce and assemble a collagen matrix,
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and a second maturation phase occurring in weeks 2 to 3 in which ECM mineralization is
observed (Hoemann et al., 2009). Mineralization has been demonstrated in BMSC
cultures that achieve a minimal ALP activity (~0.25 nmol/min/µg protein or 1.2
nmol/min/10,000 cells) at some point during the 2 to 3 week culture period, albeit some
BMSC cultures can produce high-levels of ALP in vitro without ever mineralizing
(Hoemann et al., 2009). Treatments applied here tended to speed up maturation at the
expense of proliferation, hence confluencey would be achieved more slowly (or not at all,
in this case) relative to control cultures. The effects of vitamin D on ALP activity and
mineralization of ECM on confluent OPC1 cultures is currently under way.
One limitation here is that because supra-physiological doses (≥ 10-7 M) of vitaD3
(10 µM) and 1,25OH2D3 (10 nM) were used to achieve a maximal response, it is unclear
how relevant our findings are to the action of lower vitaD3 levels within the physiologic
range. In vivo, doses of vitaD3 as low as 10 µg (400 IU) have been shown to stimulate
bone mineral augmentation in adolescents (Viljakainen , et al., 2006), and the
administration of physiological doses of 1,25OH2D3 has been shown to cure vitamin Ddependency rickets I (Vanhooke, et al., 2006). Our findings indicated, for an in vitro
system, supra-physiological doses had a positive effect on bone maturation and
mineralization and a negative response in cellular proliferation.
Another limitation is that an insufficient amount of RNA was obtained from the
groups containing vitaD3 and 1,25OH2D3 to permit simultaneous analysis by qRT-PCR of
multiple primers. This was due to the fact that both vitaD3 and 1,25OH2D3 inhibited
proliferation, which lead to a much smaller population size in comparison to the controls.
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Advancements in the design of biomedical engineering technologies, especially that
supporting regenerative medicine through cell and tissue engineering, include the use of
precursor cell lines which can consistently be manipulated to develop neotissue. The
OPC1 cell line investigated here maintained consistent proliferation, ECM synthesis, and
boney maturation, albeit during an abbreviated two-dimensional study. Future
investigations will recreate the culture scenarios in a three-dimensional, cell-biomaterial
construct with concomitant mechanical stimulation through the application of a novel
bioreactor (Mason et al., 2011). This approach will establish a surrogate living tissue
model for pharmacokinetic assessment of the dose-response relationship building off of
the foundation described here.

ACKNOWLEDGMENTS
The authors appreciate the generous support given by fellow laboratory members in the
Department of Molecular and Medical Genetics, Oregon Health & Science University.
Partial funding was provided by the National Institutes of Health (Grant No. P20
MD003350) and the Collins Medical Trust.

135

REFERENCES
Ahmed, M. S., & Shoker, A. (2010). Vitamin D metabolites; protective versus
toxic properties: molecular and cellular perspectives. . Nephrology Reviews , 2 (1).
Ando, K., Lmai, S., Isoya, E., Kubo, M., Mimura, T., Shioje, S., et al. (2009).
Effect of dynamic compressive loading and its combination with a growth factor on
chondrocytic phenotype of 3-dimmensional scaffold-embedded chondrocytes. Acta
Orthopaedica , 80 (60), 724-733.
Appleman, T. P., Mizrahi, J., Elisseeff, J. H., & Seliktar, D. (2009). The
differential effect of scaffold composition and architecture on chondrocyte response to
mechanical stimulation. Biomaterials , 30, 518-525.
Atala, A., & Lanza, R. P. (2002). Methods of Tissue Engineering. Philadelphia,
PA: Elisevier.
Atanga, E., Dolder, S., Dauwalder, T., Wetterwald, A., & Hofstetter, W. (2011).
TNFa inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone
, 49, 1090-1100.
Atkins, G. J., Andersin, P. H., Findlay, D. M., Welldon, K. J., Vincent, C.,
Zannettino, A. C., et al. (2007). Metabolism of vitamin D3 in human osteoblasts:
evidence of autocrine and paracrine activities of 1a,25-dihydroxyvitamin D3. Bone , 40,
1517-1528.
Bahney, C. S., Hsu, C. W., Yoo, J. U., West, J. L., & Johnstone, B. (2011). A
bioresponsive hydrogel tuned to chondrogenesis of human mesenchymal stem cells.
FASEB J .

136

Barbero, A., & Martina, I. (2007). Tissue Engineering (2nd ed.). (H. Hauser, & M.
Fussenegger, Eds.) Totowa, NJ: Humana.
Barlic, A., & Kregar-Velikonja, N. (2008). Re-differentiation of human articular
chondrocytes is not enhance by a rotary bioreactor system. Folia Biol , 54, 177-179.
Berg, J. P. (1999). Vitamin D-binding protein prevents vitamin D deficiency and
present itamin D for its renal a ctivation. Eur J of Endicrinology , 141, 321-322.
Biswas, P., & Zanello, L. P. (2009). 1,25(OH)2D vitamin D3 induction of ATP
secretion in osteoblasts. J Bone Miner Res , 24, 1450-1460.
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H.
F., et al. (2008). Vitamin D and human health: lessons from vitamin D receptor null mice.
Endocrine Reviews , 29 (6), 726-776.
Boyan, B. D., Hurst-Kennedy, J., Denison, T. A., & Schwartz, Z. (2009). Cellular
responses to 24R,25-dihydroxyvitamin D3 in bone and cartilage. Immun, Endoc & Metab
Agents in Med Chem , 9, 137-142.
Brannon , P. M. (2012). Key questions in vitamin D research. Scand J Clin Lab
Invest , 73 (Suppl 243), 154-162.
Brockbank, K. G. (2000). Tissue engineering constructs and comercialization.
Austin, TX: Landes Biosciene.
Cartnmell, S. H., Porter, B. D., Garcia, A. J., & Guldberg, R. E. (2003). Effects of
medium perfusion rate on cell-seeded three-dimensional bone constructs in vitro. Tissue
Eng , 9 (6), 1197-1203.

137

Chen, G., Kim, S. H., King, A. N., Zhao , L., Simpson , R. U., Christensen, P. J., et
al. (2011). CYP24A1 is an independent prognostic marker of survival in patients with
lung carcinoma. Clin Cancer Res , 17, 817.
Cheung, Y. K., Azeloglu, Shiovitz, D. A., Costa, K. D., Seliktar, D., & Sia, S. K.
(2009). Microscale control of stiffness in a cell-adhesive substrate using microfluidicsbased lithography. Angew Chem Int Ed , 48, 7188-7192.
Choi, J. B., Youn, I., Cao, L., Leddy, H. A., Cilchrist, C. L., Setton, L. A., et al.
(2007). Zonal changes in the three-dimensional morphology of the chondron under
compression: the relationship among cellular, pericellular, and extracellular deformation
in articular cartilage. J Biomech , 40, 2596-2603.
Chung, P. G., & Burdick, J. A. (2008). Engineering cartilage tissue. Adv Drug
Delivery Rec , 60 (2), 243-262.
Cooper, G. M. (2000). Signaling Molecules and Their Receptors. In G. M. Cooper,
The Cell: A Molecular Approach (2nd ed.). Sunderlan, MA: Sinauer Associates.
Flanagan, J. N., Young, M. V., Persons, K. S., Wang, L., Mathieu, J. S., Whilatch,
L. W., et al. (2006). Vitamin D metabolism in human prostate cells: impications for
prostate cancer chemoprevention by vitamin D. Anticancer Research , 26, 2567-72.
Freed, L. E., Guilark, F., Guo, E., Gray, M. L., Tranquilo, R., Holmes, J. W., et al.
(2006). Advanced tools for tissue engineering: scaffolds, bioreactors, and signaling.
Tissue Engineering , 12 (12), 3285-3305.

138

Geng, S., Zhou, S., & Glowacki, J. (2011). Effects of 25-hydroxyvitamin D3 on
proliferation and osteoblast differentiation of human marrow stromal cells require
CYP27B1/1a-hydroxylase. J of Bone and Miner Res , 26 (5), 1145-1153.
Golub, E. E., & Boesze-Battaglia, K. (2007). The role of alkaline phosphatase in
mineralization. Curr Opin Orthop , 444-448.
Halvorsen , Y. C., Franklin, D., Bond, A. L., Hitt, D. C., Auchter, C., Boskey , A.
L., et al. (2001). Extracellular matrix mineralization and soteoblast gene expression by
human adipose tissue-derived stromal cells. Tissue Engineering , 7 (6), 729-741.
Hardingham, T., Tew, S., & Murdoch. (2002). Tissue engineering: chondrocytes
and cartilage. Arthritis Res , 4, S63-68.
Hattori, K., Takakura, Y., Ohgushi, H., Habata, T., Uematsu, K., Yamauchi, J., et
al. (2005). Quantitative ultrasound can assess the regeneration proess of tissue-engineered
cartilage using a complex between adherent bone marrow cells and a three-dimensional
scaffold. Arthritis Resarch and Therapy , 7 (3), R552-R559.
Hein, A., & O'Brien, W. J. (1993). Current time-domain methods for assessing
tissue motion by analysis from reflected ultrasound echos-a review. IEEE Transcactions
on Ultrasonics, Ferroelectris and Frequency Control , 40 (2), 84-102.
Hewison, M., Zehnder, D., Chskraverty, R., & Adams, J. S. (2004). Vitamin D and
barrier function: a nove role for extra-renal 1a-hydroxylase. Molecular and Cellular
Endocrinology , 215, 31-38.

139

Hobaus, J., Thiem, U., Hummel, D. M., & Kallay, E. (2013). Role of calcium,
vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anti-Cancer
Agent in Medicinal Chemistry , 13 (1), 20-35.
Hoemann, C. D., El-Gabalawy, H., & McKee, M. D. (2009). In vitro osteogenesis
assays: influence of the primary cell source on alkaline phosphatase activity and
mineralization. Pathologie Biologie , 57, 318-323.
Hollick, M. F. (2010). Vitamin D. Boston, MA: Springer.
Hosmer, D. W., & Lameshow, S. (2000). Applied Logistic Regression. New York,
NY: Wiley.
Jones, G., Strugnel, S. A., & DeLuca, H. F. (1998). Current Understanding of the
molecualr actions of vitamin D. Physiological Reviews , 78 (4), 1193-1211.
Kohles, S. S., Bowers, J. R., Vailas, A. C., & Vanderbery, R. (1997). Ultrasonic
wave velocity measurement in small polymeric and cortical bone speciments. J Biomech
Eng , 119 (3), 232-236.
Kohles, S. S., Bradshaw, S., Mason, S. S., & Looft, F. J. (2011). A multivariate
logistical model for identifying the compressive sensitivity of single rat tactiles receptors
as nanobiosensors. J Nanotechnol Eng Med , 2 (1).
Kohles, S. S., Kohles, D. A., Karp, A. P., Erlich, V. M., & Polissar, N. L. (2004).
Time-dependent surgical outcomes following cauda equina syndrom diagnosis:
comments on a meta-analysis. Spine , 29 (11), 1281-1287.

140

Kohles, S. S., Wilson, C. G., & Bonassar, L. J. (2007). A mechanical composite
sphers analysis of engineered cartilage dynamics. ASME J Biomech Eng , 129 (4), 473480.
Kumar, R. (1990). Vitamin D metabolism and mechanisms of calcium transport. J
Am Soc Nephrol , 1 (1), 30-42.
Lanza, R., Langer, R., & Vacanti, J. (2007). Principles of Tissue Engineering. San
Diego, CA: Elisever.
Lehman, B. (2008). Role of vitamin D3 pathway in healthy and diseased skin facts, contradictions and hypotheses. Experimental Dermatology , 18, 97-108.
Lehmann, B., & Meurer, M. (2003). Extrarenal sites of calcitriol synthesis: the
particular role of the skin. . Recent Results Cancer Res , 164, 237-245.
Lian, J. B., & Stein, G. S. (1995). Develpment of the osteoblast phenotype:
molecular mechanisms mediating osteoblast growth and differentiation. The Iowas
Orthopaedic J , 15, 118-140.
Liu, P., Oyahobi, B. O., Russell, R. G., & Scutt, A. (1999). Regulation of
osteogenic differentiation of human bone marrow stromal cells: interaction between
transforming growth factor-B and 1,25(OH)2 vitamin D3 in vitro. Calcif Tissue Int , 65,
173-180.
Mason, S. S., Kohles, S. S., & Zelick, R. D. (2011). Three-dimensional culture of
cells and matrix biomolecules for engineered tissue development and biokinetic model
validation. J Nanotechnol Eng Med , 2 (2), 025001-7.

141

Naeem, Z. (2010). Vitamin D defficiency - an ingnored epidenmic. Int J Health
Sci , 4 (1), V-VI.
Owen, T. A., Aronow, M. S., Barone, L. M., Bettencourt, B., Stein, G. S., & Lian,
J. B. (1991). Pleiotropic effects of vitamin D on osteoblast gene expression are related to
the proliferative and differentiated state of the bone cell phenotype: dependency upon
basal levels of gene expression, duration of exposure, and bone matrix competency in
norma. Endocrinology , 1496-1504.
Park, K., Min, B. H., Han, D. K., & Hasty, K. (2007). Quantitive anaylsis of
temporal and spatial variation of chondrocyte nehavior in engineered cartilage during
long-term culture. Annals Biomed Eng , 35 (3), 419-428.
Pazanno, D., Mercier, K. A., Moran, J. M., Fong, S. S., DiBiaso, D. D., Rulf, J. X.,
et al. (2000). Comparison of chondrogenesis in static and perfused bioreactor culture.
Biotechnol Prog , 16, 893-896.
Pockwinse, S. M., Stein, J. L., Lian , J. B., & Stein, G. S. (1995). Developmental
stage-specific cellular responses to vitamin D and glucocorticoids during differentiation
of the osteoblast phenotype: interrelationship of morphology and gene expression by in
situ hybridization. Experimental Cell Research , 216, 244-260.
Ramage, G., Nuki, D., & Salter, M. (2009). Signaling cascades in
mechanotransduction: cell-matrix interaction and mechanical loading. Scand J Med sci
Sports , 19, 4757-4769.

142

Saha, A. K., & Kohles, S. S. (2011). A cell-matrix model of anabolic and catabolic
dynamics during cartilage biomolecule regulation. International Journal of Computers in
Healthcare .
Saha, A. K., & Kohles, S. S. (2010). A distinct catabolic to anabolic threshold due
to single-cell nanomechanical stimulation in a cartilage biokinetics model. J Nanotechnol
Eng Med , 1 (3), 031005.
Saha, A. K., & Kohles, S. S. (2010). Periodic nanomechanical stimulation in a
biokinetics model identifying anabolic and catabolic pathways associated withh cartilage
matrix homeostasis. J Nanotechnol Eng Med , 1 (4), 041001.
Schuurman, W., Gawlitta, D., Lein, T. J., Hoope, W. T., Riijen, M. H., Dhert, W.
J., et al. (2009). Zonal chondrocyte subpopulations reacquire zone-specific characteristics
durin in vitro redifferentiation. AJSM , 20 (10), 1-8.
Seiffert, M., Rech, M., Meineke, V., Tilgen, W., & Rechrath, J. (2004).
Differential biological effects of 1,25-dihydroyxy Vitamin D3 on melanoma cell lines in
vitro. J of Steroid Biochem & Molec Bio , 89-90, 375-379.
Tellisi, N., & Nureddin, A. (2007). Comparison of meshes, gels and ceramic for
cartilage tissue engineering in vitro. Eur J Plast Surg .
Tibbitt, M. W., & Anseth, K. S. (2009). Hydrogels as extracellular matrix mimics
for 3D cell culture. Biotechnol Bioeng , 103, 656-669.
Tortelli, F., & Cancedda, R. (2009). Three-dimensional cultures of osteogenic and
chondrogenic cells: a tittue engineering approach to mimic bone and cartilage in vitro.
Eur Cell Mater , 17, 1-4.

143

Vanhooke, J. L., Prahl, J. M., Kimmel-Jehan, C., Mendelsohn, M., Danielson, E.
W., Healy, K. D., et al. (2006). CYP27B1 null mice with LacX reporter gene display no
25-hydroxyvitamin D3-1a-hydroxylase promote activity in the skin. PNAS , 103 (1), 7580.
Viljakainen , H. T., Natri, A. M., Karkainen , M., Huttunen , M. M., Palssa, A.,
Jakobsen, J., et al. (2006). A positive dose-response effect of vitamin D supplementation
on site-specific bone mineral augmentation in adolescent girls: a double-blinded
randomized placebo-conrolled 1-year intervention. J Bone Miner Res , 21 (6), 836-44.
Villanueva, I., Weigal, C. A., & Bryant, S. J. (2009). Cell-matrix interactions and
dynamic mechanical loading influence chondrocyte gene expression and bioactivity in
PEG-RGD hydrogels. Acta Biomaterialia , 5 (8), 2832-2846.
Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., & Noel, D. (2009).
Cartilage engineering: a crucial combination of cells, biomaterials, and biofactors. Trens
Biotecnol , 19, 307-314.
Walker, J. M., Myers, A. M., Scluchter, M. D., Goldberg, V. M., Caplan, A. I.,
Berilla, J. A., et al. (2011). Nondestructive evaluation of hydrogel mechanical properties
using ultrasound. Annals of Biomedical Engineering , 39 (10), 2521-2530.
Wilson, C. G., Bonassar, L. J., & Kohles, S. S. (2002). Modeling the dynamic
composition of engineered cartilage. Arch Biochem Biophys , 408 (2), 246-254.
Winn, S. R., Randolph, G., Uludag, H., Wong, S. C., Hair, G. A., & Hollinger, J.
O. (1999). Establishing an Immortalized Human Osteoprecursor Cell Line: OPC1. J of
Bone and Miner Res , 14 (10), 1721-1733.

144

Yilmaz, B. C., Yilmaz, G., Yilmaz, N. S., Balli, E., & Tasdelen, B. (2010).
Optimal transport time and conditions for cartilage tissue samples and expanded
chondrocyte suspensions. Orthopaedics , 33 (1), 25.
Zhou, S., Glowacki, J., Kim, S. W., Hahne, J., Geng, S., Mueller, S. M., et al.
(2012). Clinical characterizatics influence in vito action of 1,25-dihydroxyvitamin D(3)
in human marrow stromal cells. . J Bone Miner Res , Ahead of Print.
Zuwei, M. A., Kotaki, M., Inani, R., & Ramakrishna, A. (2005). A potential of
nanofiber matrix as tissue-engineering scaffolds. . Tissue Eng , 11 ((1-2)), 101-10.

145

Chapter VI.

INVESTIGATION THE REGULATION OF MRNA EXPRESSION

INVOLVED IN EXTRA-ENDOCRINE VITAMIN D METABOLISM DURING OPC1
BONE MATURATION AND MINERALIZATION

Shelley S. Mason1
Sean S. Kohles1
Shelley R. Winn2
Randy D. Zelick1

1

Department of Biology, Portland State University, Portland, Oregon; 2Department
of Molecular and Medical Genetics, Oregon Health Science University, Portland,
Oregon.

146

Section 6.01

Preface

This chapter contains material from a manuscript that will be submitted for
publication at a later date. The work presented here is the 2nd part of a two-series
experiment on the influence of extra-endocrine vitaD3 metabolism on in vitro temporal
bone development sequence.
Section 6.02

Authors Contribution

The work presented here was carried out in collaboration between all authors.
SSM, SSK, SRW, and RDZ defined the research theme. SSM designed the methods and
experiments, carried out the laboratory experiments, analyzed the data, interpreted the
results and wrote the paper. SSK edited the manuscript. SRW co-designed the biological
experiments. All authors have contributed to, seen and approved the manuscript.
Section 6.03

Hypothesis

The overall goal of this experiment was to demonstrate the extrahepatic metabolism
of parental vitaD3 precursor to the active vitamin D metabolite 1,25OH2D3 by the
osteoblast precursor cell line OPC1, and demonstrate the subsequent influence on bone
maturation and mineralization. The global hypothesis was that the conversion of vitamin
D3 to 1,25OH2D3 would lead to an increase in alkaline phosphatase (ALP) activity
associated with osteoblast ECM maturation and an increase ECM mineralization
indicated by calcium deposition detected alizarin red stain

(ARS). It was also

hypothesized that the presence of vitaD3 would enhance the temporal bone
developmental sequence of OPC1.
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Section 6.04

Abstract

Multipotential precursor cell lines derived from human bone marrow, capable of
differentiating into cartilage or bone, may provide a useful tissue development model for
studying the regulation and metabolism of putative growth and differentiation factors
necessary for tissue regeneration. In mammals, the process of bone development depends
on the proliferation and differentiation of osteoblast lineage cells, and the subsequent
synthesis and mineralization of bone extracellular matrix (ECM). Vitamin D metabolites
play a pivotal role in bone and mineral homeostasis, and are positive factors on bone
development. Recently, it was demonstrated that human-derived engineered osteoblast
precursor cell line, OPC1, derived from human bone marrow, can metabolize the parental
precursor vitamin D3 (vitaD3) to the active

steroid 1α,25-dihydroxyvitamin D3

(1,25OH2D3), and elicit an osteogenic response that results in the decrease in proliferation
and increase of ECM synthesis during early bone development. In this study, we
investigated whether vitaD3 influences bone ECM mineralization in the same manner as
1,25OH2D3. In addition, we explored the influence of vitamin D metabolites, in
combination with other commonly used osteogenic factors, ascorbic acid, βglycerophosphate, dexamethasone (dex) and bone morphogenetic protein-2 (BMP-2) on
the osteoinduction of OPC1 during early bone development. It was demonstrated that
OPC1 expresses the mRNA for the enzymatic equipment necessary to convert vitaD3 to
1,25OH2D3, as well as the mRNA associated with the catabolic enzyme known to
regulate the concentration of active 1,25OH2D3. It was also demonstrated that mRNA
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expression for the vitamin D receptor (VDR) was influenced by both vitaD3 and
1,25OH2D3. Differential results using vitamin D metabolites in combination with
ascorbic acid, β-glycerophosphate, and either dex and/or BMP-2 were observed in ALP
activity and calcium deposition, and mRNA expression of procollagen (proColI),
osteocalcin (OC), and osteopontin (OP). Overall it was demonstrated that vitamin D in
combination with osteogenic factors influence the temporal bone development sequence
in a positive manner.
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Section 6.05

Introduction

Most of the load-bearing demand placed on the human body is transduced by skeletal
tissue, and the skeleton’s capacity to articulate in various opposing directions is essential
for mobility and locomotion [Buttery, et al., 2001]. Consequently, cartilage and bone
defects due to trauma, disease, and developmental abnormalities results in severe
disabling pain and immobility for millions of people worldwide [Mason, et al., 2011].
Multipotential precursor cell lines derived from human bone marrow, capable of
differentiating into cartilage or bone, may provide a useful tissue development model for
studying the regulation and metabolism of putative growth and differentiation factors
necessary for tissue regeneration.
There are several factors that need to be taken into consideration for in vitro model
systems, such as cell source and acquisition, phenotypic stability, reproducibility, and the
incorporation of appropriate signaling molecules. One of the challenges using
mesenchymal stromal cells (MSCs)/progenitor cells isolated from bone marrow aspirates
is isolation sufficiency and expansion, because of the relatively low frequency at which
they occur in the marrow stroma (reported to be in the range of 1/10,000 cells to
1/100,000 cells) [Hicok, et al., 1998; Buttery, et al., 2001; Huang et al., 2012]. In
addition, MSCs have a finite capacity for self-renewal, and the potential to proliferate and
differentiate diminishes with age [Buttery, et al., 2001]. In addition, MSC isolates tend to
be heterogeneous, containing progenitor cells with varying levels of potency.
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Osteoblastic precursor cell line (OPC1) is a conditionally immortalized cell line derived
from human bone, and has been demonstrated to maintain phenotypic stability and a
consistent pattern of differentiation for more than 70 passages, therefore it provides an
ideal model for the study of osteoblast differentiation and bone development as an
alternative to MSCs [Winn, et al., 1999]. OPC1 has been used in previous studies and has
shown to provide a consistent and reproducible culture system for evaluating bone
development [Mason, et al. 2013]. Recently, we were able to demonstrate the extraendocrine metabolism of vitaD3 to 1,25OH2D3 by OPC1, which resulted in decreased
proliferation and increased ALP activity and calcium deposition associated with ECM
bone maturation and mineralization.
In the early 1900’s vitamin D was the fourth identified essential vitamin, thus
named vitamin “D” by convention. It wasn’t until 50 years later that it was realized that
vitamin D is metabolized and acts as a steroid hormone in an endocrine manner, a
paradigm that has dominated the classic thought of vitamin D function until the end of
the 20th century [Morris & Anderson, 2010]. Recently, it has been demonstrated that
number of organ systems are influenced by vitamin D in an autocrine manner, that is
1,25OH2D3 is being synthesized within those cells, and/or within adjacent cells (paracrine
action). While the vitamin D endocrine system plays a principal role in the maintenance
of calcium and phosphate homeostasis, extra-endocrine metabolism has been postulated
to have cellular functions that include the regulation of proliferation, differentiation, and
apoptosis in many target tissues [Brannon, 2012; Hobaus, et al., 2013; Jones, et al., 1998;
Atkins, et al. 2007], including bone and cartilage.
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VitaD3 is biologically inactive in physiological concentrations until it is
sequentially hydroxylated and the polarity is increased. VitaD3 is activated by twosequential hydroxylations, first by the cytochrome P450 oxidase (CYP) 25-hydroxylase,
CYP27A1 (mitochondrial) and CYP2R1 (microsomal), resulting in the metabolite 25hydroxyvitamin D3 (25OHD3), and then to the active metabolite, 1,25OH2D3, by 25hydroxyvitaminD3-1α-hydroxylase (CYP27B1) [Ahmed & Shoker 2010; Norman 1998;
Jones, et al. 1998; Trump, et al., 2010].
1,25OH2D3 is the most active form of vitamin D because of its high affinity for the
intranuclear vitamin D receptor (VDR), in which it mediates its biological effects upon
binding. VDR belongs to the nuclear hormone receptor family and serves as a liganddependent transcription factor (TF) that controls the expression of vitamin D associated
target genes which include those associated with calcium homeostasis, cellular
proliferation and differentiation, cell division and cycle arrest, and apoptosis [Yamamoto,
et al., 2013; Seiffert, et al., 2004; Flanagan, et al., 2006; Hollick, 2010; Naeem, 2010].
Upon 1,25OH2D3 binding, VDR forms a heterodimer with the retinoid X receptor, which
allows it to bind to vitamin D receptor elements (VDRE) in the promoter regions of target
genes [Flanagan, et al., 2006; Brannon , 2012; Geng, et al., 2011; Trump, et al., 2010].
Coupled with other TFs, this complex induces transcription of vitamin D responsive
genes including those associated with the CYP-related enzymes required for vitamin D
metabolism [Chen, et al., 2011; Flanagan, et al., 2006; Boyan, et al., 2009; Geng, et al.,
2011; Trump, et al., 2010].
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The action of vitamin D is limited by the catabolic enzyme 24-hydroxylase
(CYP24A1), which results in a compound that is more soluble and has a substantially
lower affinity for VDR [Trump, et al., 2010; Ahmed & Shoker, 2010; Ambrecht, et
al.,1998]. CYP24A1 has been shown to hydroxylate both 25OHD3 and 1,25OH2D3 to
form 24,25OH2D3 and 1,24,25OH3D3, respectively [Flanagan, et al., 2006]. The main
function of CYP24A1 is to regulate the circulating concentration of 1,25OH2D3 by
inactivating it. The catabolic pathway of CYP24A1, collectively known as the C-24
oxidation pathway, starts with the 24-hydroxylation of 25OH2D3 or 1,25OH2D3 followed
by sequential steps of hydroxylation that lead to the progressive loss of biological activity
until vitamin D is converted to the water-soluble biliary excretory form, calcitroic acid
[Ahmed & Shoker, 2010; Jones et al., 1998; Pairse et al., 2006]. 1,25OH2D3 induces and
mediates CYP24A1 via an autocatalytic loop through VDRE located in the promoter
region of the CYP24A1 gene [Chen et al., 2011]. Generally, basal expression of
CYP24A1 is extremely low but the gene is highly induced by 1,25OH2D3 [Geng, et al.,
2011; Atkins, et al., 2007]. Thus, the synthesis and degradation of 1,25OH2D3 is highly
regulated, and the concentration is controlled at the cellular level.
Vitamin D affects many aspects of bone cell biology, and has been implicated in
the regulation of both osteoblastic and osteoclastic activity effecting both resorptive and
synthetic phases of bone remodeling [Atkins, et al., 2007]. In addition, 1,25OH2D3 has
been demonstrated to regulate osteoblast and chondrocyte gene transcription,
proliferation, differentiation, and ECM maturation [Boyan, et al., 2009; Atkins, et al.,
2007]. VDR is nearly ubiquitously expressed, almost all cells respond to 1,25OH2D3
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[Bouillon, et al., 2008], and it is known to regulate the function of more than 200 genes
[Flanagan et al., 2006; Hollick, 2010; Norman, 1998; Naeem, 2010].
In this study, OPC1 was used to study the differentiation of osteoprogenitors
towards the osteoblast lineage and the events associated with bone development in the
presence of vitamin D metabolites, vitaD3 and 1,25OH2D3, in combination with
osteogenic factors ascorbic acid, β-glycerophosphate, dexamethasone and bone
morphogenetic protein-2 (BMP-2). Because in vitro temporal bone development
encompasses three stages, proliferation, bone ECM maturation, and mineralization, and
vitamin D has been shown to significantly hamper OPC1 proliferation [Mason et al.
2013], confluent cultures were used in order to investigate the influence on bone ECM
maturation and mineralization.
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Section 6.06

Materials and Methods

(i) Materials
Vitamin D3 (cholecalciferol) and (calcitriol) 1,25OH2D3 were purchased from
Sigma-Aldrich (St. Louis, MO), and maintained in 10mM and 10µM stock
solutions in ethanol respectively. All other reagents and chemicals were
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated. Tissue
plastic-ware was obtained from USA scientific (Ocala, FL). OPC1 and rhBMP-2
were a generous gift from Dr. S. R. Winn (Department of Molecular and Medical
Genetics Laboratory, Oregon Health Science University, Portland, OR).
(ii) Methods
(a) OPC1 Cell Cultures
Cells were cultured at 2.5 X 105 in 75-cm2 tissue culture flasks in alpha
modified essential medium (α-MEM) with 5% fetal bovine serum (FBS). Once
confluent, OPCs were plated in 12-well plates after trypsin-EDTA enzymatic
removal and counted with 0.4% trypan blue (1:1) on a hemacytometer. Cultures
were prepared in duplicate at a seeding density of 3.0 x 104 cells/well in a
standard bone medium (BM-) of α-MEM supplemented with 5% FBS, 200mM LGlutamine, and antibiotics until 85-90% confluent prior to adding experimental
medium. Nine types of medium were utilized in quadruplicates. BM- with 95%
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ethanol (EtOH) in amount that equated the EtOH vehicle for vitamin D metabolite
delivery provided a negative control (group 1) and the additional groups included:
BM- supplemented with 1µM vitaD3 (group 2); BM- supplemented with 10nM
1,25OH2D3 (group 3); BM- supplemented with osteogenic factors (BM+)
comprised of 50 µg/ml ascorbic acid, 10mM β-glycerophosphate, 10nM
dexamethasone (dex), and 50 µg/ml of ascorbic acid phosphate (Wako Chemical,
Osaka, Japan) provided as a positive control (group 4); BM+ supplemented with
1µM vitaD3 (group 5); and BM+ supplemented with 10nM 1,25OH2D3 (group 6).
BM+ supplemented with rhBMP-2 (BMP+) (group 7), BMP+ with 1µM vitaD3
(group 8); and BMP+ supplemented with 10nM 1,25OH2D3 (group 9). Fresh
medium was added every 1-2 days.

(b) ALP activity associated with bone matrix maturation
OPC-1 was treated with both vitaD3 and 1,25OH2D3 in BM-, BM+, and
BMP+, in duplicate at the indicated concentrations. ALP activity was measured
every 7 days. At the end of the incubation, the cell layers were washed with cold
DPBS, and 500µl 0.1% triton-X in DPBS and stored at -80°C until the end of
each experimental period. ALP activity in the cell lysates was measured using ρnitrophenyl phosphate liquid substrate system at 37°C for 30 minutes. Protein
content was measured using a micro-volume spectrophometer system (Epoch;
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Biotek, Winooski, VT). For statistical analysis of ALP over time, a two-way
ANOVA and Bonferonni posttest control comparison was performed.

(c) Calcium deposition during bone matrix mineralization
A hystochemical analysis of mineralization was evaluated utilizing an
Alizarin Red S (ARS. ARS staining is used to evaluate calcium-rich deposits by
cells in culture, and is considered a functional in vitro endpoint reflecting
advanced cell differentiation [Hoemann et al. 2009]. In brief, every 7 days cells
were fixed in 10% neutral buffered formalin for 15 min. followed by fixation in
100% cold methanol. Each well was rinsed thoroughly with cold DPBS, and
stained with 40mM of ARS, pH 4.1, at room temperature (RT) for 20 min with
gentle shaking. The cell layers were efficiently rinsed and observed both grossly
and microscopically. For semiquantification, ARS was extracted from the cells
after incubating for one hour in at RT in 10% (v/v) acetic acid with gentle
shaking, and then the residual dye was further extracted by scraping the cells and
heating at 85°C on a heating block with a layer of mineral oil to prevent
evaporation. The samples were neutralized with 10% (v/v) ammonium hydroxide
and the extracts were read at 405 nm on a microplate-reader (Cary 50; Varian
Australia Pty. Ltd). The samples were compared to serially diluted ARS standard.
The resulting data was normalized with total protein content measured using a
micro-volume spectrophometer system (Epoch; Biotek, Winooski, VT). For
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statistical analysis of ARS over time, a two-way ANOVA and Bonferonni posttest
control comparison was performed.

(d) Quantitative RT-PCR
Established RT-PCR qualitative analysis techniques were used to
characterize the presence of CYP24A1 [Zhou, et al., 2012], CYP27A1 [Seiffert, et
al., 2004], CYP27B1 and VDR (see Table 6-1) [Seiffert, et al., 2004; Zhou, et al.,
2012], osteopontin (OP), procollagen I (proColI), and osteocalcin (OC) (see Table
6-2) [Winn, et al., 1999]. The oligionucleotide RT-PCR primer sequences (see
Table 6-3) were purchased from Intergrated DNA Technologies (Coralville, Iowa,
USA). Briefly, mRNA was isolated using 500µl TRIzol (Life Technologies,
Grand Island, NY, USA) per well of 12-well plates. Samples were collected every
7 days and stored at -80°C. The mRNA was purified from TRIzol according to the
manufacturer’s specifications and the concentration was determined by
spectrophotometric absorbance (Epoch; Biotek, Winooski, VT) of light at 260nm
and 280 nm (A260/A280) in µg/ml. The cDNA was synthesized from 2µg of mRNA
using a high capacity cDNA reverse transcriptase kit from Applied Biosystems
(Life-Technologies, Grand Island, NY, USA) according to manufacturer’s
instructions. Aliquots of the total cDNA were amplified in each PCR using fast
SYBR® green master mix from Applied Biosystems (Life-Technologies, Grand
Island, NY, USA) with the primers listed in Table 1 and performed in a RotorGene Q RT-PCR thermocycler (Qiagen, Germantown, Maryland, USA), for 45
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cycles (30s denaturation at 95°C, 45s annealing at 58°C, and 60s extension at
72°C). Quantification and analysis was carried out using Rotor-Gene Q Operating
Software and Microsoft Excel (Microsoft Corp. Seattle, WA, USA).

Table 6-1. Vitamin D biomarkers associated with vitamin D metabolism.

Vitamin D Associated
Biomarker

Function

CYP24A1

The gene that encodes the mitochondrial protein that initiates
the degradation of vitamin D metabolites 25OHD3 and
1,25OH2D3 to calcitroic acid [Schlingmann et al. 2011].

CYP27A1

The gene that encodes the mitochondrial protein involved in
the metabolism of vitamin D3 to 25OHD3 [Sawada et al. 2000].

CYP27B1

The gene that encodes the mitochondrial protein responsible
for the hydroxylation of the vitamin D metabolite 25OHD3 to
1,25OH2D3 [Jones, 2013].

VDR

The gene that encodes the nuclear hormone receptor for
vitamin D. Downstream targets of this nuclear hormone
receptor are known to be involved with mineral metabolism,
proliferation, differentiation, apoptosis, and immune response
[Freedman, 1999].
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Table 6-2. Osteoblast biomarkers associated with bone development.

Osteoblast Marker

Function

Alkaline Phosphatase (ALP)

A hydrolase involved in bone ECM maturation and
mineralization, postulated to increase inorganic
phosphate concentration. ALP is thought to be
regulated by 1,25OH2D3 [Boyan et al. 1989].

Osteocalcin (OC), bone gammacarboxyglutamate protein (BGLAP)

A noncollagenous protein found in bone that binds
Ca2+ and hydroxyapatite, is vitamin D-responsive,
related to bone mineralization, and involved in the
recruitment and differentiation of osteoclasts. OC
synthesis has been shown to be stimulated by
1,25OH2D3 [Beresford et al. 1984].

Osteopontin (OP), secreted
phosphoprotein 1 (SPP1)

A noncollagenous extracellular
glycophosphoprotein found in bone that binds to
hydroxyapatite, and plays a role in osteoblast
adhesion, migration, cell survival, and bone
remodeling [Standal, Borset, & Sundan, 2004].

Procollagen Type I (proColI)

Synthesized prior to collagen type I, the principal
structural protein of bone ECM.
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Table 6-3. Oligionucleotide primers use in quantitative real-time RT-PCR.

Primer Set

Forward

Reverse

CYP24A1

5’ – GCA GCC TAG TGC AGA TTT – 3’

5’ – ATT CAC CCA GAA CTG TTG – 3’

CYP27A1

5’ – GGC AAG TAC CCA GTA CGG – 3’

5’ – AGC AAA TAG CTT CCA AGG – 3’

CYP27B1

5’ – TGT TTG CAT TTG CTC AGA – 3’

5’ – CCG GGA GAG CTC ATA CAG – 3’

VDR

5’ – CCA GTT CGT GTG AAT GAT GG – 3’

5’ – GTC GTC GGT GAA GGA – 3’

OC

5’ – CTG GCC ACT GCA TTC TGC – 3’

5’ – AAC GGT GGT GCC ATA GAT GCG– 3’

OP/SPP1

5’ – AAA TAC CCA GAT GTG GC – 3’

5’ – AAC CAC ACT ACC TCG GC – 3’

ProColI

5’ – TGA CGA GAC CAA GAA CTG – 3’

5’ – CCA AAG TCA CCA AAC CTA CC – 3’

(e) Statistical Analysis
Statistical analysis was carried out using Prism (Irvine, CA, USA) and
Microsoft Excel Software. Data were expressed as means ± SEM of samples
characterized in three two-week sample sets plated in duplicate or quadruplicate,
and assayed in duplicate (n=12 or n=24 respectively). A two-tailed ANCOVA
with a Bonferonni posttest control comparison and non-linear regression
(polynomial quadratic function) was used for statistical analysis of treatment over
time, with *p<0.05, **p<0.01 and ***p<0.001 as significantly and very
significantly different, respectively.
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(f) Microscopic Imaging
Microscopic images were taken using an advanced transmitted light
inverted EVOS-XL microscope and accompanying software (EVOS3) from
Advanced Microscopy Group (AMG, Bothell, WA, USA). Images were
processed using FIJI, an Open Source image-processing package based on
ImageJ. To maintain consistency, each image was processed in the same manner.
The operations included the background subtraction command, mean filter and
Enhance Local Contrast (CLAHE; blocksize 100, bin 256, max. slope 2.50),
respectively.
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Section 6.07

Results

(i) Influence of vitamin D metabolites and osteogenic factors on OPC1 bone
matrix maturation.
Increased ALP activity is associated with osteoblast function and the
matrix maturation stage of bone development. ALP activity was found to be
significantly (P<0.01) higher in groups cultured in standard bone medium (BM-)
containing vitaD3 by week two of culture, and significantly higher (P<0.001) in
groups containing either vitaD3 or 1,25OH2D3 by week three compared to the
BM- ethanol vehicle control (see Figure 6-1A). For groups in osteogenic medium
(BM+) both vitamin D metabolites displayed significantly (P<0.001) higher ALP
activity compared to the BM+ EtOH control in both the second and third week
(see Figure 6-1B). All groups cultured in BM+ were significantly (P<0.001)
higher the groups cultured in BM- during the three week culture period, and
reached maximal ALP, while groups in BM- did not reach maximal ALP activity.
Groups cultured in BM+ containing rhBMP (BMP+) showed a significant
increase (P<0.001) only in the second week compared to the BMP+ EtOH
control, and by week three all groups displayed low levels of ALP activity (see
Figure 6-1C). While groups cultured in BM+ continued to increase in ALP
activity throughout the three-week culture period, BM+ reached a peak in
between week 1 and 3, and began to decline in between week 2 and 3.

163

A

B

164

C

Figure 6-1. Temporal alkaline phosphatase activity of OPC1 treated with
(A) ethanol vehicle control in standard bone medium (BM-), BM- containing
10µM vitamin D3, and BM- with 1,25OH2D3; (B) ethanol control in
osteogenic medium (BM+) containing ascorbic acid, β-glycerophosphate,
and dexamethasone, BM+ containing 10µM vitamin D3, and BM+ with
1,25OH2D3; (C) ethanol control in BM+ containing rhBMP (BMP+), BMP+
containing 10µM vitamin D3, and BM- with 1,25OH2D3. Cellular isolates
were collected on day 7, 14, and 21 during the differentiation time course.
Treatment with both vitamin D metabolites significantly (P<0.01) influenced
OPC1 ALP activity in all medium groups.
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(ii) Influence of vitamin D metabolites and osteogenic factors on OPC1 bone
matrix mineralization.
The primary function of osteoblasts is to produce and maintain mineralized
bone ECM. For samples cultured in BM- with or without vitamin D metabolites,
vitaD3 and 1,25OH2D3, calcium deposition was significantly (P<0.001) greater in
cultures containing either vitamin D metabolites compared with the BM- ethanol
control

(see Figure 6-2). OPC1 cultured in BM+ with or without vitamin D

metabolites showed a significantly (P<0.001) higher amount of calcium
deposition throughout the three week culture period compared to that of cultures
in BM-, and cultures containing either vitaD3 or 1,25OH2D3 were significantly
(P<0.001) higher than the BM+ EtOH control by the third week of culture time
(see Figure 6-3). Cultures containing rhBMP (BMP+) showed a significant
(P<0.001) amount of calcium deposition compared to that of the groups cultured
in BM- throughout the three-week culture period. The presence of vitaD3 in
BMP+ medium showed a significant (P<0.01) amount of calcium deposition
compared to that of the BMP+ EtOH control, and slightly significant (P<0.05) in
the presence of 1,25OH2D3 (see Figure 6-4).
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Figure 6-2. Calcium deposition stained with alizarin red stain (ARS) (A) of OPC1 cultured in
BM- and vitamin D metabolites vitaD3 and 1,25OH2D3. After microscopic analysis, ARS was
extracted from each culture well, and read on a microplate reader (B). By week three of
culture time, there was a significant (P<0.001) amount of calcium deposition detected by
ARS in cells treated with either vitaD3 or 1,25OH2D3 compared to that of the ethanol control.
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Figure 6-3. Calcium deposition stained with ARS (A) of OPC1 cultured in BM+ and vitaD3 or
1,25OH2D3. After microscopic analysis, ARS was extracted from each culture well, and read on a
microplate reader (B). By week three of culture time, there was a significant (P<0.001) amount of
calcium deposition detected by ARS in cells treated with either vitaD3 or 1,25OH2D3 compared to
that of the ethanol control. There was a significant (P<0.001) amount of calcium deposition
compared to all BM- groups (see Figure 6-2).
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Figure 6-4. Calcium deposition stained with ARS (A) of OPC1 cultured in BM+ containing
rhBMP-2 (BMP+) and vitaD3 or1,25OH2D3. After microscopic analysis, ARS was extracted
from each culture well, and read on a microplate reader (B). In the second week of culture
time, the BMP+ EtOH control had a significant amount of calcium deposition in comparison
with the treatment groups. By week three of culture, there was a significant (P<0.01) amount
of calcium deposition detected by ARS in cells treated with either vitaD3 or 1,25OH2D3
compared to that of the ethanol control. There was a significant (P<0.001) amount of calcium
deposition compared to all BM- groups (see Figure 6-2).
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(iii) Expression of Vitamin D Associated mRNA in OPC1.
CYP27A1 and CYP27B1 are hydroxylases demonstrated to be involved in the
metabolism of vitaD3 to 25OHD3, and convert 25OHD3 to 1,25OH2D3
respectively. OPC1 expressed both CYP27A1 (Figure 6-5A) and CYP27B1
(Figure 6-5B) in response to the presents of vitaD3, relative to the BM- EtOH
control. Significant (P<0.001) increases occurred within the first 72 hours of
treatment (treatment added on day 4 of culture), but decreased dramatically by the
second week in the continuous presents of vitaD3 (see Figure 6-5A and 6-5B). In
the groups containing osteogenic factors (BM+ and BMP+) the expression of
CYP27A1 was higher than in the BM- group treated with vitaD3, however in
groups treated with BMP+, CYP27B1 expression was lower than in the BM- and
BM+ groups treated with vitaD3. OPC1 expressed CYP24A1 and VDR mRNA in
response to vitaD3 and 1,25OH2D3 (see Figure 6-5C and 6-5D). In the first week
all groups treated with vitamin D metabolites had a significant (P<0.001) increase
in CYP24A1 and VDR expression relative to the BM- control, however BMcultures treated with vitamin D expressed a much higher amount of CYP24A1
mRNA relative to BM- control, compared to the cultures containing osteogenic
factors. After continuous presents of vitamin D, in the second week of culture
time, CYP24A1 expression decreased for the BM- groups, but increased in groups
containing BM+ and BMP+. All groups treated with vitaD3 and 1,25OH2D3 had
significant (P<0.001) VDR mRNA expression relative to the BM- control during
the first week of culture time which decreased by the second week.
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Figure 6-5. Induced mRNA expression of (A) CYP27A1, (B) CYP27B1, (C) CYP24A1, and
(D) VDR in OPC1 by vitaD3 and 1,25OH2D3 in standard bone medium (BM-) and medium
containing osteogenic factors (BM+ and BMP+). Total RNA was isolated and examined by
quantitative RT-PCR. Data was normalized to GAPDH.
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(iv) Expression of Osteogenic mRNA in OPC1
Procollagen type I

(proColI) precedes the production of ColI, a major

component of bone ECM, has been shown to be enhanced during early osteoblast
differentiation, while OC and OP are identified with later stages of osteoblast
differentiation and bone development. Real-time PCR analysis showed a
significant (P<0.001) increase in proColI mRNA expression during the first week
of OPC1 culture in all groups relative to the BM- control, and a higher increase
with treatment groups containing either vitaD3 or 1,25OH2D3 (see Figure 6-6A).
There was no significant expression of proColI mRNA in the second week in any
of the culture groups. In contrast to the expression of proColI, OP mRNA
expression was not seen in the first week of culture time in any of the groups and
increased in both second and third week of culture relative to the BM- control (see
Figure 6-6B). The BMP+ control without vitamin D displayed the highest OP
mRNA expression relative to the BM- control. Similar to OP mRNA expression,
expression of OC mRNA was highest in the BMP+ control group, but was
increased in all groups relative to the BM- control (see Figure 6-6C). However, in
contrast to OP mRNA expression, OC expression was increased in the first week,
and continued to increase during the three-week culture period.
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Figure 6-6. Induced mRNA expression of (A) proColI, (B) OC, and (C) OP mRNA in OPC1
cultures containing vitaD3 or 1,25OH2D3 and/or osteogenic factor (BM+ or BMP+). Total RNA
was isolated and examined by quantitative RT-PCR. Data was normalized to GAPDH.
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Section 6.08

Discussion

In this study, an engineered osteoblast precursor cell line, OPC1, was used to examine
the effect of vitamin D metabolites, vitaD3 and 1,25OH2D3, on the maturation and
mineralization of culture expanded cells during bone development. In comparison to the
untreated cells, vitamin D metabolites in combination with ascorbic acid, βglycerophosphate, dex and/or BMP-2, produced more calcium deposition and showed a
greater increase in ALP over time. Cultures containing osteogenic factors varied in ALP
activity depending on the present of rhBMP-2. In addition to ALP activity and calcium
deposition, mRNA expression of proColI, OC, and OP were analyzed over the threeweek culture period, as well as the mRNA expression of genes associated with vitamin D
action and metabolism.
Osteoblasts are bone-forming cells derived from multipotential progenitor cells
within the bone marrow stroma that also are capable of committing to other mesenchymal
lineages, including fibroblasts, myoblasts, chondrocytes, adipocytes, and osteoblasts
[Hicok, et al., 1998; Swolin-Eide, 2002]. Once precursors have committed to a specific
lineage, tissue specific molecules are expressed. Phenotypical characteristics of an
osteoblast include the synthesis and mRNA expression of prColI preceded by ColI, OC,
OP, VDR, increased ALP activity, and the ability to mineralize ECM. When osteoblast
precursors commit to the osteoblastic lineage, the osteoblasts express bone matrix protein
genes at different expression levels depending on the maturation level of the cells
[Komori, 2010]. For example, immature mesenchymal cells and preosteoblasts weakly
express ColI and ColII, while immature osteoblasts express OP, and bone sialoprotein
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(BSP), and mature osteoblasts strongly express OC [Komori, 2010]. Mature osteoblasts
become osteocytes when they are embedded into the bone matrix and express dentin
matrix protein 1 (DMP-1).
In vitro human osteoblasts respond to exogenous 1,25OH2D3 by decreasing their rate
of proliferation while increasing their expression of mRNA of osteogenic biomarkers
such as OC and OP. While it has been known that circulating vitamin D is derived from
the kidneys, recently a number of studies have demonstrated the extra-renal synthesis of
1,25OH2D3 from 25OHD3 in skin, liver, lymph nodes, activated monocytes/macrophages,
dendritic cells, and osteoblasts [Atkins, et al., 2007].

In contrast to extra-renal

metabolism of 25OHD3 to 1,25OH2D3, there have been occasional reports of extrahepatic metabolism of vitaD3, but no detailed analysis until now. Recently, we
demonstrated that OPC1 could metabolize vitaD3 to 1,25OH2D3 in a dose-dependent
manner, and in this experiment, we were able to demonstrate the upregulation of mRNA
expression of vitamin D associated hydroxylases CYP27A1, CYP27B1, and CYP24A1,
as well as VDR in response to vitaD3. It was also demonstrated that vitaD3 influenced the
expression of osteogenic mRNA proColI, OC, and OP in the same manner as 1,25OH2D3.
In addition to the effects of vitamin D on OPC1, vitamin D in combination with
common osteogenic factors, ascorbic acid, β-glycerophosphate, dex, and BMP-2 was
investigated. It was demonstrated that in combination with these osteogenic factors,
matrix maturation and mineralization was significantly increased. However, there were
differential results in bone maturation associated with ALP activity seen in cultures
treated with BMP+ (see Figure 6-1C). ALP expression is associated with bone cell
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phenotype, and in heavily mineralized cultures, cellular levels of ALP decline [Lian &
Stein, 1992]. OPC1 cultured with BMP+ with or without vitamin D metabolites
demonstrated an increase in mineralization, and consequently with the mRNA expression
of OC and OP, proteins that are known to increase with the accumulation of
mineralization, compared to BM- and BM+ groups with or without vitamin D
metabolites. These results indicate that rhBMP-2 had a major influence on OPC1 bone
mineralization, that may exceed the influence of vitamin D. A major limitation to this
results, was that BMP+ cultures were so heavily mineralized that by day 17 of culture
time, the monolayer began to detach from the culture vessel.
It has been demonstrated that using dex, BMP-2, and 1,25OH2D3 enhance a more
differentiated osteoblast phenotype [Jorgensen, et al., 2004], however in this study, OP
and OC mRNA expression in groups treated with vitaD3 or 1,25OH2D3 and BMP+ was
slightly lower then the BMP+ control, but higher then the osteogenic medium containing
vitamin D metabolites and no BMP (BM+) (see Figure 6-6B and 6-6C). This may be
because we used a higher dose of 1,25OH2D3, which would also explain the very
significant increase in catabolic enzyme mRNA expression of CYP24A1 seen in the
second week of culture (see Figure 6-5). In addition, it could be postulated that as a
regulator of ECM mineralization, vitamin D dampened the effects of BMP. Many in vitro
vitamin D studies investigating the anti-proliferative and pro-differentiative effects of
vitamin D are short-term and use a supra-physiological dose, howver, for long-term
cultures using vitamin D as an osteognenic factor, it may be beneficial to use a dose that
is more closely resmbles the phsyiological dose.
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It has been long recognized that long-term or excessive use of glucocorticoid
(GC) excess, whether from endogenous hypersecretion or iatrogenically, manifests
adverse skeletal effects such as osteoporosis [Walsh, et al., 2001]. In human subjects
receiving long-term GC treatment, bone loss is associated with the decrease in overall
bone formation rate and in the mean thickness of the walls on newly synthesized
trabecular bone, a pattern consistent with the decrease in number and/or activity of
osteoblasts rather than the increase in number and/or activity of osteoblasts [Walsh, et al.,
2001]. Paradoxically, several studies have demonstrated that treating cells derived from
human bone with GCs promotes osteogenic differentiation, and has been proposed as a
standard supplement for the ex vivo expansion of cells with osteogenic potential for use in
tissue reconstruction and repair [Walsh, et al, 2001]. Dexamethasone (dex) is a GC that is
commonly used as an inducer of bone marrow stromal cell differentiation, which reliably
stimulates the development of many, but not all, phenotypic features of human
osteoblasts [Jorgensen, et al., 2004]. However, GCs have deleterious effects in vivo,
resulting in inhibition of osteoblast function. Bone morphogenetic protein-2 (BMP-2) is
another inducer of osteoblast differentiation, and is essential for postnatal bone
formation. BMP-2 has been used to induce osteoblast differentiation in vitro in many
human and animal models, and is believed to provide a more physiologic stimulus than
dex, however it appears to enhance a more mature osteoblast characteristic [Jorgensen, et
al., 2004], as was seen here.
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APPENDICES

A. Modeling of OPC-1 and MC3T3-E1 Cell Proliferation

(i) Growth Model Application.
An exponential cell growth model was applied to characterize the normalized
proliferation as a percentage of the initial cell population through culture time,
C(t), such that:

C(t) = C ie t τ

(1)

Where the experimental input includes the initial cell population (Ci = 100%)
and culture time, t, in days. The result of the fitting procedure produces a
characteristic growth rate constant similar to a time constant, . This fitting
metric provides a quantitative value by which to compare cell population growth
curves, where lower values represent a shorter culture time leading to a
maximum cell count [Wilson et al., 2002; Kohles et al., 2007].
The model was applied to the aggregate cell population data for the OPC-1
and MC3T3-E1 cells as well as to the individual test group data for each cell
type. This approach constructed least squares estimates of the growth time
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constants via a quasi-Newton convergence method with commercially available
software (Solver, Frontline Systems, Inc., Incline Village, NV, and Excel,
Microsoft, Redmond, WA). The model fit was determined by minimizing the
root mean square error (RMSE in similar units) between the actual and modeled
cell population percentages for each dataset. The correlation coefficient (R2)
assayed the strength of the modeled relationship.
The aggregate plots contain all repeated measures data as well as the model
curves. The test group curves are presented in rank order of their respective time
constants. Statistical influences of the test group culture combinations were
further explored with repeated measures analysis of co-variance (MANCOVA).

Table A-1: Proliferation modeling metrics summary

Test Group
OPC-1
Aggregate
BM-Control
BM+Control
BM-VitaD3
BM+VitaD3
BM-1,25OH2D
BM+1,25OH2D

4.49
3.86
3.96
4.61
5.19
4.80
5.50

(days)
MC3T3E1
3.87
3.39
3.56
3.72
5.28
3.54
5.94

RMSE (%)
OPC-1 MC3T3E1
209
453
199
597
242
479
128
297
161
262
119
210
103
249
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OPC-1
0.77
0.91
0.85
0.89
0.73
0.89
0.85

R
MC3T3E1
0.67
0.74
0.76
0.86
0.49
0.94
0.32

Figure A-1. OPC-11 Aggregate Data, cell population over time.

Figure A-2: OPC-11 Isolated Test Group Data, cell population over time.
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Figure A-3. MC3T3
MC3T3-E1 Aggregate Data, cell population over time.

Figure A-4 MC3T3
MC3T3-E1 Isolated Test Group Data, cell population over time.
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B. Supplemental Material and Methods: Cartilage Engineering (Chapters 3
and 4)
(ii) Materials and Reagents

Chondrocyte/Cartilage Culture Medium.
Dulbecco’s modified essential medium/Ham’s F-12 (DMEM/F12) 10%
10% Fetal Bovine Serum (FBS)
200 mM L-Glutamine
1% antibiotic/antimycotic solution (AB/AM).

Liberase Blendzyme III (Roche Diagnostics, Madison, WI)
Reconstitute 5mg vial in 2ml PBS (2.5mg/ml)
Place vial on ice to rehydrate the enzyme
Gently agitate the vial at 2-8ºC until enzyme is dissolved
Store unused stock solution in single used aliquots at -15 20ºC.

Collagenase (Sigma-Aldrich)
Cell or tissue dispersal 0.5-2.5mg/ml
Cartilage dispersal is 1-2mg/ml
solubilized in calcium-free DPBS
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(iii) Methods
(a) Harvesting Cartilage Tissue
Tissue is excised from articular cartilage of bovine metacarophalangeal
joints within 8 hours of slaughter. After dissection, chondrocytes are
isolated from tissue fragments by mechanically disaggregation and
enzymatic digestion. Freshly isolated chondrocytes cultured are expanded in
2D monolayers and /or seeded within a 3D biomatieal scaffold according to
conventional cell culture techniques.
Procedure:
1. Obtain

several

calf

hooves

that

include

the

first

joint

(metacarpophalangeal joint or fetlock) above the hoof.
2. Wash and scrub each hoof with water and antibacterial soap to
remove all traces of dirt from the skin and the hoof.
3. Once all dirt is removed and water runs clear, generously spray the
specimen with 70% ethanol.
4. Using a no. 23 disposable scalpel, make a lengthwise incision and
dissect away the skin, taking care not to pierce the joint capsule.
Wash the skinned limb with water, than generously spray with 70%
ethanol.
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5. Place the skinned limb upright, anterior side forward, inside the
hood, and on top of an absorbent protective sheet (see Figure A5A). Flex the limb back at the joint.
6. Make a horizontal incision through the anterior side of the joint
capsule, taking care not to cut into cartilage (see Figure A-5B), and
continue the incision around the side until the joint is exposed on
three sides. Carefully sever the internal ligament and open the joint
fully (see Figure A-5C), and wash away the clear viscous synovial
fluid with sterile PBS. If blood is visible in the joint capsule when it
is opened, the joint should be discarded, as it may be necrotic or
contaminated with microorganisms.
7. Using a sterile no. 15 disposable scalpel, obtain shavings from the
metacarpophalangeal chondylar surface (see Figure A-5D). Follow
the curve of the joint as closely as possible so as to obtain long,
uniformly shaped shavings, ideally in one or two long pieces per
joint surface. Long pieces are especially desirable when cartilage is
to be sectioned into chips. If uniformity of cartilage shavings is not
critical (i.e., if chips are to be enzymatically digested to release
chondrocytes for culture), it can also be excised from other surfaces
within the joint to increase the overall yield of chondrocytes.
Excessive oozing blood from the shavings indicates that the
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incision was deep and included bone, which (unlike cartilage) is
vascularized.
8. As the cartilage is scrapped off the joint, transfer the shavings to a
petri-dish containing 0.1% collagenase and 2.5% AB/AM in cold
PBS to prevent sticking and contamination. Shavings from each
hoof should be placed in a separate dish to minimize the possibility
of cross-contamination.
9. Wash the shavings three times with 2.5% AB-AM in cold PBS and
immerse washed tissue in growth media containing 1-2.5%
AB/AM.
10. Add 30 ml of sterile growth medium to each sample
11. [OPTIONAL]

To

allow

timely

detection

of

microbial

contamination, it has been suggested to incubate chips for 24-48 hrs
before digestion. Microbial contamination typically presents as
cloudy medium (bacteria) or visible mold.
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Figure A-5. Dissection of cartilage from the bovine
metacarpophalangeal joint. (A) The skins is removed, exposing
the outer joint capsule. (B) An incision through the anterior
surface of the join capsule is made which spares the cartilage
within. (C) After the joint has been opened and exposed, a scalpel
is used to excise articular cartilage by shaving along the curved
surface of the exposed joint. (D) The same joint with some of the
cartilage removed, revealing the underlying bone [Liebman and
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(b) Mechanical Disaggregation of Tissue.
Mincing or chopping tissue in liquid medium releases cells from the
supporting matrix. Most disaggregation procedures begin with a mechanical
step to reduce the tissue to small fragments, providing a larger surface area
for exposure to the digesting enzymes and facilitating penetration of
enzymes into the tissue [Harris et al.; 2006]. Soft tissues can be minced
finely with scissors and harder tissues chopped with scalpels. Further
release of cells from minced tissue is achieved by vigorous pipetting of the
smaller fragments in the suspending fluid, creating shear forces strong
enough to separate cells from the fragments.
Procedure:
1. Place the freshly harvest cartilage tissue into the glass petri dish and
moisten its surface with a small volume of 5% AB/AM in calciumfree Hank’s buffered salt solution (HBSS).
2. Using sterile dissecting scissors or scalpels mince the tissue into
small fragments. (Note 1: It is easier to cut or mince the tissue if the
volume is kept small because the fragments then stay on the surface
of the dish and cannot float away from the dissecting instruments.
Note 2: Mince soft tissue with scissors and chop harder tissue with
two opposed scalpel blades.)
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3. Tilt the dish to an angle of ~30° from the horizontal and allow the
medium and released cells to wash down into the angle of the dish.
Use a sterile pastette to aspirate the cell suspension and transfer it to
a sterile culture tube.
4. Add a small volume of HBSS to the dish with a pastette and wash
it over the fragments and surface to release and recover more cells.
5. Repeat the last three steps two more times, aiming to reduce the
tissue fragments ~1-2 mm across. Pool the released cells from each
stem. Keep the fragments for further digestion.
6. Centrifuge the cell suspension at 1000 rpm for 5 min. (Note: If the
cell suspension is of low viability it may be enhanced by keeping
the recovered cell at 4 °C. Released cells may be of low viability
because damaged cells separate more easily from the surrounding
matrix and the physical forces involved damage cells. However,
some tissues are disaggregated effectively with mechanical
methods.)
7. Decant the supernatant from the cell pellet and resuspend the cells
in 10 ml of storage medium. Store in refrigerator at 4 °C. (Note: the
volume of medium added should be increased to 20 ml if the cell
pellet is >5ml.)
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(c) Enzymatic Digestion of Cartilage Tissue
Isolation of chondrocytes is a two-step procedure: digestion of cartilage
tissue and isolation of cells from the tissue digest. Freshly harvested
cartilage tissue is rinsed several times and transferred to a digestion vessel
after weighing. For tissue weighing <300 mg w use a 50-ml tube as the
digestion vessel and for a larger amount of tissue use a 225-ml spinner flask
[Atala and Lonza, 2002].
Trypsin Digestion. Trypsin damages cells if exposure is prolonged and
care must be taken to minimize this when devising tissue-specific
protocols. Trypsinization can be carried out at 37°C (warm trypsinization)
or at 4 °C (cold trypsinization). DNA released from damaged cells
becomes viscous and its presence impairs the recovery of free cells.
DNAse is therefore included at low concentrations to digest DNA and
reduce viscosity. Serum contains trypsin inhibitors and these must be
washed away from the tissue before digestion is started. Conversely, the
action of trypsin is neutralized by the addition of serum.

0.25% Trypsin
1ml of 2.5% stock solution
9ml cation-free DPBS or HBSS
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0.4% DNAse Type I
0.4g per ml cation-free DPBS or HBSS
Filter-sterilize through a sterile 0.22 µm filter membrane
Store as 1 ml aliquots in sterile containers at -20 °C.

0.25% Trypsin/0.004% DNAse
Thaw out 1 ml aliquot of DNAse
Add to 100 ml 0.25% trypsin

Procedure:
1. Rinse the minced fragments from mechanical disaggregation in 3 X
10 ml washes of HBSS to remove trypsin inhibitors in the serum
and discard the washings.
2. Transfer the minced tissue mince from the petri dish to the conical
flask containing a sterile magnetic stirrer bar. Add 10 volumes of
0.25% trypsin/0.004% DNAse (pre-warmed to 37°C) to 1 volume
of tissue.
3. Re-cap the flask with the aluminum foil lid and place on the stirrer.
Set the stir speed to keep the fragments in suspension; there should
be a small vortex with no frothing.
4. Carry out trypsinization for 20-30 minutes.
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5. Remove the flask from the stirrer and allow the larger undigested
fragments to settle. Remove the foil cap and carefully decant the
enzyme solution containing released cells into a universal container.
This can be done by using a sterile filter (70 µm) large enough to
contain the left over fragments (should appear more gelatinous then
solid) or by using a long-form pastette or 10 ml pipette. For the
latter, tilt the flask and allow the fragments to settle in the angle of
the flask and aspirate the cell suspension from the fragments.
6. Add an equal volume of serum-containing medium to neutralize the
effects of trypsin.
7. Centrifuge the cell suspension at 1000 rpm for 5 min and resuspend
the cells in medium. Label T1 and store at 4°C.
8. Add fresh pre-warmed 0.25% trypsin/0.004% DNAse to the flask
and repeat the last two steps two times (T2 and T3). (Note:
trypsinization is complete when only fluffy white connective tissue
remain.)
9. Pool freshly isolated cells and calculate cell number and viability
using 0.4% trypan blue and hemacytometer.
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Collagenase Digestion. Literature suggests a large range of collagenase
concentrations (0.1-0.5%) depending on the collagenase used. The
digestion time can range from 4 to 24 hours depending on brand.
Collagenase and dispase (neutral protease) are less harmful to cells then
trypsin and digestion with these enzymes can be carried out in the
presence of serum. Contaminating fibroblasts are more likely in
collagenase digest because it is more effective against the connective
tissue matrix in which fibroblasts are found; this may be less irrelevant if
cells are not to be cultured because there is no opportunity for fibroblast
overgrowth. Collagenase Type I and IV are mainly used for tissue
disaggregation, though crude collagenase is sometimes recommended
because it contains small amounts of non-specific proteases, which
contribute to matrix break-down [Harris et al. 2006].

Collagenase (Crude, Type I or IV)
Dissolve in HBSS (10X Stock Solution)
Filter sterilize
Dispense into 1ml aliquots
Store at -20°C. high.
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Procedure:
1. Transfer

fragments

from

mechanical

disaggregation

and/or

trypsinization into a culture flask using either a sterile spatula or
teaspoon. Use a size of flask appropriate to the volume of tissue (aim
to add ~10 volumes of enzyme per 1 volume of tissue fragments).
2. Incubate the flask horizontally in a 37°C incubator overnight. Note:
Different media have different buffering capacities and the metabolic
activity and the incubation period need to be taken into consideration
when deciding about the medium to use. Phenol red is used as a pH
indicator and the buffering system is based on bicarbonate
concentration. Hanks = 0.35 g/l: Earle's =2.2 g/l; Dulbecco's = 3.75 g/l.
HBSS is suitable when metabolic activity and CO2 production is low
and a low buffering capacity is sufficient. Earle's is used when
tissue/cells are metabolically active and a higher buffering capacity is
needed; most culture media are based on Earle's salts.
3. The following day use a wide-bore pastette to aspirate the fragments
several times and release loosened cells. Check the flask under an
inverted phase-contrast microscope for cell release; continue digestion
if cell yield is low and/or cells can still be seen within the tissue
fragments. Note: If the medium becomes viscous, add DNAse at
0.004%.
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4. Decant the cells from the tissue using a sterile pastette or use a sterile
filter to separate the cells and media from the tissue.
5. Centrifuge the cells, discard the supernatant, and resuspend the cell
pellet in culture medium.
6. Rinse and repeat at least 3 times to ensure no residual collagenase is
present. It is best to rinse the cells with DPBS the first couple of times,
and add 1ml of PBS the last time, resuspend in 1ml PBS and take 100
µl for cell count and viability.
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(d) 3D Culture Seeded in Biomaterial Scaffold
Scaffolds play a critical role in the reorganization of neotisues. The majority
of mammalian cell types are anchorage-dependent, and will die if an
adhesive substrate is not provided. The scaffold must provide a suitable
substrate for cell attachment, cell proliferation, differentiated function, and
cell migration [Khang et al. 2007].

Polyethylene Glycol (PEG) Biomaterial Scaffold. Degradable synthetic
PEG-based hydrogels can be used as an inert structural platform due to its
hydrophilicity and resistance to protein absorption [Raeber, Lutolf, &
Hubbell, 2005].

PEG-Diacrylate (PEGDA)
1.0 g PEGDA
10 ml 1% AB/AM in DPBS

Procedure:
1. Allow PEGDA and PBS to come to room temperature.
2. Under Aseptic conditions prepare PEGDA hydrogel solution by
mixing in 1ml sterile PBS with penicillin (100 u/ml) and
streptomycin (100 mg/ml) to 0.1g PEGDA for a 10% (w/v)
solution.
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3. Invert the solution several times to dissolve. The solution will be
clear and slightly viscous.
4. The photo-initiator, 1-hydroxycyclohexyl phenyl ketone (Sigma
Aldrich), is added and mixed thoroughly to make a final
concentration of 0.05% (w/w). It is best to make this a separate
solution and add to the PEGDA/PBS from step 1.
5. Immediately before photo-encapsulation, cells are re-suspended in
polymer solution. 100 ml of cells-PEGDA solution containing
~106 cells are transferred to mold and exposed to 365 nm light
(long wave) for 5-15 min to form hydrogel. Make sure the UV
light is in close proximity to the hydrogel solution.
6. Hydrogels are removed from their molds and incubated up to 21
days in chondrogenic medium containing 5% FBS.
7. Unused PEGDA solution can be stored at -20ºC for up to one
month. Protect from light.
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(e) Cartilage Staining with Safranin-O, Fast Green and Toluidine Blue.
Toluidine blue, Safranin-O and Fast Green can be used to easily detect
aggrecan and type II collagen in cartilage. Toluidine blue and Safranin-O
are cationic stains (basic dyes) that stain acidic proteoglycan present in
cartilage tissues. Toluidine blue, also called metachromatic dye, shows
subtle color changes depending on the tertiary structure of the sample.
Cytoplasm stains light blue, nuclear region dark blue, and mast cell purple.
Safranin-O, which binds to glycosaminoglycan and shows an orange color,
is often used to stain articular cartilage. Fast green, the contrast stain of
Safranin-O, is a sulfate-group containing acidic substrate, which binds
strongly to the amino group on protein and thereby strongly stains the
noncollagen sites.

0.1% Toluidine Blue O (Sigma-Aldrich)
0.1g Toluidine Blue/100 ml distilled water

0.1% Safranin (Sigma-Aldrich)
0.1g Safranin/100ml distilled water

0.1% Fast Green (Sigma-Aldrich)
0.1g Fast Green/100ml distilled water
224

Procedure (cells):
1. Remove culture medium for culture
2. Add 500µl of fixation solution per ml of culture (~1x106 cells/ml) and let
stand at room temperature for 10 minutes to fix the cells.
3. Remove the fixation solution from each sample after diluting it with 2-4
ml of sterile PBS. Wash each sample twice with 2-4ml of sterile PBS and
remove the final wash.
4. Add 500-µl of 1% Acetic acid to each sample, allow to react for 10-15
seconds and then remove the 1% Acetic acid.
5. Add 500-µl of stain solution (Toluidine, Safranin, or Green) and let stand
at room temperature for 5 minutes to stain the cells.
6. Wash 3 times with sterile PBS. Adjust the color level by altering the
number of washes.
7. Microscopic observation may be done in the presence of PBS.
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Procedure (tissue sections):
1. Prepare sections or paraffin sections. Paraffin sections require
deparafinization:

2. Add 100-200µl
200µl of fixation solution to each tissue section for 1 – 4 hours
minimum. Remove the fixation solution.
3. Add 200µl of 1% acetic acid to each tissue section, allow to react for 1010
15 seconds then remove acetic acid.
4. Add a 200µl aliquot of stain solution (0.1% of Safranin, Toluidine, or Fast
Green) to each tissue section and let stand at room temperature for 5
minutes to stain the tissue. Remove stain solution.
5. Add absolute ethanol for destai
destaining. Destain until the color reaches the
appropriate level.
6. Perform dehydration, clearing and mounting. Adjust the volume of
fixation solution and stain depending on the size of the tissue section.
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C. Supplemental Materials and Methods: Bone Development and VitaD3
Metabolism (Chapters 5 and 6)
(iv) Materials and Reagents

1mM VitaD3 Stock Solution
3.85mg vitaD3 (MW 384.6) [C9756, Sigma-Aldrich]
10ml Ethanol
store at -20°C until use

10uM 1,25OH2D3 Stock Solution
10 µg vile 1,25OH2D3 (MW 416.64) [D1530, Sigma-Aldrich]
2.4 ml ethanol
Store at -20°C until use

rhBMP-2 (stock 0.5µg/ml)
(50ng/ml) 5µl/50ml media
(100ng/ml) 10µl/50ml media

Standard Bone Medium (BM-)
500 ml α-MEM
25-ml FBS (5%)
5-ml antibiotic/antimycotic (1%)
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2.5ml L-Glut

5X Osteogenic Medium (BM+)
250 ml BM(-)
Dissolve 2.7 g β-glycerophosphate
Dissolve 0.025 g ascorbate-2-phosphate
Add 50µl 1mM Dexamethasone (in ethanol)
Sterile Filter

Osteogenic medium (BM+)
20 ml 5X BM(+)
80 ml BM(-)

BM(+) + rhBMP-2
20µl rhBMP
100ml BM(+)

BM(-) + 1 µM VitaD3
100 ml BM(-)
100 µl 1mM vitaD3 Stock Solution
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BM(+) + 1 µM VitaD3
100ml BM(+)
100ul 1mM vitaD3 Stock Solution

BM(+) + rhBMP-2 + 1 µM VitaD3
100 ml BM(+) + rHBMP-2
100 µl 1-mM vitaD3 Stock Solution

BM(-) + 10 nM 1,25OH2D3
100 ml BM(-)
100 µl 10-µM 1,25OH2D3 Stock Solution

BM(+)+ 10 nM 1,25OH2D3
100 ml BM(+)
100 µl 10-µM 1,25OH2D3 Stock Solution

BM(+) + rhBMP-2 + 10 nM 1,25OH2D3
100ml BM(+) + BMP
100 µl 10-µM 1,25OH2D3 Stock Solution
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(v) Methods
(a) Cell Culture.
Culture OPC-1 into 12 well plates at an initial seeding density of 25,000
cells per well, or 6 well plates at a seeding density of 100,000 cell per well.
Maintain in standard bone medium (BM-) consisting of α-MEM, 5% fetal
bovine serum (FBS), 200mM L-Glutamine, and antibiotics/antimycotics for
at least 4 hours (preferably overnight) following trypsinization (0.025%
trypsin-EDTA). Remove standard growth medium and replace with 1 mL
of appropriate medium; e.g., duplicates or quadruplicates of:
a. BM(-) with 100l 95% ethanol (Control)
b. BM(+) with 100 l 95% ethanol (Control)
c. BM(+) + rhBMP-2 with 100ul 95% ethanol (control)
d. BM(-) with 1 µM 25OHD
e. BM(+) with 1 µM 25OHD
f. BM (+) + rhBMP-2 with 1 µM 25OHD
g. BM(-) with 10 nM 1α,25OHD
h. BM(+) with 10 nM 1α,25OHD
i. BM (+) + rhBMP-2 with 10 nM 1α,25OHD
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(b) Vitamin D.
VitaD3 is soluble in ethanol at 50 mg/ml. Stock solutions are prepared at
1mM (3.85 mg/10ml 95% EtOH) and kept at -20°C. Add 100 µl stock
solution to 100 mL of medium to obtain 1 µM vitaD3 for the experimental
group. Add 100 µl of ethanol to the control medium (BM- and BM+ without
vitamin D). 1,25OH2D3 is diluted into medium from 10 µM stock solutions
prepared in ethanol (4.2 µg/ml). For 1 vile of 1,25OH2D3 containing 10 µg
add 2.38 ml of ethanol and store at -20°C until use. Add 100µl to 100 ml of
medium for experimental group.

(c) Feeding/Sample Collection Schedule.
Maintain cultures with the feeding schedule outlined below. Medium is
replaced every 1-2 days with freshly diluted 10 nM dexamethasone, 5 mM
β-glycerophosphate, and 50-µg/mL ascorbate-2-phosphate. From Day 2
onwards, cells (that require vitamin D) are cultured in the continuous
presence of 1 µM 25OHD, and/or 10 nM 1,25OH2D3. Because of the
sensitivity to light, vitamin D has to be freshly diluted whenever the media
is replaced.
D1: Cell lines are plated in 12 well cell culture plates at an initial
seeding density of 25,000 cells per well in BM(-).
D2: BM(-) from D1 is removed and 1 mL of appropriate medium is
added to each well.
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D3, D7, D(end): Every 3 to 4 days supernatant and cells are
collected/prepared for crystal violet (CV) proliferation assay, alkaline
phosphatase (ALP) assay, qRT-PCR, and on the last day of the sample
set alizarin red S (ARS) assay. Supernatant is stored at -20°C and cells
are scraped from the bottom of the wells and stored in PBS containing
0.1% triton X-100 at -80°C. Prior to use, cell lysates are freeze/thawed
(3X) or sonicated. Cells from the other well are lysed with TRIzol and
prepared for PCR and stored at -80°C until qRT-PCR is conducted. For
CV and ARS, wells are fixed and stained prior to sample collection.
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(d) Alkaline Phosphatase (ALP) Assay (Based on Lowry Method)
ALP is a membrane bound enzyme that is often used as a marker for
osteogenic assay. This is a colorimetric assay in which the colorless paranitrophenol phosphate (ρNPP) turns yellow as it is cleaved to paranitrophenol + phosphate. The cell number is normalized by measuring
protein.

2-Amino-2 Methyl-1-Propanol (AMP)
For working solution, 1.5 M balanced to pH 10.25 with HCl, Prepare
50ml; store in 4C frig (good for 1 month). 7.18ml/50ml and
3.59ml/25ml.

ρ-Nitrophenyl Phosphate (ρNPP)
For working solution, 20mM, prepare 50ml, store in 4C and protect
from light. Good for 1 month. 263.10mg/50ml, 131.55mg/25ml.
[N7653, liquid pNPP system; Sigma-Aldrich] Ready to use. Already
has magnesium chloride buffer system in it.

MgCl2 (100% MgCl2)
For working solution, 10mM; prepare 25ml; store in 4C. Good for 7
days. 0.2ml 1M/25ml.
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1M NaOH
For working solution, prepare 50 or 25ml depending on number of
samples; mix fresh each day; maintain at room temperature. 1g/25ml.

Ultrapure water or 0.05% Triton X-100
Use the one your sample is suspended in.

Buffer Solution (AMP-ρNPP-MgCl2)
For working solution, prepare fresh solution from above. Prepare each
day and maintain at room temperature. Combine AMP, pNPP, and
MgCl2 in a 1:1:1 ratio.

ρ-Nitrophenyl Standard (ρNP)
Combine 1 part stock with 9 parts ultrapure (1:10 dilution). Make 500ul
aliquots and store in 4C.

Procedure
1.

Label microcentrifuge tubes appropriately.

2.

Remove media from each well and transfer to sterile labeled

microcentrifuge tubes. Freeze tubes.
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3.

Carefully wash each well with 0.25 ml EBSS (calcium and

magnesium free). Remove and fill each well again with 0.25-ml EBSS.
4.

Replace medium with 0.25ml of 0.025% trypsin (37°C). Cap the

tubes, mix well, vortex and freeze for at least 60min in -80°C or until
assayed.
5.

Tubes for ALP assay should contain at least 50 µl of FBS

containing medium to inactivate the trypsin. Once the cells come off
the plastic of the well, pipette up and down to generate homogenous
cell dispersion and place in tubes. Wash each well with 0.25ml of
EBSS (calcium and magnesium free) and collect into the same tubes.
6.

Pellet cells by centrifugation for 5min. Remove supernatant and

discard. Resuspend the pellet in 300ul of the APase buffer.
7.

Prepare reagents for APase assay according to the Lowry method.

The APase buffer solution should be kept in 37°C water bath until use.
Prepare 1M NaOH (4 pellets NaOH with 10 ml ultrapure). Mix tubes
well, and load test wells in duplicate in 96-well plate with 100 µl of
sample starting with D1.
8.

Load 100 µl/test well with APase buffer solution (only to samples).

Note the time carefully as the test is time dependent. Place multi-well
plate in 37°C incubator. For reactive samples, check reaction color after
5 min. To stop the enzyme reaction, add 100 µl of the 1 N NaOH to the
test samples as needed. Be careful not to allow the test reaction to
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proceed too long (and become too yellow) as the plate reader will
measure an absorbance at 405 nm up to 3.5, but not higher.
9.

While the plate is in the incubator, make the standard solutions for

the modified standards. To each standard add 500 µl of ultrapure water.
In descending order, add 250, 245, 240, 230, 220, and 210 µl of the
APase buffer to each tube. Finally add 0, 5, 10, 20, 30, and 40 µl of the
pNP stock solution to each tube, cap the tubes and mix each adequately.
In triplicate, add 100 µl of each solution to A1, B1, C1,…to A6, B6, C6
for an increasing concentration of ρNP. Immediately add 100 µl of the
1M NaOH to each standard well to stop the reaction. After 100 µl of the
1M NaOH has been added to all of the test samples and the standards
have been loaded, the plate can be read on the multiplate reader at 405
nm.
Table A-2. ALP standards.

Tube
H2O
APase
pNP

1
500ul
250ul
0

2
500ul
245ul
5ul

3
500ul
240ul
10ul
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4
500ul
230ul
20ul

5
500ul
220ul
30ul

6
500ul
210ul
40ul

(e) Alizarin Red S Assay (ARS).
ARS is used to evaluate ECM mineralization and calcium deposits from
cells in culture. ARS can be extracted from a stained monolayer and
assayed. This method is for the recovery and semiquantification of ARS in a
stained monolayer based on acetic acid extraction and neutralization with
ammonium hydroxide followed by colorimetric detection at 405nm.

Alizarin Red S [A5533, Sigma; MW 342.26g/mol]
40mM prepare in dH2O
1.369g ARS in 100ml dH2O
pH adjusted to 4.1 using 10% (v/v) NaOH

Procedure:
1. Remove medium and rinse cell layers with PBS.
2. Fix cells with ice cold 70% ethanol for 1 hour at 4°C, or Fix cells in
10% neutral buffered formalin for 5-10 minutes.
3. Rinse with distilled water and air dry.
4. Add 1ml of 40mM ARS (pH 4.1) per well and incubate at room
temperature for 20 min with gentle shaking.
5. Aspirate the unincorporated dye from each well.
6. Wash each well 4X with 1ml dH2O while shaking for 5 min.
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7. Remove excess water by leaving the plates at an angle for 2 min.
Aspirate again and then store plates at -20°C.
8. Stained monolayers are visualized by phase microscopy using an
inverted microscope.
9. For quantification of staining: add 800ul 10% (v/v) acetic acid to
each well and incubate at room temperature for 30 min with
shaking.
10. Scrape cell from plate and transfer (with 10% (v/v) acetic acid) to a
1.5ml microcentrifuge tube.
11. Vortex for 30 sec.
12. Overlay slurry with 500ul mineral oil.
13. Heat to 85°C for 10 min, and transfer to ice for 5 min. Tubes should
not be opened until fully cooled.
14. Centrifuge at 20,000g for 15min.
15. Remove 500ul of supernatant and add to new 1.5ml microcentrifuge
tube.
16. Add 200ul of 10% (v/v) ammonium hydroxide to neutralize.
17. Aliquot 150 µl in duplicate or triplicate into a 96 well plate (Opaque
walled transparent bottom plates). Read at 405nm.
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Table A-3. Alizarin Red Standard Curve.

Tube Standard (Concentration of
Alizarin Red S stain)
A
1 mg/ml
B
500 ug/ml
C
250 ug/ml
D
100 ug/ml
E
50 ug/ml
F
25 ug/ml
G
10 ug/ml
H
5 ug/ml
I
0 ug/ml
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Alizarin Red
Stain
50 ul Stock
500 ul of A
400 ul of B
500 ul of C
500 ul of D
500 ul of E
400 ul of F
500 ul of G
0 ul

Solubilization
Solution
950 ul
500 ul
500 ul
600 ul
500 ul
500 ul
600 ul
500 ul
500 ul

(f) Crystal Violet Proliferation Assay.
This is a simple assay useful for obtaining information about the relative
density of cells adhering to multi-well cluster dishes. The dye in this assay,
crystal violet, stains DNA. Upon solubilization, the amount of dye taken up
by the monolayer can be quantitated in a spectrophotometer or plate reader.
Procedure
1. Remove culture medium from wells.
2. Wash plate gently with PBS warmed at least to room temperature:
(0.2ml/96 well plate, 0.5ml/48 well plate, 1ml/24 well plate, 2ml/12
well plate, or 3ml/ 6 well plate)
3. Carefully remove PBS and fix in ethanol by adding 95% ethanol
per well and incubate at RT for 10 min. (50µl/96 well plate,
100µl/48 well plate, 200µl/24 well plate, 500µl/12 well plate,
750µl/6 well plate)
4. Add crystal violet solution. Incubate 10 min at room temperature
(50µl/96 well plate, 100µl/48 well plate, 200µl/24 well plate,
500µl/12 well plate, 750µl/6 well plate).
5. Wash wells extensively with dH2O to remove excess stain.
6. Add 1% SDS or 0.2% Triton X in dH2O and agitate. (50µl/96 well
plate, 100µl/48 well plate, 200µl/24 well plate, 500µl/12 well plate,
750µl/6 well plate).
7. Read absorbance of each well at 570nm.
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(g) Quantitative Reverse Transcriptase RT-PCR

RNA extraction with TRIzol
1. Rinse cell monolayer with ice cold PBS once.
2. (homogenization) Lyse cells directly in a culture dish by adding 1
ml of TRIZOL reagent per 3.5 cm diameter dish and scrapping with
cell scrapper. The amount of TRIZOL reagent added is based on the
area of the culture dish (1ml per 10cm2) and not on the number of
cells present. An insufficient amount of TRIZOL reagent may result
in DNA contamination of the isolated RNA.
3. Pass the cell lysate several times through a pipette and vortex
thoroughly.
4. Incubate the homogenized sample for 5 minutes at RT to permit the
complete dissociation of nucleoprotein complexes.
5. Centrifuge to remove cell debris and transfer the supernatant to new
tube. It is recommended to freeze in Trizol at least 1 hour at -80°C
after incubating at RT. This is a potential stopping point. Samples
can be kept at -80°C indefinitely because RNA is stable in Trizol
and TrIzol inactivates after 5 minutes. Thaw samples on ice.
6. (Phase Separation) Add 0.2ml of chloroform per 1 ml of TRIZOL
reagent. Cap sample tubes securely.
7. Vortex samples vigorously for 15 seconds and incubate at RT for 2
to 3 minutes.
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8. Centrifuge the samples at no more than 12,000 x g for 15 minutes at
2-8°C.
9. Work on ice from this point on. Following centrifugation, the
mixture separates into lower red, phenol chloroform phase, an
interphase, and a colorless aqueous phase. RNA remains
exclusively in the aqueous phase carefully without disturbing the
interphase into a fresh tube. Leave behind a small amount of clear
phase; do NOT pick up any pink phenol-chloroform phase; use
pipette tips with a large hole to prevent this from happening.
Measure the volume of the aqueous phase. (The volume of the
aqueous phase is about 60% of the volume of TRIZOL reagent used
for homogenization). Incubate 1+hr at -80°C. This is another
potential indefinite stopping point.
10. (RNA Precipitation) Precipitate the RNA from aqueous phase by
mixing with isopropyl alcohol (IPA). Use 0.5ml of IPA per 1ml of
TRIZOL reagent used for the initial homogenization.
11. Incubate samples at 15 to 30°C for 10 minutes and centrifuge for no
more than 12,000 x g for 10 minutes at 2 to 4°C. The RNA
precipitate, often invisible before centrifugation, forms a gel-like
pellet on the side and bottom of the tube.
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12. (RNA Wash) Remove the supernatant completely. Wash the RNA
pellet once with 75% ethanol. Adding at least 1ml of 75% ethanol
per 1 ml of TRIZOL Reagent used for the initial homogenization.
13. Mix the samples by vortexing and centrifuge at no more than 7,500
x g for 5 minutes 2 to 8°C. Repeat above washing procedure once.
Remove all leftover ethanol.
14. Air-dry or vacuum dry or vacuum dry RNA pellet for 5-10 minutes.
So not dry the RNA pellet by centrifuge under vacuum. It is
important not to let the RNA pellet dry completely as this will
greatly decrease its solubility.
15. Partially dissolved RNA samples have an A260/A280 ration <1.6.
Dissolve RNA in DEPC-treated water by passing solution a few
times through a pipette tip.
16. The pellet should be resuspended in 12.5-15µl of Nuclease-free
water/DEPC-treated water. Incubate at RT for 2-3 min then place
on ice.
17. (RNA Quantification) Spectrophotometric analysis: dilute 1µl of
RNA with 39µl of DEPC-treated water (1:40 dilution). Using 10µl
microcuvette, take OD at 260nm and 280n, to determine a sample
concentration and purity. The A260/A280 ratio should be above
1.6. Apply the convention that 1 OD at 260 equals 40µg/ml RNA.
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Nanodrop quantification: quantify total RNA using a Nanodrop.
Store total RNA indefinitely at -80°C.
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